Page last updated: 2024-11-04

reserpine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5770
CHEMBL ID772
CHEBI ID28487
SCHEMBL ID2589
MeSH IDM0018861

Synonyms (449)

Synonym
AC-13142
smr000059122
MLS002154046
yohimban-16-carboxylic acid,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-, methyl ester, (3.beta.,16.beta.,17.alpha.,18.beta.,20.alpha.)-
nsc-237659
nsc237659
KBIO1_000012
DIVK1C_000012
NCI60_004446
EU-0100073
alserin
usaf cb-27
raunervil
methyl reserpate 3,5-trimethyloxybenzoic acid
component of metatensin
sedaraupin
reserpex
banasil
serpate
raucap
key-serpine
reserlor
resocalm
component of renese r
raunova
lemiserp
serpalan
reserpina
vio-serpine
component of regroton
serpaloid
79 more names available
rauvlid
restran
sandron
serp-afd
tempo-reserpina
component of naquival
roxinoid
serpipur
raudixoid
ascoserpina
kitine
hiserpia
crystoserpine
raulen
.gamma.-serpine
r-e-s
escaspere
serpanray
ent 50146
rau-sed
raumorine
serpasil
mephaserpin
neoserfin
rausedyl
serfin
reserpene
austrapine
serpoid
deserpine
rauwoleaf
riserpa
maviserpin
hypersil
NSC59272 ,
rezerpin
purserpine
respital
serpasol
sk-reserpine
ryser
elserpine
rauwilid
serpena
serpicon
raurine
apoplon
sertina
sandril
resperin
mayserpine
eserpine
eberpine
benz[g]indolo[2, 1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-3-hydroxy-2,11-dimethoxy-, methyl ester, 3,4,5-trimethoxybenzoate
reserpanca
neo-antitensol
rausingle
3,5-trimethoxybenzoyl methyl reserpate
serpivite
serpivate
rausan
rausedan
serpazol
nsc-59272
3.beta., 18.beta.-hydroxy-11,17.alpha.-dimethoxy- methyl ester 3,4,5-trimethoxybenzoate (ester)
serpentil
rauserpol
helfoserpin
interpina
eskaserp
unilord
enipresser
serfolia
3-.beta., 18-.beta.-hydroxy-11,17-.alpha.-dimethoxy-,methyl ester, 3,4,5-trimethoxybenzoate (ester)
serpine (pharmaceutical)
rauwasedin
sertens
sedserp
carditivo
resercaps
serolfia
roxel
raupasil
nci-c50157
bioserpine
benazyl
reserpal
resercen
carrserp
t-serp
serpine
raupoid
rauloydin
rautrin
resine
reserjen
neoserp
methyl reserpate 3,5-trimethoxybenzoic acid ester
resedrex
rivasin
eskaserpine
raudiford
rauserpine
serpasil premix
serpentina
reserp
raugal
rawilid
sedaraupina
component of butiserpazide
loweserp
serpone
reserpinum
wln: t f6 d5 c666 em on&&tttj ho1 sovr co1 do1 eo1& to1 uvo1
idsoserp
residine
rauwipur
apsical
serpogen
reserpamed
reserpil
reserpoid
rausedil
alkarau
temposerpine
serpiloid
sertabs
serpen
reserbal
quiescin
rauserpin-alk
hypersine
h 520
residin
raunorine
3p reserp
reserpur
triserpin
hiposerpil
apoplon (tn)
reserpine (jp17/usp/inn)
D00197
serpalan (tn)
hydropine
3,4,5-trimethoxybenzoyl methyl reserpate
mallopress
chloroserpine-500
hydro-fluserpine #1
hydropres 25
gilucard
3beta,20alpha-yohimban-16beta-carboxylic acid, 18beta-hydroxy-11,17alpha-dimethoxy- methyl ester 3,4,5-trimethoxybenzoate (ester)
rese-lar
einecs 200-047-9
hydropres 50
diupres 500
c33h40n2o9
hydroserpine #1
diupres 250
hydrosine 25
vixo
methyl 18beta-hydroxy-11,17alpha-dimethoxy-3beta,20alpha-yohimban-16beta-carboxylate 3,4,5-trimethoxybenzoate (ester)
hsdb 213
recipin
rcra waste no. u200
chloroserp-250
methyl o-(3,4,5-trimethoxybenzoyl)reserpate
SPECTRUM_000109
carpacil
11,17-dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)yohimban-16-carboxylic acid methyl ester
metatensin #4
brn 0102014
reserpina [inn-spanish]
metatensin
hydro-reserpine-50
resedril
chloroserpin-250
resaltex
(-)-reserpine
hydroserpalan
epa pesticide chemical code 123101
nembuserpin
hydroserp
3-beta,20-alpha-yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-11,17-alpha-dimethoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester)
chloroserp-500
rauwita
diurese-r
klimanosid
methyl 11,17alpha-dimethoxy-18beta-(3,4,5-trimethoxybenzoyloxy)-3beta,20alpha-yohimbane-16beta-carboxylate
hydromox-r
hydroserpine plus
metatensin #2
gammaserpine
rcra waste number u200
nsc 237659
reser-ar
reserpic acid methyl ester 3,4,5-trimethoxybenzoate (ester)
reserpidefe
yohimban-16-carboxylic acid, 11,17-dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)-, methyl ester, (3beta,16beta,17alpha,18beta,20alpha)-
reserfia
(3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester
ai3-50146
methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-bis(methyloxy)-18-({[3,4,5-tris(methyloxy)phenyl]carbonyl}oxy)yohimban-16-carboxylate
hydro-reserpine-25
methyl reserpate 3,4,5-trimethoxybenzoic acid ester
caswell no. 722a
ccris 550
neo-serp
methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate
ACON1_000086
MEGXP0_001904
PRESTWICK_147
cas-50-55-5
BPBIO1_001045
UNM000011053801
IDI1_000012
PRESTWICK2_000875
PRESTWICK3_000875
BSPBIO_000949
SPECTRUM5_001415
LOPAC0_000073
NCGC00091250-01
C06539
reserpine
50-55-5
reserpin
CHEBI:28487 ,
DB00206
NCGC00091250-04
KBIO2_005685
KBIO3_001808
KBIO2_003117
KBIOSS_000549
KBIO2_000549
KBIOGR_001397
SPECTRUM4_000989
PRESTWICK1_000875
SPBIO_002870
PRESTWICK0_000875
NINDS_000012
SPECTRUM3_000894
SPECTRUM1500526
NCGC00091250-02
NCGC00091250-05
NCGC00091250-06
NCGC00091250-03
methyl reserpate; 3,4,5-trimethoxybenzoic acid ester
HMS2092G05
R 0875 ,
NCGC00091250-08
CHEMBL772 ,
ent-50146
AKOS000277559
HMS500A14
HMS1570P11
HMS1920P04
STK801975
methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-{[(3,4,5-trimethoxyphenyl)carbonyl]oxy}yohimban-16-carboxylate
bdbm50017712
NCGC00091250-09
NCGC00091250-10
NCGC00091250-07
HMS3260O07
HMS2097P11
tox21_300537
NCGC00259944-01
tox21_202395
NCGC00254489-01
nsc-757309
nsc757309
pharmakon1600-01500526
tox21_111107
dtxsid7021237 ,
dtxcid201237
methyl (1r,15s,17r,18r,19s,20s)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyloxy)-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4,6,8-tetraene-19-carboxylate
CCG-204168
HMS2234E24
reserpine [usp:inn:ban:jan]
l-carpserp
8b1qwr724a ,
4-25-00-01319 (beilstein handbook reference)
unii-8b1qwr724a
LP00073
reserpine component of hydro-reserp
serpasil-apresoline component reserpine
reserpine [ep monograph]
reserpine component of unipres
reserpine [jan]
reserpine [hsdb]
hydromox r component reserpine
dralserp component reserpine
regroton component reserpine
reserpine component of diutensen-r
reserpine component of h.r.-50
metatensin component reserpine
reserpine component of serpasil-apresoline
hydrap-es component reserpine
ser-ap-es component reserpine
diutensen-r component reserpine
reserpine component of metatensin
reserpine component of hydralazine hydrochloride-hydrochlorothiazide-reserpine
reserpine [orange book]
reserpine component of cam-ap-es
naquival component reserpine
reserpine component of naquival
hydro-reserp component reserpine
reserpine component of salutensin
reserpine component of serpasil-esidrix
reserpine [iarc]
methyl 18.beta.-hydroxy-11,17.alpha.-dimethoxy-3.beta.,20.alpha.-yohimban-16.beta.-carboxylate 3,4,5-trimethoxybenzoate (ester).
reserpine [vandf]
reserpine component of ser-ap-es
reserpine component of dralserp
hydropres component reserpine
reserpinum [hpus]
hydralazine hydrochloride-hydrochlorothiazide-reserpine component reserpine
reserpine component of hydromox r
reserpine [usp-rs]
reserpine component of hydroserpine plus (r-h-h)
reserpine [inn]
unipres component reserpine
reserpine component of demi-regroton
h.r.-50 component reserpine
reserpine component of ser-a-gen
reserpine [who-dd]
reserpine component of hydropres
serpasil-esidrix component reserpine
cam-ap-es component reserpine
reserpine [mi]
renese-r component reserpine
methyl (3.beta.,16.beta.,17.alpha.,18.beta.,20.alpha.)-11,17-dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)yohimban-16-carboxylate
hydroserpine plus (r-h-h) component reserpine
reserpine [usp monograph]
demi-regroton component reserpine
reserpine component of regroton
reserpine component of renese-r
ser-a-gen component reserpine
reserpine [mart.]
reserpinum [who-ip latin]
reserpine component of hydrap-es
reserpine [who-ip]
salutensin component reserpine
gtpl4823
HY-N0480
CS-1913
BBL028800
SCHEMBL2589
NCGC00091250-12
tox21_111107_1
KS-5106
tox21_500073
NCGC00260758-01
QEVHRUUCFGRFIF-MDEJGZGSSA-N
MLS006011754
(3?,16?,17?,18?,20?)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester
AC-34405
Q-100566
(3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18- [(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxyl ic acid methyl ester
HB1895
methyl (1s,2r,3r,4as,13br,14as)-2,11-dimethoxy-3-((3,4,5-trimethoxybenzoyl)oxy)-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylate
AB01562943_01
mfcd00005091
methyl (1r,15s,17r,18r,19s,20s)-6,18-dimethoxy-17-[(3,4,5-trimethoxyphenyl)carbonyloxy]-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4,6,8-tetraene-19-carboxylate
reserpine, crystallized, >=99.0% (hplc)
reserpine standard for lc-ms, analytical standard, for lc-ms
reserpine, united states pharmacopeia (usp) reference standard
reserpine, certified reference material, tracecert(r)
methyl(1r,15s,17r,18r,19s,20s)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
reserpine, vetec(tm) reagent grade
reserpine, 99%
reserpine, european pharmacopoeia (ep) reference standard
reserpine, pharmaceutical secondary standard; certified reference material
SBI-0050061.P004
HMS3714P11
NCGC00091250-14
rkl10049
SW196458-3
A913268
Q407841
50-55-5 (free)
HMS3677D20
(1s,2r,3r,4as,13br,14as)-methyl 2,11-dimethoxy-3-((3,4,5-trimethoxybenzoyl)oxy)-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylate
reserpine,(s)
HMS3413D20
BRD-K95921201-001-07-0
SDCCGSBI-0050061.P005
HMS3884I21
NCGC00091250-25
AMY591
yohimban-16-carboxylic acid,11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-, methyl ester,(3b,16b,17a,18b,20a)-
yohimban-16-carboxylic acid, 11,17-dimethoxy-18-(3,4,5-trimethoxybenzoyl)oxy-, methyl ester, (3.beta.,16.beta.,17.alpha.,18.beta.,20.alpha.)-
BR164333
methyl (1r,15s,17r,18r,19s,20s)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyloxy)-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4(9),5,7-tetraene-19-carboxylate
EN300-84477
(1s,2r,3r,4as,13br,14as)-methyl2,11-dimethoxy-3-((3,4,5-trimethoxybenzoyl)oxy)-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylate
(3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)yohimban-16-carboxylic acid methyl ester
methyl 18beta-hydroxy-11,17alpha-dimethoxy-3beta,20alpha-yohimban-16beta-carboxylate 3,4,5-trimethoxybenzoate (ester).
3beta,20alpha-yohimban-16beta-carboxylic acid, 18beta-hydroxy-11,17alpha-dimethoxy-methyl ester 3,4,5-trimethoxybenzoate (ester)
reserpine (usp-rs)
reserpine (usp:inn:ban:jan)
methyl (3r,16s,17r,18r,20s)-11,17-dimethoxy-18-(3,4,5-trimethoxybenzoyloxy)yohimban-16-carboxylate
methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)yohimban-16-carboxylate
rezide
tri-hydroserpine
reserpine (usp monograph)
3beta,20alpha-yohimban-16beta-carboxylic acid, 18beta-hydroxy-11,17alpha-dimethoxy-, methyl ester, 3,4,5-trimethoxybenzoate
serathide
hiposepil
reserpine (ep monograph)
reserpine (iarc)
serpazide
reserpine (mart.)
salazide-demi
yohimban-16-carboxylic acid,11,17-dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)-, methyl ester, (3beta,16beta,17alpha,18beta,20alpha)-
trichlortensin
c02aa02
reserpina (inn-spanish)
Z1251172867

Research Excerpts

Overview

Reserpine is a natural indole alkaloid isolated from Rauwolfia serpentina. It has potent antioxidant, antimicrobial, and anti-mutagenic properties. Administration can induce Parkinson's disease (PD)-like symptoms in humans and animals.

ExcerptReferenceRelevance
"Reserpine is an effective antihypertensive drug, but its role in routine practice has declined such that it is rarely used. "( The effects of reserpine on depression: A systematic review.
Cave, J; Jauhar, S; Javed, RR; Strawbridge, R; Young, AH, 2023
)
2.71
"Reserpine is a natural indole alkaloid isolated from Rauwolfia serpentina and has potent antioxidant, antimicrobial, and anti-mutagenic properties. "( Reserpine inhibits DNA repair, cell proliferation, invasion and induces apoptosis in oral carcinogenesis via modulation of TGF-β signaling.
Ahmed Abdul, BA; Alarifi, S; Ali, D; Ramu, AK; Syed Abuthakir, MH, 2021
)
3.51
"Reserpine (RES) is an irreversible inhibitor of VMAT2 used to study Parkinson's disease (PD) and screening for antiparkinsonian treatments in rodents. "( Changes in the mesocorticolimbic pathway after low dose reserpine-treatment in Wistar and Spontaneously Hypertensive Rats (SHR): Implications for cognitive deficits in a progressive animal model for Parkinson's disease.
Abílio, VC; Conceição, IM; Freitas, TA; Izídio, GS; Leão, AHFF; Medeiros, AM; Meurer, YSR; Ribeiro, AM; Silva, RH, 2021
)
2.31
"Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2) and monoamine releaser, so it can be used as a pharmacological model of depression. "( Withdrawal from repeated administration of a low dose of reserpine induced opposing adaptive changes in the noradrenaline and serotonin system function: a behavioral and neurochemical ex vivo and in vivo studies in the rat.
Antkiewicz-Michaluk, L; Michaluk, J; Możdżeń, E; Romańska, I; Wąsik, A, 2015
)
2.1
"Reserpine is a well-known medicine for the treatment of hypertension and schizophrenia, but its administration can induce Parkinson's disease (PD)-like symptoms in humans and animals. "( The anti-hypertensive drug reserpine induces neuronal cell death through inhibition of autophagic flux.
Kim, MJ; Koh, H; Lee, JI; Lee, KI; Namkoong, S; Oh, WK; Park, J, 2015
)
2.16
"Reserpine is a monoterpene indole alkaloid used to treat hypertension because of its hypotensive property and psychiatric disorders because of its tranquilizing effect. "( Influence of auxins combinations on accumulation of reserpine in the callus of Rauvolfia tetraphylla L.
Anitha, S; Kumari, BD, 2007
)
2.03
"Reserpine functions as an anti-stress agent providing relaxation to animals under stressful conditions. "( Ascorbate defense system and response of steroid producing glands under reserpine treatment in albino rats (Rattus norvegicus).
Mehta, P; Singh, KB, 2009
)
2.03
"Reserpine treatment is a putative animal model of orofacial dyskinesia, tremor, and Parkinsonism. "( Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice.
Barbosa, NB; Barreto, KP; Burger, ME; Busanello, A; Fachinetto, R; Farias, LE; Peroza, LR, 2011
)
2.04
"Reserpine, which is a chemical denervation of sympathetic nerves has no effect on the active accumulation of TAG."( Accumulation of peptide Tyr-D-Ala-Gly by choroid plexus during ventriculocisternal perfusion of rat brain.
Huang, JT, 1982
)
0.99
"As reserpine is an adrenergic neuron blocker, these results suggest that catecholamines may play an essential role in the maintenance or control of NaK ATPase activity, and that the stria vascularis may be one of the target organs of catecholamines."( Reserpine inhibits the NaK ATPase activity of the stria vascularis in the cochlea.
Kanoh, N, 1994
)
2.25
"As reserpine is an adrenergic neuron blocker, and L-threo DOPS is the precursor of noradrenaline, it seems that noradrenaline converted from L-threo DOPS was able to restore the Na-K ATPase activity in the reserpinized animals."( The role of L-threo DOPS in the control of Na-K ATPase activity of the marginal cells in the stria vascularis of reserpinized guinea pigs.
Kanoh, N; Nomura, J, 1995
)
0.81
"Reserpine is a modulator of MDR in which these domains are present in a well-defined conformation."( Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.
Bach, NJ; Beck, WT; Cirtain, MC; Pearce, HL; Safa, AR; Winter, MA, 1989
)
1.22
"Reserpine is a very potent, competitive inhibitor of the catecholamine transporter and can be used to investigate the characteristics of the catecholamine transporter."( Effects of the sulfhydryl reagent N-ethylmaleimide on reserpine binding to the catecholamine transporter in chromaffin granule membranes.
Deupree, JD; Hitchcock, JJ, 1988
)
1.24
"Reserpine is a potent inhibitor."( Steady-state kinetics of catecholamine transport by chromaffin-granule "ghosts".
Phillips, JH, 1974
)
0.97

Effects

Reserpine has a stimulatory effect on the pars intermedia of the rat pituitary, probably mediated by its action on regulatory catecholaminergic nerves. Reserpine induces a general increase in the activity of the processing enzymes.

Reserpine (RES) has been reported to increase the brain's neural oxidative stress and cause cognitive dysfunction. Reserpine has been used clinically to control hypertension, schizophrenia, insomnia and insanity.

ExcerptReferenceRelevance
"As reserpine has a similar effect on proenkephalin in chromaffin cells, the results suggest that reserpine induces a general increase in the activity of the processing enzymes, partially by an increase in protein synthesis."( Reserpine-induced processing of chromogranin A in cultured bovine adrenal chromaffin cells.
Robinson, I; Watkinson, A, 1992
)
2.24
"Reserpine has a stimulatory effect on the pars intermedia of the rat pituitary, probably mediated by its action on regulatory catecholaminergic nerves. "( The effect of reserpine on the pars intermedia of the rat pituitary. An electron-microscopic, fluorescence-histochemical and immunohistochemical study.
Bäck, N; Rechardt, L, 1985
)
2.07
"Reserpine has been confirmed to induce cognitive dysfunction and increase brain neural oxidative stress. "( (-)Epigallocatechin-3-gallate prevents the reserpine-induced impairment of short-term social memory in rats.
Chang, KC; Chang, Y; Soung, HS; Tseng, HC; Wang, MH, 2015
)
2.12
"Reserpine (RES) has been reported to increase the brain's neural oxidative stress and cause cognitive dysfunction. "( Nitric oxide pathway activity modulation alters the protective effects of (-)Epigallocatechin-3-gallate on reserpine-induced impairment in rats.
Chang, KC; Chen, CN; Lin, RF; Shih, RL; Soung, HS; Tsai, CC; Tseng, HC; Wang, MH, 2016
)
2.09
"Reserpine has been used clinically to control hypertension, schizophrenia, insomnia and insanity."( Green tea modulates reserpine toxicity in animal models.
Afzal, M; Al-Bloushi, S; Mousa, SA; Safer, AM, 2009
)
1.4
"Reserpine has been used as a second-line therapy in some of those trials."( Blood pressure lowering efficacy of reserpine for primary hypertension.
Perez, MI; Shamon, SD, 2009
)
1.35
"Reserpine has no effect on adenosinetriphosphatase activity."( Effects of reserpine, chlorpromazine and sodium salicylate on the enzymic activity of rat liver.
KIRPEKAR, SM; LEWIS, JJ, 1960
)
1.35
"Reserpine has been previously shown to generally enhance femoral arterial vasodilator responses as indicated by increased slopes of regression lines relating decreases in resistance produced by injections of vasodilator agents to resistance prior to the injections. "( Effects of 6-hydroxydopamine pretreatment on in vivo femoral arterial responses to vasodilator agents.
Cauvin, C; Devia, C; Kirkendol, P, 1982
)
1.71
"Reserpine has been shown to inhibit expression of cell-mediated immune responses in mice, probably by causing intercellular release and degradation of vasoactive amines."( The pathogenesis of interstitial pneumonitis induced by trehalose dimycolate. II. Reserpine prevents formation of lesions.
Goren, MB; Kirkpatrick, CH; Seggev, JS, 1984
)
1.21
"As reserpine has a similar effect on proenkephalin in chromaffin cells, the results suggest that reserpine induces a general increase in the activity of the processing enzymes, partially by an increase in protein synthesis."( Reserpine-induced processing of chromogranin A in cultured bovine adrenal chromaffin cells.
Robinson, I; Watkinson, A, 1992
)
2.24
"Reserpine has been shown to attenuate the pneumotoxicity induced by NMTB."( Effect of reserpine on N-methylthiobenzamide-induced pulmonary edema: role of lung norepinephrine and hypothermia.
Gibbs, LS; Traiger, GJ, 1989
)
1.4
"Reserpine has a stimulatory effect on the pars intermedia of the rat pituitary, probably mediated by its action on regulatory catecholaminergic nerves. "( The effect of reserpine on the pars intermedia of the rat pituitary. An electron-microscopic, fluorescence-histochemical and immunohistochemical study.
Bäck, N; Rechardt, L, 1985
)
2.07
"Reserpine may have been lifesaving and should be considered in propranolol-resistant hyperthyroidism and in hyperthyroid patients in whom propranolol is contraindicated."( Reserpine in propranolol-resistant thyroid storm.
Anaissie, E; Tohmé, JF, 1985
)
2.43
"Reserpine has no effect on DNA synthesis when administered simultaneously with the labelled thymidine 2 h before killing.4."( Decreased synthesis of DNA in regenerating rat liver after the administration of reserpine.
Cihák, A; Vaptzarova, K, 1973
)
1.2

Actions

Reserpine could cause cerebral injury and depressive disorder in mice. The mechanism of which is related to steroid hormone biosynthesis, chemical carcinogenesis, nucleotide excision repair and retinoic acid-inducible gene I-like (RIG-I-like) receptor signaling.

ExcerptReferenceRelevance
"Reserpine could cause cerebral injury and depressive disorder in mice, the mechanism of which is related to steroid hormone biosynthesis, chemical carcinogenesis, nucleotide excision repair and the retinoic acid-inducible gene I-like (RIG-I-like) receptor signaling."( Label-free quantitative proteomic analysis of reserpine-induced depression in mice intervened by berberine.
Wang, Y; Yang, N; Zou, L, 2022
)
1.7
"Reserpine was found to cause hepatic damage, with elevated levels of oxidative stress markers, such as Thiobarbituric Acid Reactive Substances (TBARS), transaminases and cholesterol."( Green tea modulates reserpine toxicity in animal models.
Afzal, M; Al-Bloushi, S; Mousa, SA; Safer, AM, 2009
)
1.4
"Reserpine was found to cause kidney proximal tubule damage, such as stripping and clustering of ribosomes from the rough endoplasmic reticulum (rER) and demolishing of mitochondrial christae with elevated level of oxidative stress markers, such as TBARS."( Inhibition property of green tea extract in relation to reserpine-induced ribosomal strips of rough endoplasmic reticulum (rER) of the rat kidney proximal tubule cells.
Abdel-Majeed, S; Mohammad, A; Mohammad, R; Mousa, SA; Shaima, AB, 2009
)
1.32
"Reserpine was shown to produce an increase in the concentration of these compounds in the cerebrospinal fluid."( Drug-induced changes in the concentration of 5-OR indolyl compounds in cerebrospinal fluid and caudate nucleus.
ASHCROFT, GW; SHARMAN, DF, 1962
)
0.96
"Reserpine can increase gastric acidity, induce mental depression, and when used with digitalis lead to ventricular premature beats."( Dangers in the use of some potent drugs.
SPAULDING, WB, 1962
)
0.96
"Reserpine can inhibit its active efflux mechanism, and has synergistic effect with quinolone, which hold therapeutic potential for S."( [A study on the active efflux mechanism in Staphylococcus aureus resistant to quinolone].
Duan, DQ; Lin, YG; Xu, F, 2004
)
1.04
"Reserpine did not increase cofactor levels in liver, kidney, or corpus striatum but decreased that of the pineal gland."( Tetrahydrobiopterin increases in adrenal medulla and cortex: a factor in the regulation of tyrosine hydroxylase.
Abou-Donia, MM; Viveros, OH, 1981
)
0.98
"Reserpine was shown to generate a liquid membrane. "( Liquid membrane phenomenon in reserpine action.
Bhise, SB; Marwadi, PR; Mathur, SS; Srivastava, RC, 1983
)
2
"Reserpine provoked an increase of 20% in the electrochemical peak and the 5-HIAA outflow blocker probenecid gave rise to a sustained plateau of about 60% above control values.(ABSTRACT TRUNCATED AT 250 WORDS)"( Differential pulse voltammetry in the dorsal horn of the spinal cord of the anesthetized rat: are the voltammograms related to 5-HT and/or to 5-HIAA?
Chiang, CY; Ory-Lavollee, L; Rivot, JP, 1983
)
0.99
"Reserpine which promotes catecholamine release from the tissues, leads to the diminution of the rate of the MR of the shudder type in rats of the same age."( [Adrenergic mechanisms regulating the motor reactions of rats in the early postnatal period].
Praznikov, VP, 1984
)
0.99
"Reserpine was found to enhance the effect of ACNU on ACNU-resistant C6 glioma (C6/ACNU). "( [Enhanced effect of reserpine on growth-inhibitory action of ACNU on ACNU resistance C6 glioma].
Hayakawa, T; Mogami, H; Sakamoto, Y; Shimizu, K; Ushio, Y; Yoshida, T, 1984
)
2.03
"A reserpine-induced increase in the turnover of [3H]noradrenaline caused a transient increase of the catechol glycol followed by elevated levels of the two glycol sulfates."( On the metabolism of [3H]noradrenaline in different compartments of rat brain with respect to the role of catechol-O-methyltransferase.
Breuer, H; Goede, E; Köster, G, 1984
)
0.83
"Both reserpine and FLA-63 cause a reduction in the diameter and electron density of the synaptic bars, and a dramatic loss of synaptic vesicles surrounding the bars."( Ultrastructural and pharmacological studies on the afferent synapse of lateral-line sensory cells of the African clawed toad, Xenopus laevis.
Monaghan, P, 1975
)
0.71
"Reserpine induced an increase in lanthanum (La3+) resistant 45Ca uptake."( Tension development and associated calcium influx of control and reserpine pretreated rabbit aortae in response to norepinephrine, isoproterenol and acetylcholine.
Carrier, O; Hester, RK, 1978
)
1.22
"Reserpine was found to inhibit the secretion of luteinising hormone when injected into intact and gonadectomised fowl at a dose rate which caused heavy sedation. "( The effect of reserpine on plasma LH concentrations in intact and gonadectomised domestic fowl.
Sharp, PJ, 1975
)
2.06
"Reserpine did not inhibit the apomorphine-induced stereotyped behavior though the drug elicited markedly the behavioral depression and alpha-methyl-p-tyrosine also did not block the stereotyped behavior."( Effects of penfluridol and other drugs on apomorphine-induced stereotyped behavior in monkeys.
Shintomi, K; Yamamura, M, 1975
)
0.98
"The reserpine-induced increase in tyrosine hydroxylase mRNA was significantly correlated with the reserpine-induced increase in galanin mRNA."( Tyrosine hydroxylase and galanin mRNA levels in locus coeruleus neurons are increased following reserpine administration.
Austin, MC; Cottingham, SL; Crawley, JN; Paul, SM, 1990
)
0.98
"The reserpine-induced increase in plasma NPY-LI and the depletion of NPY-LI in the heart and skeletal muscle was to a large extent prevented by guanethidine."( Reserpine-induced depletion of neuropeptide Y from cardiovascular nerves and adrenal gland due to enhanced release.
Al-Saffar, A; Lundberg, JM; Saria, A; Theodorsson-Norheim, E, 1986
)
2.19
"Reserpine enhance ENK precursor processing."( [Regulation of enkephalin biosynthesis in chromaffin cells].
Affolter, HU; Castanas, E; Eiden, LE; Giraud, P; Hotchkiss, A; Oliver, C, 1986
)
0.99
"Reserpine-induced increase in acid secretion may have been mediated by the vagus nerves, probably as a result of central and/or peripheral diminution in noradrenergic inhibitory mechanisms."( Dissociation between acid secretion and mucosal blood flow after treatment of rats with reserpine.
Fujiwara, M; Kitagawa, H; Kurahashi, K, 1986
)
1.21
"Reserpine was shown to enhance the cytotoxicity of ACNU in both C6 and C6/ACNU rat glioma cells in vitro and also to enhance the chemotherapeutic effect of ACNU in C6/ACNU-bearing rats (C6/ACNU meningeal gliomatosis rats), in which ACNU resistance could be partially overcome by reserpine. "( [Overcoming of ACNU resistance in a subline of rat glioma in vitro and in vivo by reserpine].
Hayakawa, T; Mogami, H; Sakamoto, Y; Shimizu, K; Ushio, Y; Yoshida, T, 1986
)
1.94
"Reserpine was found to enhance the cytotoxicity of ACNU on ACNU-resistant C6 glioma (C6/ACNU) cells in vitro. "( Enhanced effect of reserpine upon growth-inhibitory action of ACNU on ACNU-resistant C6 glioma.
Hayakawa, T; Mogami, H; Sakamoto, Y; Shimizu, K; Ushio, Y; Yoshida, T, 1986
)
2.04
"The reserpine-induced increase in NIL glandular kallikrein was completely blocked by concurrent administration of bromocriptine: this effect was blocked by haloperidol."( Dopaminergic regulation of glandular kallikrein in the intermediate lobe of the rat pituitary.
Powers, CA, 1986
)
0.75
"The reserpine-induced increase in content of NPY-LI in the stellate ganglion was also inhibited by clonidine and oxymetazoline.(ABSTRACT TRUNCATED AT 250 WORDS)"( Differential effects of clonidine and reserpine treatment on neuropeptide Y content in some sympathetically innervated tissues of the guinea-pig.
Franco-Cereceda, A; Lundberg, JM; Nagata, M; Svensson, TH, 1987
)
1.02
"Reserpine did not inhibit depletion of catecholamines produced by 6-hydroxydopamine.7."( Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine.
Breese, GR; Traylor, TD, 1971
)
0.97

Treatment

B-HT 958 produced a most a weak locomotion and no change in the apomorphine-induced increase in motor activity. In reserpine-pretreated animals administration of clonidine (0.5 mg/kg) potentiated the GH releasing effect of morphine.

ExcerptReferenceRelevance
"Reserpine treatment significantly reduced the pain threshold in the pressure application measurement (PAM) and electronic von frey (eVF) test."( Skimmetin/osthole mitigates pain-depression dyad via inhibiting inflammatory and oxidative stress-mediated neurotransmitter dysregulation.
Bhatti, R; Garg, S; Kaur, A; Singh, L, 2021
)
1.34
"The reserpine-treated animals were subdivided into: Reserpine, Hesperetin (10 and 20 mg/kg), ECT and ECT+Hesperetin (10 and 20 mg/kg)."( Hesperetin ameliorates electroconvulsive therapy-induced memory impairment through regulation of hippocampal BDNF and oxidative stress in a rat model of depression.
Alizadeh Makvandi, A; Amiri Moghaddam, S; Khalili, M; Roghani, M, 2021
)
1.1
"The reserpine treated larvae had an impaired histamine-dependent dark-induced flash response seen during the first second after onset of darkness, implying that function of the histaminergic network is VMAT2 dependent."( Storage of neural histamine and histaminergic neurotransmission is VMAT2 dependent in the zebrafish.
Panula, P; Puttonen, HAJ; Semenova, S; Sundvik, M, 2017
)
0.94
"Reserpine treatment increased GFAP-ir in both WT and iNOS KO."( Differential behavioral and glial responses induced by dopaminergic mechanisms in the iNOS knockout mice.
Abreu, GHD; Bortolanza, M; Del-Bel, E; Duarte, T; Issy, AC; Nascimento, GC; Tristão, FS, 2018
)
1.2
"The reserpine-treated animal may be useful for the research of not only fibromyalgia syndrome but also FSS, especially for the research focusing on the hypothesis that FSS is associated with the disturbance of endogenous monoamine system."( Monoamine system disruption induces functional somatic syndromes associated symptomatology in mice.
Azuma, R; Kawasaki, S; Miwa, M; Murai, S; Nagakura, Y; Ohsaka, N; Saito, H; Takahashi, S; Takebayashi, Y, 2018
)
0.96
"Reserpine treatment in rodents has been shown to induce depression-like behaviors that mimic monoamine dysfunction implicated in the development of depression. "( BDNF mediates the protective effects of scopolamine in reserpine-induced depression-like behaviors via up-regulation of 5-HTT and TPH1.
Chen, Z; Lv, D; Shen, M; Wang, C; Yu, H; Zhang, Y; Zhou, D, 2019
)
2.2
"Reserpine treatment was found to cause an increased anxiety as revealed by increased time spent in closed arm of the elevated plus maze (EPM)."( Ameliorative effect of imperatorin in chemically induced fibromyalgia: Role of NMDA/NFkB mediated downstream signaling.
Bhatti, MS; Bhatti, R; Kaur, A; Singh, L; Singh, N, 2019
)
1.24
"The reserpine treated mice were tested with thermal hyperalgesia, mechanicial allodynia and forced swimming tests, and the SOD and NO levels of hippocampus and frontal cortex were measured."( [Influence of ferulic acid on the pain-depression dyad induced by reserpine].
Pan, JC; Shi, HM; Wang, QD; Zhang, L, 2013
)
1.11
"Reserpine treatment led to remarkable down-regulation of cardiac-specific genes, proteins and mesodermal marker genes."( Evidence for a critical role of catecholamines for cardiomyocyte lineage commitment in murine embryonic stem cells.
Hescheler, J; Lehmann, M; Nguemo, F; Pfannkuche, K; Reppel, M; Wagh, V, 2013
)
1.11
"Reserpine treatment increased VCMs and decreased locomotor activity."( Effect of Hypericum perforatum on different models of movement disorders in rats.
Athayde, ML; Boligon, AA; Busanello, A; Fachinetto, R; Leal, CQ; Reckziegel, P; Reis, EM; Röpke, J; Wagner, C, 2013
)
1.11
"Reserpine treatment significantly increased the immobility time in the forced swim test, which is indicative of depression in the animals."( The effects of Phα1β, a spider toxin, calcium channel blocker, in a mouse fibromyalgia model.
Castro, CJ; da Costa Lopes, AM; da Silva, CA; da Silva, JF; de Souza, AH; Ferreira, J; Gomez, MV; Klein, CP; Pereira, EM, 2014
)
1.12
"Reserpine treatment elevated CD8+ and 5-HT7 cells."( 5-HT7 receptors and tryptophan hydroxylase in lymphocytes of rats: mitogen activation, physical restraint or treatment with reserpine.
Arroyo, R; Lima, L; Urbina, M, 2014
)
1.33
"Reserpine treatment inhibits the active efflux of Enterococcus species to ciprofloxacin, gatifloxacin and levofloxacin in vitro and reduces the MIC of Enterococcus species to these three fluoroquinolones."( Prevalence and antimicrobial resistance of Enterococcus species: a hospital-based study in China.
Jia, W; Li, G; Wang, W, 2014
)
1.12
"Reserpine treatment elongated the striatal neuronal cilia in D1-null mice but not in D2-null mice."( Lack of dopaminergic inputs elongates the primary cilia of striatal neurons.
Asanuma, M; Kasahara, K; Katayama, T; Kumamoto, N; Matsuzaki, S; Miyazaki, I; Miyoshi, K; Murakami, S; Sasaoka, T; Sato, A; Takeshima, M, 2014
)
1.12
"Reserpine treatment (1mg/kgs.c."( (-) Epigallocatechin-3-gallate attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum.
Chang, KC; Lin, RF; Soung, HS; Tsai, CC; Tseng, HC; Wang, MH, 2015
)
1.4
"Reserpine treatment induced the formation of enlarged autophagosomes by inhibiting the autophagic flux and led to accumulation of p62, an autophagy adapter molecule."( The anti-hypertensive drug reserpine induces neuronal cell death through inhibition of autophagic flux.
Kim, MJ; Koh, H; Lee, JI; Lee, KI; Namkoong, S; Oh, WK; Park, J, 2015
)
1.44
"Reserpine-treated mice displayed locomotor activity deficits in the open field and agmatine had no effect on this response."( Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptors.
Blum-Silva, CH; Colle, D; Cunha, AS; Cunha, MP; Farina, M; Matheus, FC; Moretti, M; Poli, A; Prediger, RD; Reginatto, FH; Rodrigues, AL; Sampaio, TB; Sandjo, LP; Santos, DB, 2016
)
1.48
"Reserpine treatment led to decreased NE re-uptake at 1d and 5d compared to saline treatment."( Depletion of cardiac catecholamine stores impairs cardiac norepinephrine re-uptake by downregulation of the norepinephrine transporter.
Buss, SJ; Haass, M; Katus, HA; Kreusser, MM; Lehmann, LH; Lossnitzer, D, 2017
)
1.18
"Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however, coadministration of Hibiscus rosa sinensis roots extract (100, 200 and 300 mg/kg, per orally) attenuated the effects."( Effect of Hibiscus rosa sinensis on reserpine-induced neurobehavioral and biochemical alterations in rats.
Dwivedi, S; Kawale, LA; Nade, VS; Upasani, CD; Yadav, AV, 2009
)
1.35
"Reserpine-treated animals also showed poor retention of memory in the elevated plus maze paradigm."( Korean ginseng extract attenuates reserpine-induced orofacial dyskinesia and improves cognitive dysfunction in rats.
Barhate, SA; Kasture, SB; Mahajan, MS; Mohan, M; Sanghavi, CR, 2011
)
1.37
"Reserpine treatment is a putative animal model of orofacial dyskinesia, tremor, and Parkinsonism. "( Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice.
Barbosa, NB; Barreto, KP; Burger, ME; Busanello, A; Fachinetto, R; Farias, LE; Peroza, LR, 2011
)
2.04
"Reserpine treatment increased both CPE and PC activity in extracts of cultured chromaffin cells; total protein levels were unaltered for any enzyme."( Regulation of neuropeptide processing enzymes by catecholamines in endocrine cells.
Fricker, LD; Helwig, M; Lindberg, I; Vivoli, M, 2011
)
1.09
"Reserpine treatment of males reduced sperm transfer in a dose-dependent manner."( Effects of reserpine on reproduction and serotonin immunoreactivity in the stable fly Stomoxys calcitrans (L.).
Li, AY; Liu, SS; Pérez de León, AA; Witt, CM, 2013
)
1.5
"In reserpine-treated rats (97% decrease in endogenous norepinephrine content of the heart), the amplitude of the transient outward current was decreased by 48% and Kv4.2 and Kv4.3 mRNA levels were decreased by 57% and 34%, respectively."( Expression of heart K+ channels in adrenalectomized and catecholamine-depleted reserpine-treated rats.
Bru-Mercier, G; Capuano, V; Coulombe, A; Deroubaix, E; Renaud, JF; Ruchon, Y; Rücker-Martin, C, 2003
)
1.06
"Reserpine treatment did not significantly alter pre- or post-ischaemic adenosine efflux."( Enhanced adenosine A(2B) mediated coronary response in reserpinised rat heart.
Harrison, GJ; Headrick, JP; Rose'Meyer, RB, 2003
)
1.04
"Reserpine treatment did not alter the mechanical efficiency of the heart despite its depletion of noradrenaline."( The effect of mephentermine on isolated dog hearts, normal and pretreated with reserpine.
FAWAZ, G, 1961
)
1.19
"Reserpine pretreatment of cats abolished the action of ephedrine to induce spontaneous beating in papillary muscles obtained from these animals. "( Effect of reserpine pretreatment on the response of isolated papillary muscle to ephedrine.
CAIROLI, VJ; REILLY, JF; ROBERTS, J, 1962
)
2.09
"In reserpine-treated rats, unilateral injection of L-SOP (2000 and 2500 nmol in 2.5 microl) into the GP produced a significant increase in net contraversive rotations compared to vehicle, reaching a maximum of 83+/-21 rotations 120 min(-1) (n=8)."( Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat.
Duty, S; MacInnes, N; Messenger, MJ, 2004
)
1.04
"Reserpine-treated animals also showed poor retention of memory in elevated plus-maze task paradigm."( Reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction by quercetin.
Kulkarni, SK; Naidu, PS; Singh, A, 2004
)
1.42
"Reserpine treatment (5 mg/kg) produced a significant increase in the urinary excretion of VMA, 5-HIAA and HVA while RMN at doses of equal to and double the equimolar doses of reserpine (5 and 10 mg/kg) produced significant increase in VMA and 5-HIAA excretion without producing any effect on HVA excretion compared to control animals. "( Reserpine methonitrate, a novel quaternary analogue of reserpine augments urinary excretion of VMA and 5-HIAA without affecting HVA in rats.
Boini, KM; Nammi, S; Sreemantula, S, 2004
)
3.21
"Reserpine treated animals also showed poor retention of memory in the elevated plus maze task paradigm."( Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction.
Kulkarni, SK; Naidu, PS; Singh, A, 2006
)
1.31
"reserpine-treated rats and adding samples of heart and brown adipose tissue to the testing."( Depletion and recovery of catecholamines in several organs of rats treated with reserpine.
Martínez-Olivares, R; Piñón, M; Racotta, R; Villanueva, I, 2006
)
1.28
"In reserpine-treated animals, specific delta opioid binding was increased in premotor cortex (+30%), sensorimotor striatum (+20%), and associative striatum (+17%) rostrally, but was not changed in caudal forebrain."( Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia.
Brotchie, JM; Hallett, PJ, 2007
)
0.85
"Reserpine treatment makes the worms highly thermotolerant."( Reserpine can confer stress tolerance and lifespan extension in the nematode C. elegans.
Arya, U; Dwivedi, H; Kumar, S; SoundaraRajan, T; Srivastava, D; Subramaniam, JR, 2008
)
2.51
"Reserpine treatment was found to cause an 50% increase in the noradrenaline-stimulated cyclic AMP accumulation, while treatment with imipramine and the combination lithium-imipramine decreased the noradrenaline-stimulated cyclic AMP accumulation by 40%."( No change in rat cerebral cortex calmodulin content following chronic treatment with lithium, reserpine, imipramine, and lithium combined with reserpine or imipramine.
Andersen, PH; Geisler, A; Klysner, R, 1984
)
1.21
"In reserpine pretreated rats apomorphine produced an increase in type I inhibitor activity after about 5 times lower doses than in control rats."( Effect of supersensitivity of pre- and postsynaptic dopamine receptors on the activity of endogenous inhibitor of cAMP dependent protein kinase in rat striatum.
Szadowska, A; Szmigielska, H; Szmigielski, A, 1984
)
0.78
"Reserpine-pretreated tissues developed hypersensitivity to catecholamines, while acetylcholine produced effects similar to those observed in control preparations."( The effects of drugs on pacemaker regions of isolated rabbit renal pelvis.
Bernardini, C; Constantinou, CE; Del Tacca, M, 1981
)
0.98
"Reserpine treatment or insulin-induced hypoglycemia in rats produces a statistically significant increase in the tetrahydrobiopterin content of both the adrenal medulla and the cortex."( Tetrahydrobiopterin increases in adrenal medulla and cortex: a factor in the regulation of tyrosine hydroxylase.
Abou-Donia, MM; Viveros, OH, 1981
)
0.98
"Reserpine pretreatment (5 mg/kg, i.p., 24 h) did not alter the responses to histamine and PEA."( Identification and specific blockade of histaminergic receptors in guinea pig vasa deferentia.
Joshi, DP; Verma, SC, 1981
)
0.98
"Reserpine pretreatment abolished the inhibitory effect of CPZ on the MSR."( Supraspinal tonic influence on spinal reflexes and involvement in the effect of chlorpromazine.
Fukuda, H; Hino, M; Ono, H, 1984
)
0.99
"In reserpine-treated mice, B-HT 958 produced a most a weak locomotion and no change in the apomorphine-induced increase in motor activity."( B-HT 958 stimulates dopamine autoreceptors but blocks noradrenaline autoreceptors in the brain.
Andén, NE; Grabowska-Andén, M, 1984
)
0.78
"Reserpine pretreatment, at intervals of 1--21 days prior to [3H]-fucose or leucine injection into the LC, resulted in marked alterations in the turnover of [3H]glycoproteins and proteins in the LC and hypothalamus which were present for up to 14 days and varied according to the time after reserpine pretreatment."( Effects of reserpine on fast, intermediate and slow axonal transport of proteins in rat locus coeruleus neurons.
Levin, BE, 1980
)
1.37
"Reserpine pretreatment and pindolol did not affect the direct action of adenosine."( Modification by islet-activating protein of direct and indirect inhibitory actions of adenosine on rat atrial contraction in relation to cyclic nucleotide metabolism.
Endoh, M; Maruyama, M; Taira, N,
)
0.85
"Reserpine pretreatment prevented most of the changes such as the early increase in dopamine metabolites."( [The effects of cerebral ischemia on the level of metabolites of dopamine and serotonin in the rat cerebrospinal fluid].
Capdeville, C; Ceballos, I; Elghozi, JL; Laude, D,
)
0.85
"In reserpine-pretreated animals administration of clonidine (0.5 mg/kg) potentiated the GH releasing effect of morphine."( Importance of norepinephrine alpha 2-receptor activation for morphine-induced rat growth hormone secretion.
Edén, S; Eriksson, E; Modigh, K, 1981
)
0.78
"Reserpine treatment depleted the skin flaps of noradrenaline and counteracted the fall in ATP and the cyclic AMP accumulation."( On the mechanism by which antiadrenergic drugs increase survival of critical skin flaps.
Fredholm, BB; Hjemdahl, P; Jurell, G, 1983
)
0.99
"Reserpine pretreatment markedly diminished the inhibition of spontaneous or field-stimulated phasic contractions by distention or field stimulation of a distal site."( Neurotensin inhibition of canine intestinal motility in vivo via alpha-adrenoceptors.
Daniel, EE; Fox, JE; Jury, J; Sakai, Y, 1984
)
0.99
"Reserpine pretreatment reduced ECS threshold and decreased the anticonvulsant effect of d-amphetamine in chicks."( Studies on the pharmacology of d-amphetamine on maximal electroconvulsive seizure in young chicks.
Ngur, D; Osuide, G; Wambebe, C, 1983
)
0.99
"In reserpine-treated mesenteric arteries also, electrical transmural stimulation produced a contraction and this was neither suppressed nor potentiated by prazosin and other alpha antagonists but was attenuated by alpha-2 agonists."( Nonadrenergic nature of prazosin-resistant, sympathetic contraction in the dog mesenteric artery.
Kigoshi, S; Muramatsu, I; Oshita, M, 1984
)
0.78
"Reserpine pretreatment did not affect basal activity or histamine-stimulated adenylate cyclase activity."( Enhanced serotonin-stimulated adenylate cyclase activity in membranes from adult guinea pig hippocampus.
Green, JP; Maayani, S; Shenker, A; Weinstein, H, 1983
)
0.99
"Reserpine pretreatment significantly reduced the volume of saline required to elicit the micturition reflex."( Reserpine-induced detrusor hyperreflexia: an in vivo model for studying smooth muscle relaxants at urinary bladder level.
Maggi, CA; Meli, A, 1983
)
2.43
"Reserpine treatment in doses of 1.0 and 5.0 mg/kg body weight, given 6 h before antigen challenge significantly suppresses the contact sensitivity reaction to picryl chloride in sensitized mice. "( Reserpine and the suppression of both edema formation and cellular infiltrate of the contact sensitivity reaction in the mouse.
Bäck, O; Groth, O, 1983
)
3.15
"Reserpine pretreatment exacerbated this syndrome of inactivity in pCA more than in FpCA rats even though the reserpinized groups did not differ from each other in the concentrations of the three amines."( P-chloroamphetamine and a side-chain fluorinated analog: effects on brain amine levels and behavior.
Baker, GB; Beck, CH; Chow, HL; Coutts, RT, 1984
)
0.99
"Reserpine pretreatment increased slopes of these regression lines for adenosine, nitroglycerin, acetylcholine and isoproterenol, suggesting a general enhancement of vasodilator responses by reserpine."( Effect of reserpine pretreatment on in vivo femoral arterial responses to vasodilator agents.
Cauvin, CA; Devia, CJ; Kirkendol, PL, 1981
)
1.39
"Reserpine treatment decreased the growth of both tumors, whether unseparated or tumor-cell-enriched, and whether injected into the foot or the flank."( I. Tumor growth in mice with depressed capacity to mount inflammatory responses: possible role of macrophages.
Hopper, KE; Nelson, DS; Nelson, M, 1981
)
0.98
"Reserpine treatment induced supersensitivity in the aorta to KCl, but not to either NA or 5-HT in normal medium, whereas in Mg++-free medium, it induced partial contraction and inhibited both maximal responses and sensitivity to NA and 5-HT but not to KCl."( Effect of reserpine on Mg++-induced calcium fluxes and reactivity of the rat aorta.
Krishnamurty, VS; Mukherjee, A, 1981
)
1.39
"Reserpine-treated rats contained 1.4 times more mucin in intestinal tissue than control rats (P less than 0.05) and incorporated [1-14C]glucosamine in vivo at 1.52 times the rate of controls (P less than 0.01)."( Intestinal secretion of mucin in chronically reserpine-treated rats.
Forstner, J; Maxwell, B; Roomi, N, 1981
)
1.24
"3. Reserpine pretreated tissues were supersensitive to glyceryl trinitrate, but not to adenosine or hydralazine."( Effect of reserpine on relaxant responses of canine femoral arterial strips.
Cauvin, CA; Devia, CJ; Kirkendol, PL,
)
1.05
"Reserpine pretreatment of SCG did not affect [3H]XYL accumulation."( Xylamine, an irreversible inhibitor of norepinephrine uptake, is transported by this same uptake mechanism in cultured rat superior cervical ganglia.
Cho, AK; Fischer, JB; Ransom, RW; Waggaman, LA, 1983
)
0.99
"Reserpine treatment moderately increases the number of immunostainable LHRH cells, while ovariectomy is ineffective in this respect."( Immunohistochemical study of the LHRH-synthesizing neuron system of aged female rats.
Horváth, J; Lengvári, I; Merchenthaler, I; Sétáló, G, 1980
)
0.98
"In reserpine-treated animals, tyrosine administration (200 mg/kg, i.p.) caused further increases in brain tyrosine, DOPAC, and HVA, but not in brain MHPG-SO4."( Effect of tyrosine on brain catecholamine turnover in reserpine-treated rats.
Oishi, T; Wurtman, RJ, 1982
)
1.03
"Reserpine pretreatment increased the inotropic potency (pD2) of dl-isoproterenol (beta), but had no effect on the potencies of histamine (H2), phenylephrine (alpha) or pyridylethylamine (H1)."( Effect of reserpine pretreatment on guinea pig ventricular performance and responsiveness to inotropic agents.
McNeill, JH; Rodgers, RL, 1982
)
1.39
"In reserpine pretreated hearts, in which we observed a marked increase in the number of glycogen granules (Fig."( [Protective effect of endogenous catecholamine depletion against hypoxic and reoxygenation damage in isolated rat heart: an ultrastructural study (author's transl)].
de Leiris, J; Feuvray, D; James, F, 1980
)
0.78
"Reserpine treatment depletes the catecholamine content in diverse parts of the brain differently. "( [Central depletion of transmitters by reserpine and motor behavior in the rat (author's transl)].
Funk, KF; Schmidt, J; Westermann, KH, 1980
)
1.97
"(5) Reserpine pretreatment completely abolished the responses to histamine and 4 MH in the rat uterus but did not alter the response in the guinea pig uterus."( Pharmacological investigations into the effects of histamine and histamine analogs on guinea pig and rat uterus.
Goyal, RK; Verma, SC, 1981
)
0.74
"Reserpine retreatment prevented the hypotensive and enhanced the hypertensive response to dopamine, and in this situation dopamine induced cardiac arrhythmia."( Enhancement of blood pressure response to dopamine by angiotensin II.
Perez-Olea, J; Quevedo, M; Silva, R,
)
0.85
"Reserpine pre-treatment potentiated lower doses of NA and the threshold dose of NA was significantly decreased."( Comparative studies of the effects of 5-hydroxytryptamine and noradrenaline on the rat anococcygeus muscle.
Goyal, RK; Patel, NM; Verma, SC, 1981
)
0.98
"Reserpine treatment (5 mg/kg, i.p., 18 h before sacrifice) induced marked gastric glandular ulceration and elicited the release of free beta-glucuronidase from lysosomes in the gastric mucosa."( Reserpine-induced gastric ulcers: protection by lysosomal stabilization due to zinc.
Cheema, A; Cho, CH; Pfeiffer, CJ; Saltman, D, 1980
)
2.43
"In reserpine-treated rabbits the pressor response to raised ICP was not observed."( Clonidine on the pressor response to raised intracranial pressure.
Kim, YI; Kim, YJ; Lee, JH; Woo, JH, 1980
)
0.78
"Reserpine pretreatment almost abolished the response and after-response."( The isolated circular muscle layer of the vas deferens of the guinea-pig.
Anstey, MD; Birmingham, AT, 1980
)
0.98
"Reserpine pretreatment enhanced 45Ca++ efflux from rat aorta without a changed in 45Ca++ uptake in normal Mg++-free medium."( Influences of Mg++ and reserpine on calcium fluxes and sensitivity of the rat aorta.
Gulati, OD; Krishnamurty, VS, 1980
)
1.29
"Reserpine pretreatment abolished the inotropic response of histamine in the rat heart."( Effects of histamine on rat isolated atria.
Laher, I; McNeill, JH, 1980
)
0.98
"Reserpine treatment resulted in altered enzyme secretion from rat pancreatic acini in response to carbamylcholine and secretin (1,2). "( Alterations of pancreatic amylase secretion in the reserpinized rat model of cystic fibrosis. Effects of cerulein and EGF.
Benrezzak, O; Bérubé, FL; Morisset, J; Vanier, M, 1994
)
1.73
"Reserpine treatment also increased the expression of nNOS protein; however, reserpine treatment did not affect the distribution pattern of nNOS-positive cells (NADPH-diaphorase-positive cells) in the adrenal medulla.(ABSTRACT TRUNCATED AT 250 WORDS)"( Regulation of neuronal nitric oxide synthase in rat adrenal medulla.
Hanai, K; Iwai, N; Kinoshita, M; Kitamura, Y; Tooyama, I, 1995
)
1.01
"Reserpine treatment potentiated the positive inotropic response of isolated perfused hearts to histamine at doses ranging from 0.3 to 3 micrograms (23 to 57% increase for reserpine-treated animals vs."( Hyperresponsiveness of cardiac muscles to histamine in reserpine-treated guinea pigs.
Nasa, Y; Okazaki, N; Takagi, N; Takeo, S; Tanonaka, K; Yamasaki, T; Yoshida, S, 1994
)
1.26
"Reserpine pretreatment did not affect the response to ischaemia or to preconditioning, although LDH release tended to be greater than in normal hearts, especially in the non-preconditioned group."( Endogenous catecholamines are not necessary for ischaemic preconditioning in the isolated perfused rat heart.
Baird, AJ; Dzwonczyk, S; Grover, GJ; Murray, HN; Sleph, PG; Weselcouch, EO, 1995
)
1.01
"Both reserpine pretreatments enhanced the amplitude of reflex bladder contractions."( Interactions between glutamatergic and monoaminergic systems controlling the micturition reflex in the urethane-anesthetized rat.
de Groat, WC; Roppolo, JR; Yoshiyama, M, 1994
)
0.74
"In reserpine- and prazosin-treated anesthetized fowl, [Val5]ANG II caused dose-dependent vasodepressor actions inhibited by neither losartan (10 mg/kg) nor PD-123319 (10 mg/kg)."( Novel angiotensin receptor subtypes in fowl.
Chiu, AT; Keiser, J; Madison, AB; Nishimura, H; Patton, CM; Walker, OE, 1994
)
0.8
"Reserpine treatment was used to examine whether short- and long-term neural stimulation regulates rat adrenal medullary dopamine beta-hydroxylase (DBH, EC 1.14.17.1) through transcriptional activation and to examine the extent of coordinate control of DBH and phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28). "( Neural control of dopamine beta-hydroxylase in vivo: acute and chronic effects.
Wang, W; Wong, DL, 1994
)
1.73
"Reserpine pretreatment (5 mg kg-1, 18 h) totally eliminated the nitrous oxide effect but not that of amphetamine (5 mg kg-1)."( Locomotor effects of nitrous oxide in mice: requirement of newly-synthesized and main intraneuronal storage pools of dopamine.
Dorris, RL; Truong, V, 1993
)
1.01
"Reserpine pretreatment significantly depleted tissue and decreased plasma norepinephrine levels; tracer norepinephrine uptake increased slightly, and there was a substantial decrease in the rate of release of unlabeled norepinephrine."( Constitutive nonexocytotic norepinephrine release in sympathetic curves of in situ canine heart.
Cousineau, D; De Champlain, J; Goresky, CA; Rose, CP, 1994
)
1.01
"Reserpine treatment significantly reduced total wheel-running activity and the monoamine levels in the hypothalamus, striatum and pons/medulla.(ABSTRACT TRUNCATED AT 250 WORDS)"( Monoamine depletion alters the entrainment and the response to light of the circadian activity rhythm in hamsters.
Penev, PD; Turek, FW; Zee, PC, 1993
)
1.01
"Reserpine treatment produced a 50% decrease in both the Bmax and the apparent Kd in the corpus striatum and nucleus accumbens, but binding parameters in the cortex and septum were unaltered."( Altered histamine H3 binding in rat forebrain after reserpine treatment.
Cumming, P; Vincent, SR, 1993
)
1.26
"Reserpine treatment caused a significant decrease in immunoreactivity to the neuronal isoform of NOS in the nerve fibres that innervate adrenal medullary cells. "( Effect of reserpine treatment and hypophysectomy on the nitric oxide synthase immunoreactivity and NADPH-diaphorase staining in the rat adrenal gland.
Afework, M; Burnstock, G, 1996
)
2.14
"Reserpine pretreatment was associated with an increase in NPY mRNA levels in both types of ganglia."( Reserpine-induced increases in neuropeptide Y mRNA of guinea pig sympathetic ganglia using in situ hybridization.
Dey, RD; Huffman, LJ; Schmidt, EA, 1996
)
2.46
"In reserpine-treated animals, alpha 2-adrenoceptor, clonidine, induced antinociception and increased that of baclofen."( Opposite influences of different adrenoceptors on baclofen-induced antinociception in mice.
Doost-Mohammady, R; Sabetkasai, M; Zarrindast, MR, 1997
)
0.81
"Reserpine pretreated rat hearts also showed significant decrease in tracer retention of 95% compared to controls."( Myocardial kinetics of carbon-11-epinephrine in the isolated working rat heart.
Chakraborty, P; DeGrado, TR; Nguyen, NT; Schwaiger, M; Wieland, DM, 1997
)
1.02
"In reserpine-treated rats, basal levels of dopamine in the SNr were greatly reduced, and were further lowered by focal application of NMDA antagonists, suggestive of the removal of a high glutamatergic tone."( Dopamine and glutamate control each other's release in the basal ganglia: a microdialysis study of the entopeduncular nucleus and substantia nigra.
Biggs, CS; Starr, MS, 1997
)
0.81
"Reserpine treatment leads to a rapid trans-synaptic increase of the tyrosine hydroxylase (TH) gene transcription rate and mRNA levels in catecholaminergic tissues including the adrenal medulla (AM) and the superior cervical ganglia (SCG). "( AP-1 mediates trans-synaptic induction of tyrosine hydroxylase gene expression in adrenal medulla but not in superior cervical ganglia.
Biguet, NF; Mallet, J; Trocmé, C, 1997
)
1.74
"Reserpine treatment decreased the extracellular dopamine concentration in both regions below the detection level (<10% of basal value)."( 3-Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra.
Bergquist, F; Elverfors, A; Jonason, J; Lagerkvist, S; Nissbrandt, H; Pileblad, E, 1997
)
1.02
"Reserpine pretreatment attenuated this protective effect of preconditioning on reperfusion-induced arrhythmias."( The possible role of adrenergic component in ischemic preconditioning.
Sharma, A; Singh, M, 1997
)
1.02
"Reserpine treatment decreased striatal guanosine by 41% and increased guanine by 50%, while LD decreased guanosine by 48% (all p < 0.01 vs."( Altered guanosine and guanine concentrations in rabbit striatum following increased dopamine turnover.
Camp, DM; DeMaggio, AJ; Juneau, PL; LeWitt, PA; Loeffler, DA; Matson, WR; Milbury, P; Rathbone, MP, 1998
)
1.02
"Reserpine pre-treatment caused reductions in core body temperature; heating the rats to normal body temperature for 3 h prior to AMPH or MDMA, and during the 4 h post-treatment period partially reversed the reserpine-induced attenuation of dopamine release."( Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis.
Sabol, KE; Seiden, LS, 1998
)
2.46
"Reserpine treatment also enhanced the sustained [Ca2+]i increase following these stimuli."( Alterations in Ca2+ storage and mobilization in submandibular acinar cells of reserpine-treated rats.
Helmke, RJ; Martinez, JR; Mörk, AC; Sugita, K; Zhang, GH, 1998
)
1.25
"Reserpine pretreatment did not affect the positive inotropic response to NKA."( Characterization of responses to neurokinin A in the isolated perfused guinea pig heart.
Chang, Y; Hancock, JC; Hoover, DB, 1998
)
1.02
"Reserpine treatment increased both basal and maximal striatal DA-stimulated 35S-GTP-gamma-S binding."( Effects of single and multiple treatments with L-dihydroxyphenylalanine (L-DOPA) on dopamine receptor-G protein interactions and supersensitive immediate early gene responses in striata of rats after reserpine treatment or with unilateral nigrostriatal le
Bennett, JP; Khan, SM; Smith, TS, 1999
)
1.21
"Reserpine pretreatment did not affect amphetamine-mediated dopamine release from either pretreatment group but completely ablated K+-mediated dopamine release."( Enhanced amphetamine- and K+-mediated dopamine release in rat striatum after repeated amphetamine: differential requirements for Ca2+- and calmodulin-dependent phosphorylation and synaptic vesicles.
Gnegy, ME; Hewlett, GH; Kantor, L, 1999
)
1.02
"Reserpine treatment resulted in decreased respiratory activity in liver and brain mitochondria with the two NAD+-linked substrates: glutamate and pyruvate + malate with succinate ATP synthesis rate decreased in liver mitochondria only."( Effect of catecholamine depletion on oxidative energy metabolism in rat liver, brain and heart mitochondria; use of reserpine.
Dave, KR; Katyare, SS; Shukla, VH, 2000
)
1.24
"Reserpine treatment depleted endogenous dopamine by more than 90% and significantly increased the binding of [(125)I]NCQ 298 to D2 receptors in the nucleus accumbens, ventral pallidum, and substantia nigra."( Differential regulation of dopamine D2 and D3 receptors by chronic drug treatments.
Lucki, I; McGonigle, P; Stanwood, GD, 2000
)
1.03
"Reserpine treatment caused a topographically organized reduction in CB1 receptor mRNA expression in the striatum (ranging from 11.6% medially to 53.6% laterally and dorsally)."( Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.
Brotchie, JM; Crossman, AR; McGuire, S; McInnes, A; Silverdale, MA, 2001
)
1.27
"Reserpine treatment alone did not change the levels of DA or 2,3-DHBA, while the combined treatment with both MPP(+) and reserpine clearly decreased 2,3-DHBA, as well as DA levels, compared to those in the group treated with MPP(+) alone."( Release of dopamine by perfusion with 1-methyl-4-phenylpyridinium ion (MPP(+)) into the striatum is associated with hydroxyl free radical generation.
Kinemuchi, H; Obata, T; Oreland, L; Yamanaka, Y, 2001
)
1.03
"Reserpine treatment leads to a trans-synaptic increase of the tyrosine hydroxylase (TH) gene transcription rate, mRNA and protein levels in catecholaminergic tissues including the adrenal medulla (AM) and the superior cervical ganglia (SCG). "( CREM and ICER are differentially implicated in trans-synaptic induction of tyrosine hydroxylase gene expression in adrenal medulla and sympathetic ganglia of rat.
Biguet, NF; Mallet, J; Ravassard, P; Sassone-Corsi, P; Trocmé, C, 2001
)
1.75
"in reserpine-treated monkeys; 0.01-0.1 mg/kg, i.m."( Effect of huperzine A on working memory in reserpine- or yohimbine-treated monkeys.
Cai, JX; Ou, LY; Tang, XC, 2001
)
1.09
"Reserpine treatment decreased tissue norepinephrine content by 97%."( Depressed transient outward potassium current density in catecholamine-depleted rat ventricular myocytes.
Bru-Mercier, G; Coulombe, A; Deroubaix, E; Renaud, JF; Rousseau, D, 2002
)
1.04
"Reserpine treatment produced a slow decrease in self-stimulation (SS) rates during the first 12 h; SS rates were 85% of control values 24 h after reserpine treatment."( Effects of various inhibitors of tyrosine hydroxylase and dopamine beta-hydroxylase on rat self-stimulation after reserpine treatment.
Cardo, B; Stinus, L; Thierry, AM, 1976
)
1.19
"Reserpine pretreatment resulted in a 3-fold increase in locomotor activity following injection of d-amphetamine, 5 mg/kg."( Changes in brain norepinephrine associated with sensitization to d-amphetamine.
Short, PH; Shuster, L, 1976
)
0.98
"Reserpine pretreatment antagonized the CK release by electrical fibrillation, whereas it increased excessively the enzyme liberating effect of higher digoxin concentrations."( Digoxin induced release of creatine kinase from isolated guinea-pig hearts.
Bernauer, W, 1979
)
0.98
"Reserpine treatment decreased the enhanced stereotype activity after D- and L-amphetamine but did not decrease the effect on the copulatory behaviour."( The effects of different amphetamines on copulatory behaviour and stereotype activity in the female rat, after treatment with monoamine depletors and synthesis inhibitors.
Meyerson, BJ; Michanek, A, 1977
)
0.98
"Reserpine treatment also produced stimulation of taurine influx with no effect on biosynthesis."( The effects of isoproterenol on taurine concentration in the rat heart.
Chubb, J; Huxtable, R, 1978
)
0.98
"Reserpine pretreatment markedly reduced basal SMA levels; such pretreatment caused both d- and l-amphetamine to act as stimulants of SMA."( Drug interactions with brain biogenic amines and the effects of amphetamine isomers on locomotor activity.
Levine, RM; Maickel, RP; Zabik, JE, 1978
)
0.98
"Reserpine treatment resulted in a marked increase in the number of granulated vesicles during the dark, but led to a slight decrease during the photoperiod."( Effects of reserpine and p-chlorophenylalanine on the circadian rhythm of granulated vesicles in the pinealocytes of mice.
Benson, B; Krasovich, M, 1979
)
1.37
"Reserpine treatment produced a marked decrease of the in vitro binding of estradiol to the nuclear fraction of the uterus. "( Reserpine induced changes in the estradiol uptake by the pituitary and the uterus in ovariectomized rats.
Endröczi, E; Kovács, Z; Tallián, F, 1975
)
3.14
"Reserpine treatment resulted in a significant decrease in the estradiol-induced increase of uterine weights (p less than .001)."( Reserpine induced changes in the estradiol uptake by the pituitary and the uterus in ovariectomized rats.
Endröczi, E; Kovács, Z; Tallián, F, 1975
)
2.32
"Reserpine pretreatment or propranolol decreased or abolished the phenylephrine-induced biochemical changes without affecting the contractile response."( Biochemical and mechanical effects of phenylephrine on the heart.
McNeill, JH; Verma, SC, 1976
)
0.98
"Reserpine pretreatment did not significantly affect the contractile responses of either amine."( Cyclic AMP and the positive inotropic effect of norepinephrine and phenylephrine.
Martinez, TT; McNeill, JH, 1977
)
0.98
"Reserpine pretreatment does not alter the affinities of either alpha- or beta-receptor 3H-ligands."( 3H-Catecholamine binding to alpha-receptors in rat brain: enhancement by reserpine.
Snyder, SH; U'Prichard, DC, 1978
)
1.21
"Reserpine pretreatment produced a parallel reduction in the response of the aorta to tyramine and mercury."( Catecholamine release: mechanism of mercury-induced vascular smooth muscle contraction.
Hollenberg, NK; Solomon, HS, 1975
)
0.98
"In reserpine-pretreated mice only amphetamine, apomorphine, L-dopa and D.L-threo-dihydroxyphenyl-serine effectively reversed hypothermia."( The role of dopamine and noradrenaline in temperature control of normal and reserpine-pretreated mice.
Cox, B; Tha, SJ, 1975
)
1
"Reserpine pretreatment eliminated the differences between control and withdrawn animals."( Effects of withdrawal from chronic amphetamine intoxication on exploratory and stereotyped behaviors in the rat.
Hitzemann, BA; Hitzemann, RJ; Loh, HH; Sampath-Khanna, S; Tseng, LF, 1977
)
0.98
"Reserpine pretreatment diminished the response of the vas to tyramine; however, methyldopa restored the responses to a greater magnitude suggesting the formation of methyldopamine and methylnoradrenaline."( Methyldopa abolishes neurally evoked contractions of the vas deferens in vitro.
Tayo, FM, 1979
)
0.98
"Reserpine treatment did not change the dissociation constant differences between the two brain regions."( Effect of a single injection of reserpine on kinetics of 3H-dexamethasone binding to receptors of the cat hypothalamus and hippocampus.
Stith, RD; Weingarten, DP, 1979
)
1.26
"Reserpine treatment decreased the fluorescence intensity in the pars intermedia and in thin-layer chromatography, and the staining of the fluorescent band with amido black was also decreased."( Quantitative fluorescence histochemistry of combined formaldehyde-chloral-induced fluorescence of amino-terminal tryptophyl-peptide in model experiments and in the pars intermedia of the rat hypophysis.
Bäck, N; Partanen, S, 1979
)
0.98
"Reserpine treatment increased the amplitude of the spontaneous phasic contraction (SPC) of portal veins obtained from rabbit and guinea pig but did not alter that of rat. "( Calcium influx and spontaneous phasic contractions of portal veins after treatment with reserpine, 6-hydroxydopamine, and cocaine.
Kaiman, M; Shibata, S, 1978
)
1.92
"Reserpine-pretreated or normal rabbit aortic strips (whose noradrenaline-metabolizing enzymes were inhibited by treatment with 0.5 mM pargyline and by the presence of 0.1 mM U-0521) were incubated with 1.18 muM labelled noradrenaline for 30 min. "( The effect of cocaine on the distribution of labelled noradrenaline in rabbit aortic strips and on efflux of radioactivity from the strips.
Eckert, E; Henseling, M; Trendelenburg, U, 1976
)
1.7
"Reserpine-treated rats also showed a significant increase in the total protein recovered in the lung lavage fluid with a 233% increase in the absolute and relative amounts of a low molecular weight glycoprotein (15,000 mol wt)."( The chronically reserpinized rat as a possible animal model for cystic fibrosis. IV. The protein composition of pulmonary lavage fluid.
Martinez, JR; Quissell, DO; Thompson, FE; Williams, CH, 1976
)
0.98
"Reserpine pretreatment or propranolol did not affect contractile responses to DMSO in the absence or presence of atropine."( Cardiac chronotropic mechanisms of dimethyl sulphoxide: inhibition of acetylcholinesterase and antagonism of negative chronotropy by atropine.
Karow, AM; Matheny, JL; Shlafer, M, 1976
)
0.98
"Reserpine pretreatment resulted in a decrease of the kaliuretic fuorsemide effect, whereas after 6-OH-dopamine this decrease could not be observed."( [Effects of diuretics after pretreatment with reserpine and 6-OH-dopamine (author's transl)].
Heidland, A; Hennemann, HM; Hörl, WH, 1976
)
1.24
"Reserpine-treated atria had greater resting and maximum rates of beat than did untreated atria."( The influence of reserpine on the responsiveness to norepinephrine and electrolyte contents of rabbit atria.
Carrier, O; Healy, MD; Ramirez, SG; Turlapaty, PD, 1976
)
1.32
"In reserpine-pretreated mice (5 mg/kg, 24 hours), no relationship was obtained with size, hydrophobic or electronic effects individually or together."( Structure-activity relationships between meta-substituted N-ethylamphetamines and locomotor activity in mice.
Counsell, RE; Lu, M; Tessel, RE; Woods, JH, 1975
)
0.74
"Reserpine treatment of toads caused a concomitant decrease in serotonin and bufotenin in the brain, but not in the skin of the animals."( Determination of serotonin and bufotenin as their dansyl derivatives.
Bruder, K; Seiler, N, 1975
)
0.98
"Reserpine treatment 2 hr after L-DOPA, decreased the amplitude of the AAER but had not marked effect on the neuronal recovery function."( Effects of reserpine and L-DOPA in the globus pallidus of freely behaving rats.
Dafny, N, 1975
)
1.37
"Reserpine pretreatment reduced but did not abolish the CNS effects of OHPEA and PEA."( Behavioral and electrophysiological effects of phenylethanolamine and 2-phenylethylamine.
Flavin, D; Sabelli, HC; Vazquez, AJ, 1975
)
0.98
"Reserpine pre-treatment caused a considerable reduction in the FFA mobilizing action of T3."( Cyclical effects of triiodothyronine on blood-free fatty acid and glucose concentrations in warm-adapted and cold-adapted rats.
Doi, K; Kurahashi, M; Kuroshima, A, 1975
)
0.98
"2 Reserpine-treatment potentiated the contractile responses to CaCl2."( The relationship between calcium and increased sensitivity of rabbit aortae four hours after reserpine.
Carrier, O; Hester, RK, 1976
)
1.03
"in reserpine (R)-pretreated intact females, and 2."( Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats.
Gräf, KJ; Horowski, R; Neumann, F, 1976
)
0.77
"Reserpine treatment had no effect on the affinity (Kd) of [3H]SCH 23390 or [3H]spiperone for D-1 and D-2 sites."( Acute reserpine treatment induces down regulation of D-1 dopamine receptor associated adenylyl cyclase activity in rat striatum.
Jenner, P; Marsden, CD; Rose, S; Thomas, KL, 1992
)
1.49
"Reserpine pretreatment also affected steady state levels of submandibular guanine nucleotide-binding proteins."( Effects of chemical and surgical sympathectomy on expression of beta-adrenergic receptors and guanine nucleotide-binding proteins in rat submandibular glands.
Bahouth, SW, 1992
)
1
"Reserpine treatment, shown previously to increase levels of TH, was found to increase both LC firing rate and levels of soluble cAMP-dependent protein kinase activity in the LC."( Coordinate regulation of the cyclic AMP system with firing rate and expression of tyrosine hydroxylase in the rat locus coeruleus: effects of chronic stress and drug treatments.
Duman, RS; Haycock, JW; Melia, KR; Nestler, EJ; Rasmussen, K; Terwilliger, RZ, 1992
)
1
"Reserpine treatment in conjunction with alpha-methyl-p-tyrosine treatment blocked amphetamine-induced locomotion for the first 4 days only, with full recovery of amphetamine-induced unconditioned locomotion by the last treatment day."( Evidence for presynaptic dopamine mechanisms underlying amphetamine-conditioned locomotion.
DiLullo, SL; Martin-Iverson, MT, 1992
)
1
"reserpine treatment. Ablation of the area postrema with some damage to extremely adjacent areas abolished the vomiting induced by each alpha-adrenoceptor agonist."( Central alpha-adrenoceptor subtypes involved in the emetic pathway in cats.
Akiba, T; Hikasa, Y; Iino, Y; Matsukura, M; Ogasawara, S; Takase, K, 1992
)
1
"Reserpine pretreatment (5 mg/kg, i.p.) did not affect the enhanced ouabain-induced DA efflux (P less than 0.01) in the subchronic MAP group, and the levels of DOPAC (P less than 0.01), 5-HIAA (P less than 0.01) and HVA (P less than 0.01) were also significantly higher in the subchronic MAP than in the control group."( Subchronic methamphetamine treatment enhances ouabain-induced striatal dopamine efflux in vivo.
Akiyama, K; Kanzaki, A; Otsuki, S, 1992
)
1
"Reserpine pretreatment decreased the effect of KW-6055, indicating that KW-6055 acted on cholinergic neurons through catecholaminergic neurons."( [Effects of KW-6055, a novel benzylpyridine derivative, on central cholinergic systems].
Ishii, A; Kanda, T; Kurokawa, M; Mori, A; Shiozaki, S; Yoshizaki, R, 1992
)
1
"Reserpine pretreatment at doses (1.0 mg/kg) sufficient to cause greater than 90% depletion of striatal dopamine levels blocked this amphetamine-enhanced washout (10%/hr; p less than 0.05)."( Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates.
al-Tikriti, M; Baldwin, RM; Hoffer, PB; Innis, RB; Laruelle, M; Malison, RT; Seibyl, JP; Smith, EO; Sybirska, EH; Zoghbi, SS, 1992
)
1
"Reserpine treatment (5 mg/kg, IP, for 6 days) caused similar effects on the dorsal and ventral striopallidal system, and the direct injection of 6-hydroxydopamine (10 micrograms/5 microliters) into the CP led to the appearance of MEAGL-immunoreactive neurons in accordance with the depleted dopaminergic terminal area."( Immunocytochemical survey of haloperidol-induced immunoreactive changes of [Met]enkephalin-Arg6-Gly7-Leu8 in the rat forebrain.
Ibata, Y; Ichitani, Y; Matsumoto, Y; Nakajima, T; Okamura, H; Yanaihara, N, 1992
)
1
"3. Reserpine pretreatment (1 mg kg-1) selectively reduced 5-HT levels in the blood, spleen, liver, brain and lung of normal mice."( The effect of lipopolysaccharide, interleukin-1 and tumour necrosis factor on the hepatic accumulation of 5-hydroxytryptamine and platelets in the mouse.
Endo, Y; Nakamura, M, 1992
)
0.8
"Reserpine treatment caused an increase in NPY mRNA content in bone marrow and spleen."( Detection of neuropeptide Y-like immunoreactivity and messenger RNA in rat platelets: the effects of vinblastine, reserpine, and dexamethasone on NPY expression in blood cells.
Ericsson, A; Hemsén, A; Lundberg, JM; Persson, H, 1991
)
1.21
"In reserpine-pretreated rats, SDZ 208-911 and terguride dose-dependently reduced striatal DOPA formation (NSD 1015 treatment) with similar efficacy (-80%) and potency as the selective D2 receptor agonist quinpirole (LY 171555)."( Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.
Carlsson, A; Ekman, A; Hoffmann, WE; Lum, JT; Piercey, MF; Svensson, K, 1991
)
0.8
"Reserpine treatment provoked supersensitivity of AC to isoproterenol, without affecting the response to CGRP."( Different natures of supersensitivity of adenylate cyclase stimulated by calcitonin gene-related peptide and isoproterenol in rat diaphragm after denervation and reserpine treatment.
Matsumoto, N; Uchida, S; Wang, XB, 1992
)
1.2
"Reserpine treatment of rats (0.5 mg kg-1 day-1 for 7 days) increased muscarinic receptor density in the vas deferens coincident with a shift in the low affinity pKi for AF-DX 116 to a value comparable to high affinity binding, and abolished the enhanced PI hydrolysis."( Subacute reserpine treatment reveals preferential coupling between the M3 muscarinic receptor subtype and phosphatidylinositol turnover.
Gardier, RW; Killian, LN, 1992
)
1.42
"Reserpine pre-treatment causes a considerable decrease in typical red-orange doxorubicin fluorescence of the organs examined (kidney, large intestine, spleen) and a similar picture is observed after calcium antagonists administration. "( Effect of reserpine and calcium antagonists on doxorubicin storage in various organs of young and senescent rats.
Breschi, MC; Paparelli, A; Pellegrini, A; Soldani, P,
)
1.98
"Reserpine treatment produced an 86% decrease in DA levels, an enhanced stereotyped responsiveness to apomorphine, and an increase of both D2 (28%) and D1 receptors (26%)."( Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatment.
Joyce, JN, 1991
)
1.19
"Reserpine pretreatment blunted the diuretic and natriuretic response to intravenous administration of ANF."( Renal dopamine not renal nerve mediates diuretic and natriuretic effect of ANF in rats.
Huang, WC; Kau, MM, 1991
)
1
"3. Reserpine treatment also resulted in a significant decrease in immunoactive met-enkephalin content in both the hypothalamus (25%) and the anterior lobe (50%), but not in the neurointermediate lobe of the pituitary."( Effect of reserpine on catecholamine contents and met-enkephalin and beta-endorphin levels in the hypothalamus and the pituitary.
Tang, F, 1991
)
1.2
"The reserpine-treated rats also exhibited stereotypy in response to acute injection of the D1-selective agonist SKF-38393 (10 mg/kg), which was not observed in control rats."( Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment.
Lucki, I; McGonigle, P; Neisewander, JL, 1991
)
0.97
"Reserpine pretreatment could also diminish CL seizure-induced accumulation of cAMP."( [Effect of reserpine on both CL seizures and cAMP levels in seizure mice brain].
Chen, Q; Huang, M; Xie, Y, 1990
)
1.39
"Reserpine treatment of rats (0.5 mg kg-1 day-1 for 7 days) produced a decrease in peak tension in response to methacholine without changing the muscarinic receptor character (Kd 3H-QNB), population density (Bmax in fmol mg-1 protein), or function (methacholine EC50)."( Reserpine-induced post-receptor reduction in muscarinic-mediated airway smooth muscle contraction.
Blaxall, HS; Cunningham, J; Gardier, RW; Killian, LN, 1991
)
2.45
"6. Reserpine treatment significantly increased platelet alpha 2-adrenoceptor number (identified with [3H]- yohimbine or [3H]-RX821002) with no change in Kd values."( Reserpine induces vascular alpha 2-adrenergic supersensitivity and platelet alpha 2-adrenoceptor up-regulation in dog.
Berlan, M; Estan, L; Montastruc, JL; Senard, JM; Tran, MA, 1990
)
2.24
"In reserpine-pretreated, adrenalectomized cats, labetalol produced quantitatively the same effects as in spinal cats, indicating that the cardiovascular effects observed in cats with no resting sympathetic tone are due to a direct action of labetalol rather than via catecholamine release."( Intrinsic sympathomimetic activity of labetalol.
Novak, PJ; Tadepalli, AS,
)
0.65
"Reserpine treatment in vitro for 24 h of acinar cells from control rats significantly decreased amylase activity (20 to 70%), an effect similar to that of reserpine treatment in vivo."( Impairment of pancreatic acinar function by reserpine in vivo and in vitro.
Brannon, PM; Scott, D, 1987
)
1.26
"In reserpine-pretreated rats, the degree of utilization of 5-HT and the number of 5-HT1 ([3H]5-HT) and 5-HT2 ([3H]ketanserin) binding sites were significantly increased compared with the figures for the vehicle-pretreated rats."( Phencyclidine-induced head-weaving and head-twitch through interaction with 5-HT1 and 5-HT2 receptors in reserpinized rats.
Ishikawa, K; Kameyama, T; Nabeshima, T; Yamaguchi, K; Yoshida, S, 1987
)
0.79
"Reserpine-treated rats fed high carbohydrate, however, had significantly lower (64%) amylase activity than high carbohydrate-fed control rats."( Effects of reserpine treatment on dietary adaptation of the rat exocrine pancreas.
Brannon, PM; Hazlett, DA, 1988
)
1.39
"In reserpine treated tissues, the stimulatory effect of clonidine on beta-agonist-induced secretion disappeared, but the inhibitory effect on alpha 1-agonist-induced secretion remained unchanged."( Dual effects of clonidine on amylase secretory responses of rat parotid tissue induced by beta- and alpha 1-agonists.
Hata, F; Ishida, H; Kondo, E, 1988
)
0.79
"Reserpine pretreatment, or propranolol 3 x 10(-7) mol/l, or propranolol plus prazosin 10(-6) mol/l decreased the maximum chronotropic effect of Bay K 8644 by about 60%."( Positive chronotropic effect of Bay K 8644: participation of endogenous norepinephrine.
Cingolani, HE; de Hurtado, MC; Gende, OA, 1989
)
1
"Reserpine-pretreated rats were injected with (+)8-OH-DPAT (0.03-1.0 mg/kg s.c.), (+)ALK-3 (0.3-10.0 mg/kg s.c.) or (-)ALK-3 (3.0-10.0 mg/kg s.c.), and components of the '5-HT behavioural syndrome' were scored."( Partial postsynaptic 5-HT1A agonist properties of the novel stereoselective 8-OH-DPAT analogue (+)cis-8-hydroxy-1-methyl-2-(di-n-propylamino)tetralin, (+)ALK-3.
Hacksell, U; Hjorth, S; Sharp, T, 1989
)
1
"Reserpine treatment increased beta-adrenergic receptor-stimulated adenosine 3',5'-cyclic monophosphate (cAMP) accumulation by 49% over control in the renal cortex."( Reserpine but not surgical denervation regulates rat renal beta-adrenergic receptors.
Fortin, TL; Sundaresan, PR, 1989
)
2.44
"In reserpine pretreated animals amphetamine 5.4 microM shifted to the right the concentration-response curve (CRC) to clonidine 0.62 +/- 0.05 log units with a KB value of 1.83 +/- 0.30 microM."( Amphetamine antagonizes the presynaptic inhibitory effect of clonidine through an interaction at the level of the alpha 2-adrenoceptors.
Fiszman, ML; Luchelli-Fortis, MA; Stefano, FJ, 1989
)
0.79
"Reserpine treatment also increases the labeling density in sympathetic ganglia."( Regulation of tyrosine hydroxylase mRNA in catecholaminergic cells of embryonic rat: analysis by in situ hybridization.
Jonakait, GM; Morrell, JI; Rosenthal, M, 1989
)
1
"Reserpine treatment did not change the effects of NPY."( Evidence for co-transmitter role of neuropeptide Y in the pig spleen.
Hamberger, B; Lundberg, JM; Rudehill, A; Sollevi, A, 1989
)
1
"In reserpine-pretreated mice, the dopamine (DA) agonist apomorphine, which stimulates both the D1 and D2 subtypes of DA receptors, increases body temperature according to a mechanism insensitive to the specific D2 DA antagonist sulpiride (Horowski 1978) or the preferential D2 DA antagonist haloperidol (Danielson, Coutts, Keashly and Tang 1985)."( Stimulation of central D1 dopamine receptors reverses reserpine-induced hypothermia in mice.
Costentin, J; Duterte-Boucher, D; Michael-Titus, A; Panissaud, C, 1989
)
1.04
"Reserpine treatment decreased the stimulation of BAT 5'D induced by acute cold exposure (4 degrees C, 2 h) without a significant decrease in the basal 5'D activity, whereas stimulation of BAT 5'D elicited by noradrenaline (0.4 and 0.8 mg kg-1 s.c."( Effect of reserpine pretreatment on brown fat iodothyronine 5'-deiodinase of mouse.
Muraki, T; Nomoto, T; Oike, N; Tsukahara, F, 1989
)
1.4
"Reserpine pretreatment (72 h) or omission of calcium did not prevent nicotine's inhibitory effect on accumulation, but did reduce or inhibit nicotine-induced catecholamine release, suggesting that adrenal [3H]noradrenaline accumulation may be regulated by processes involved with stimulus-secretion coupling (e.g., sodium gradient and/or depolarization) which are independent of release."( [3H]noradrenaline accumulation in cultured bovine adrenal medullary cells: modulation of accumulation by nicotine.
McKay, DB, 1989
)
1
"3. Reserpine pretreatment reduced dialysate 5-HT concentration before PCA was given but the net increase (AUC) over the 1 h after PCA did not differ significantly from that seen in animals pretreated with vehicle."( An in vivo dialysis and behavioural study of the release of 5-HT by p-chloroamphetamine in reserpine-treated rats.
Adell, A; Curzon, G; Hutson, PH; Sarna, GS, 1989
)
1.01
"2. Reserpine treatment almost completely depleted the heart of noradrenaline (NA)."( Effects of reserpine treatment on arrhythmogenesis during ischaemia and reperfusion in the isolated rat heart.
Lee, AY; Tang, F; Wong, TM; Zhan, CY, 1989
)
1.18
"Reserpine pretreatment did not prevent the effects of 8-OH-DPAT."( 5-HT1A and alpha-2 adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-n-propylamino)tetralin in the conscious rat.
Chaouloff, F; Jeanrenaud, B, 1987
)
0.99
"Reserpine pretreatment, however, had no effect on the sensitivity to methoxamine."( Cardiac alpha- and beta-adrenoceptor sensitivity and binding characteristics after chronic reserpine pretreatment.
Broadley, KJ; Chess-Williams, RG; Grassby, PF; Sheridan, DJ, 1987
)
1.21
"In reserpine-treated mice, B-HT 920 did not cause any motor activity by itself but it markedly potentiated the slight stimulating effect of the D1 dopamine agonist SKF 38 393."( Stimulation of D1 dopamine receptors reveals direct effects of the preferential dopamine autoreceptor agonist B-HT 920 on postsynaptic dopamine receptors.
Andén, NE; Grabowska-Andén, M, 1988
)
0.79
"Reserpine pretreatment (thereshold dose 0.5 mg X kg-1) caused a dose- and time-dependent reduction of the content of NPY-LI in the heart."( Differential effects of reserpine and 6-hydroxydopamine on neuropeptide Y (NPY) and noradrenaline in peripheral neurons.
Franco-Cereceda, A; Goldstein, M; Hökfelt, T; Lundberg, JM; Saria, A; Terenius, L, 1985
)
1.3
"The reserpine pretreatment was undertaken to eliminate brain monoaminergic influence on GH secretion, hence obtaining a low GH baseline from which a drug induced increase could be easily detected."( Does alprazolam, in contrast to diazepam, activate alpha 2-adrenoceptors involved in the regulation of rat growth hormone secretion?
Carlsson, M; Eriksson, E; Nilsson, C; Söderpalm, B, 1986
)
0.75
"Reserpine treatment (2.5 mg/kg s.c.) decreased the frequency of the MMC to a greater extent than that produced by 6-OHDA treatment."( Effects of cholinergic blockade, adrenergic blockade and sympathetic denervation on gastrointestinal myoelectric activity in guinea pig.
Costa, M; Furness, JB; Galligan, JJ, 1986
)
0.99
"Reserpine pretreatment did not alter the magnitude of the thrombin-induced contraction in the femoral and central ear artery, indicating that the response and its sensitivity to alpha adrenoceptor blockade was not related to the release of NE from nerve stores."( Alpha adrenoceptor antagonists selectively reduce thrombin-stimulated contraction in rabbit arteries.
Bevan, JA; Garland, CJ, 1986
)
0.99
"In reserpine-treated chromaffin cells, norepinephrine (100 microM) inhibits only by 27% nicotine-stimulated secretion of leucine-enkephalin with an IC50 of 50 microM."( Nonadrenergic modulation by clonidine of the cosecretion of catecholamines and enkephalins in adrenal chromaffin cells.
De Léan, A; Nguyen, TT, 1987
)
0.79
"Reserpine-treated cultures, however, responded to serotonin with a 28% decrease in glycogen content and contained higher levels of glycogen than non-reserpine-treated controls (a 55% increase)."( Effects of neurotransmitters on astrocyte glycogen stores in vitro.
Cambray-Deakin, M; Morrow, C; Murphy, S; Pearce, B, 1988
)
1
"Reserpine pretreatment of the rats in-vivo did not modify the accumulation of MPP+ in the striatal slices."( The effects of 1-methyl-4-phenylpyridinium ion (MPP+) on the efflux and metabolism of endogenous dopamine in rat striatal slices.
Carlsson, A; Ekman, A; Engel, J; Magnusson, T; Pileblad, E; Snape, BM, 1988
)
1
"Reserpine pretreatment, the addition of phentolamine, tetrodotoxin, verapamil or lowering the sodium concentration abolished the responses to the toxin."( Effects of tityustoxin on the rat isolated tail artery.
Catanzaro, OL; Savino, EA, 1985
)
0.99
"Reserpine treatment in rats induces morphological and functional disturbances in exocrine glands which resemble those produced by cystic fibrosis. "( Reserpine treatment increases viscosity of fluid in the epididymis of rats.
Wen, RQ; Wong, PY, 1988
)
3.16
"Reserpine-treated tissue, in contrast, was refractory to treatment with carbachol as well as trifluoperazine."( Colonic glycoprotein secretion and calmodulin-acceptor proteins in the reserpine-treated rat.
Brady, RC; Dedman, JR; Karnaky, KJ, 1985
)
1.22
"Reserpine pretreatment led to smaller responses than prazosin plus rauwolscine."( Analysis of the alpha-adrenoceptor-mediated, and other, components in the sympathetic vasopressor responses of the pithed rat.
Flavahan, NA; Grant, TL; Greig, J; McGrath, JC, 1985
)
0.99
"Reserpine treatment reduced the NA content of the spleen as well as the stimulation-evoked NA release by greater than 90%."( Frequency- and reserpine-dependent chemical coding of sympathetic transmission: differential release of noradrenaline and neuropeptide Y from pig spleen.
Hamberger, B; Lundberg, JM; Rudehill, A; Sollevi, A; Theodorsson-Norheim, E, 1986
)
1.35
"Reserpine pretreatment (5 mg/kg SC) caused a 5-fold increase in plasma levels of NPY-LI with a maximum after 4 h."( Reserpine-induced depletion of neuropeptide Y from cardiovascular nerves and adrenal gland due to enhanced release.
Al-Saffar, A; Lundberg, JM; Saria, A; Theodorsson-Norheim, E, 1986
)
2.44
"Reserpine pre-treatment (2 mg/kg I.M.) markedly decreased the endogenous NA content to 1-2% of untreated cats and the net uptake of [3H]NA was lowered to 25% both in cat hypogastric nerve and atria."( Presence of a noradrenaline uptake system on a ligated cat sympathetic nerve.
Ceña, V; García, AG; Pi, F; Sánchez-García, P, 1986
)
0.99
"Reserpine pretreatment or bilateral 6-hydroxydopamine lesions of the nucleus accumbens (NAS) potentiates apomorphine-induced LA but attenuates piribedil- and S3608-induced LA."( A comparative study of the locomotor activity effects of apomorphine and the "atypical dopamine agonists" (piribedil and S3608).
Offermeier, J; van Rooyen, JM, 1986
)
0.99
"Reserpine and 6-OHDA treatment markedly reduced the NA content of all peripheral organs investigated."( Reserpine-induced depletion of neuropeptide Y in the guinea-pig: tissue-specific effects and mechanisms of action.
Amann, R; Franco-Cereceda, A; Lundberg, JM; Nagata, M; Saria, A, 1987
)
2.44
"Reserpine treatment led to surface alterations of Type I epithelial lung cells and diminished food uptake."( Clearance of Pseudomonas aeruginosa in different rat lung models.
Dauner, HM; Döring, G, 1988
)
1
"Reserpine pretreatment depleted both NA and NPY-LI from skeletal muscle."( Co-release and functional interactions of neuropeptide Y and noradrenaline in peripheral sympathetic vascular control.
Pernow, J, 1988
)
1
"Reserpine or tyramine treatment resulted in depletion of endogenous cardiac NE in control and diabetic rats."( Norepinephrine storage, distribution, and release in diabetic cardiomyopathy.
Beamish, RE; Dhalla, KS; Dhalla, NS; Ganguly, PK; Innes, IR, 1987
)
0.99
"Both reserpine pretreatment and chronic sympathetic denervation greatly decreased the NA contents."( Catecholamine contents of rabbit gingiva and dental pulp.
de la Lande, IS; Parker, DA; Parker, I, 1986
)
0.73
"Reserpine treatment had no effect on basal or Gpp(NH)p (10(-7) M)-stimulated activities."( Reserpine-induced supersensitivity in adenylate cyclase preparations from guinea-pig heart.
Cros, GH; McNeill, JH, 1987
)
2.44
"Reserpine treatment fails to induce any reduction of catechol- and indoleamine content visible to histochemical observation."( Preliminary histochemical and electron microscopic observations on the nervous system of hydra.
Carolei, A; Del Piano, M; Lauro, GM; Margotta, V; Medolago-Albani, L; Nicosia, R; Palladini, G; Venturini, G, 1986
)
0.99
"Reserpine pretreatment lowered resting cardiovascular parameters."( Differences in cardiovascular responses to peripherally administered GABA as influenced by basal conditions and type of anaesthesia.
Giuliani, S; Maggi, CA; Meli, A, 1986
)
0.99
"Reserpine treatment produced profound effects on the molecular weight profile of nearly all enkephalin-containing peptides."( Reserpine-induced alterations in the processing of proenkephalin in cultured chromaffin cells. Increased amidation.
Lindberg, I, 1986
)
2.44
"Reserpine pretreatment (10 mg/Kg, i.p.) did not significantly attenuate the pressor response in urethane anesthetized animals."( Cardiovascular effects of cocaine in anesthetized and conscious rats.
Marwah, J; Pitts, DK; Udom, CE, 1987
)
0.99
"Reserpine treatment, which is known to deplete brain nerve terminal stores of catecholamines, likewise did not result in any loss of neuropeptide Y."( The effect of 6-hydroxydopamine, reserpine and cold stress on the neuropeptide Y content of the rat central nervous system.
Allen, JM; Bloom, SR; Kelly, JS; Kent, A; Schon, F; Yeats, JC, 1986
)
1.27
"Reserpine pretreatment (5 mg/kg s.c., 24 h) combined with alpha-methyl-p-tyrosine (300 mg/kg i.p., 2 h) reduced endogenous dopamine levels by 99.9%, but, under these conditions, beta-PEA, TYR and AMPH still retained their inhibitory effect on [3H]ACh, release."( Trace amines inhibit the electrically evoked release of [3H]acetylcholine from slices of rat striatum in the presence of pargyline: similarities between beta-phenylethylamine and amphetamine.
Arbilla, S; Baud, P; Cantrill, RC; Langer, SZ; Scatton, B, 1985
)
0.99
"Reserpine treatment increased binding in the cerebral cortex and hippocampus, but not in the striatum or hypothalamus."( Effects of pargyline, reserpine and neurotoxin lesions on [3H]tryptamine binding sites in rat brain.
Cascio, CS; Kellar, KJ, 1986
)
1.31
"Reserpine-pretreatment potentiated (+)-3PPP-induced yawning."( Dopamine receptors mediating yawning: are they autoreceptors?
Collu, M; Gessa, GL; Serra, G, 1986
)
0.99
"Reserpine pretreatment of the animals, external calcium removal or the presence of 10(-6) M cocaine, 10(-6) M diphenhydramine or 10(-3) M colchicine in the superfusion medium significantly reduced this effect of histamine (10(-4) M)."( Indirect adrenergic effect of histamine in cat right atrium.
Arranz, JA; Balfagón, G; Marco, EJ, 1985
)
0.99
"Reserpine treatment did not alter the infarct size significantly."( Pharmacological interventions and myocardial infarct size in rat.
Kumar, C; Singh, M, 1985
)
0.99
"Reserpine treatment of toads kept at 20 degrees C did not affect the adrenaline but reduced the noradrenaline content of the ventricle.4."( Temperature dependence of catecholamine depletion by reserpine in the heart of the toad (Bufo marinus).
Chang, P; Rand, MJ, 1971
)
1.22
"Reserpine pretreatment (0.3 mg/kg, s.c., 4 days prior to the experiment) reduced the noradrenaline levels in the smooth muscle of the nictitating membrane to about 10% of the control values while granular retention of [(3)H]-noradrenaline had recovered to nearly 40% of the controls.3."( Influence of reserpine-induced depletion of noradrenaline on the negative feed-back mechanism for transmitter release during nerve stimulation.
Enero, MA; Langer, SZ, 1973
)
1.34
"Reserpine pretreatment, on the other hand, prevented any e.c.g."( Role of the sympathetic nervous system in daunomycin-induced arrhythmia in the monkey.
Burka, B; Herman, E; Vick, J, 1970
)
0.97
"Reserpine pretreatment antagonized the antinociceptive effect of morphine; this effect was reversed by intraventricular injection of 5-HT.4."( Antinociceptive activity of morphine after injection of biogenic amines in the cerebral ventricles of the conscious rat.
Sparkes, CG; Spencer, PS, 1971
)
0.97
"Reserpine pretreatment potentiates turning produced by (-)-ephedrine.7."( Turning behaviour as an index of the action of amphetamines and ephedrines on central dopamine-containing neurones.
Christie, JE; Crow, TJ, 1971
)
0.97
"Reserpine pretreatment considerably augmented the amplitude of responses to low concentrations of phenylephrine, noradrenaline and nordefrine (Cobefrine).3."( Effects of reserpine on the disposition of sympathomimetic amines in vascular tissue.
Kalsner, S; Nickerson, M, 1969
)
1.36
"In reserpine-treated rats, 5-HT was released into the stomach but transmural stimulation did not produce true peristalsis and only rhythmic contractions occurred.6."( The release of 5-hydroxytryptamine from the rat stomach in vitro.
Bennett, A; Bucknell, A; Dean, AC, 1966
)
0.76
"Treatment with reserpine was associated with increased expression of the proapoptotic protein Bax, whereas that of the antiapoptotic protein Bcl-2 was significantly decreased."( Amylin prevents TRAIL-mediated apoptotic effects of reserpine in the rat gastric mucosa.
Bernardini, R; Cantarella, A; Cantarella, G; Clementi, G; Di Benedetto, G; Loreto, C; Martinez, G; Prato, A, 2009
)
0.94
"Pretreatment with reserpine regularly depressed or abolished the hypertensive response to eserine."( Factors influencing the hypertensive effect of eserine in the rat.
LESIC, R; VARAGIC, V, 1961
)
0.56
"Treatment with reserpine increased the heart's sensitivity to noradrenaline without changing initial heart rate."( Cardiac noradrenaline stores.
FAWAZ, G; SIMAAN, J, 1963
)
0.58
"The treatment with reserpine produced supersensitivity in the contractile responses of the rat tail artery to phenylephrine, 5-HT and KCl, resulting in leftward shift of concentration-response curves (11.6-, 2.5- and 1.1-fold at EC(50) value, respectively)."( Alpha-1D adrenoceptors are involved in reserpine-induced supersensitivity of rat tail artery.
Hiraizumi-Hiraoka, Y; Israilova, M; Kunitomo, M; Muramatsu, I; Shinozuka, K; Suzuki, F; Taki, N; Tanaka, T; Taniguchi, T; Zhang, L, 2004
)
0.91
"The treatment with reserpine resulted in akinesia, catalepsy and rigidity and up-regulation of proenkephalin and down-regulation of preprotachykinin mRNA in caudate putamen, indicating a severe depletion."( Effect of apomorphine on striatal synaptotagmin 7 mRNA levels in reserpinized rats.
Glavan, G; Jernej, B; Milutinovic, A; Pal, R; Zivin, M, 2007
)
0.66
"Pretreatment with reserpine caused a decrease in the frequency of spontaneous contractions in the proximal, but not in the middle or distal regions."( The effects of drugs on pacemaker regions of isolated rabbit renal pelvis.
Bernardini, C; Constantinou, CE; Del Tacca, M, 1981
)
0.59
"Pretreatment with reserpine (1 mg/100 g b.w., i.p.) abolished not only the natural GH burst but also the GH response to FK 33-824."( Involvement of alpha-adrenergic mechanisms in growth hormone release induced by opioid peptides in conscious rats.
Hiroto, S; Imura, H; Katakami, H; Kato, Y; Matsushita, N; Shimatsu, A, 1981
)
0.59
"Pretreatment with reserpine (1 mg/kg, im, 24 hours before experiments) or hexamethonium (3 mg/kg, iv) prevented the LAD ligation-induced increase in the glycogen phosphorylase activity, but adrenalectomy did not."( A neural factor involved in increase of the glycogen phosphorylase activity after coronary ligation in both ischemic and nonischemic areas of the dog heart.
Abiko, Y; Sakai, K, 1982
)
0.59
"Pretreatment with reserpine (2.5 mg/kg s.c., 24 h before the experiment) did not affect the KD or Bmax values of [3H]RX 781094 binding."( [3H]RX 781094: a new antagonist ligand labels alpha 2-adrenoceptors in the rat brain cortex.
Langer, SZ; Pimoule, C; Scatton, B, 1983
)
0.59
"Pretreatment with reserpine (1 mg/kg, i.m.) or ganglionic blockade with hexamethonium (10 mg/kg, i.v.) plus atropine (1 mg/kg, i.v.) abolished the GABA-induced hypotension and bradycardia."( The role of the sympathetic nervous system in the cardiovascular effects of systemically administered gamma-aminobutyric acid.
Barletta, M; Vemulapalli, S, 1984
)
0.59
"Pretreatment with reserpine decreased the amount of radioactivity transported to the RDN by 40%."( Retrograde axonal transport following injection of [3H]serotonin in the olfactory bulb. I. Biochemical study.
Araneda, S; Bobillier, P; Buda, M; Pujol, JF, 1980
)
0.58
"Pretreatment with reserpine caused significant reductions in the concentration of uterine adrenaline and noradrenaline as measured by a fluorometric assay but had no effect on the extent or time-course of oestrogen-induced myometrial quiescence."( Oestrogen-induced myometrial quiescence in the post-partum rat is not mediated by adrenaline or by alpha- or beta-adrenoceptor activation.
Downing, SJ; Porter, DG, 1980
)
0.58
"Pretreatment with reserpine (10 mg/kg), given 24 h before the experiment, significantly suppressed pulsatile LH secretion in these rats."( Role of alpha-adrenergic mechanism in regulating tonic luteinizing hormone release in conscious ovariectomized rats.
Imura, H; Katakami, H; Kato, Y; Kinoshita, F; Nakai, Y, 1981
)
0.59
"Treatment with reserpine (2 mg/kg/day, twice) almost completely prevented the release of NE by CTS, such pretreatment had no affect on the ability of CTX to potentiate responses to NE and K+."( Mode of the ciguatoxin-induced supersensitivity in the guinea-pig vas deferens.
Ishida, Y; Ohizumi, Y; Shibata, S, 1982
)
0.6
"Pretreatment with reserpine produces rapid and selective development of supersensitivity to the postjunctional beta 2-mediated inhibitory response of isoprenaline in this preparation."( Characterization of the adrenoreceptor activities of isoprenaline in the field stimulated rat vas deferens: selective supersensitivity to beta 2-mediated responses following reserpine treatment.
Cerino, D; Kling, P; Lotti, VJ, 1982
)
0.78
"Pretreatment with reserpine abolished the 5-HT effects of LSD in the vesicular fraction."( Nerve terminal effects of indoleamine psychotomimetics on 5-hydroxytryptamine.
Halaris, AE, 1982
)
0.59
"Pretreatment with reserpine failed to modify the concentration-response curve for both Tyr and 5-HT."( Inhibition of norepinephrine- and 5-hydroxytryptamine-induced contraction on rat aorta by dihydroergocristine.
D'Agostino, G; Dondi, G; Grana, E; Zonta, F, 1984
)
0.59
"Pretreatment with reserpine abolished the contraction to dopamine without affecting its relaxant response."( Pharmacological analysis of the responsiveness of guinea-pig lung parenchymal strip to dopamine.
Cortijo, J; Esplugues, J; Morcillo, EJ; Perpiñá, M, 1984
)
0.59
"Pre-treatment with reserpine did not alter the inhibitory response, either in the presence or absence of atropine, therefore, adrenergic inhibitory mechanisms did not appear to be involved."( Motor effects of gastrin releasing peptide (GRP) and bombesin in the canine stomach and small intestine.
Fox, JE; McDonald, TJ, 1984
)
0.59
"Treatment with reserpine prior to 5-hydroxydopamine increased the proportion of large dense-cored vesicles and decreased the overall number of vesicles in the terminals."( Effect of 5-hydroxydopamine on the large dense-cored vesicles in the axon terminals of the myenteric ganglia of the guinea-pig stomach.
Barber, P; Grant, K; Hoyes, AD; Jagessar, H, 1983
)
0.61
"Pretreatment with reserpine attenuated the contractions of mesenteric arteries induced by angiotensin II, but did not alter the response of cerebral arteries to 5-hydroxytryptamine."( Responsiveness to vasoactive agents of cerebral and mesenteric arteries isolated from control and reserpine-treated dogs.
Hayashi, S; Miyazaki, M; Toda, N, 1980
)
0.8
"Pretreatment with reserpine reduced the effect of (-)cathinone moderately; in reserpinized mice the effect of (-)cathinone was antagonized by the uptake inhibitors mazindol and nomifensine."( The effect of the alkaloid (-)cathinone on the motor activity in mice.
Kalix, P; Valterio, C, 1982
)
0.59
"Pretreatment with reserpine (0.5 mg/kg), at the time of separation, prevented the development of hyperactivity over the ensuing 24-hr, whereas the same dose in mothered littermates had no residual effects on behavior the next day."( Effects of reserpine and amphetamine on the development of hyperactivity in maternally deprived rat pups.
Hofer, MA, 1980
)
0.97
"Pretreatment with reserpine (1 mg/kg i.p.) or guanethidine (15 mg/kg i.v.) delayed the manifestation of the antihypertensive action of dl-propranolol (1 mg/kg) observed in untreated (control) animals."( Effects of adrenolytic drugs on the antihypertensive action of beta-blocking agents in the acute neurogenic hypertensive dog.
Montastruc, JL; Montastruc, P; Morales-Olivas, F,
)
0.45
"Treatment with reserpine induced the appearance of annulate lamellae in the cytoplasm of cells containing very small granules and having the morphology of thyrotrophs."( Pituitary serotonin: responsiveness of levels to hormonal change and ultrastructural alterations associated with amine depletion.
Gershon, MD; Nunez, EA; Silverman, AJ, 1980
)
0.6
"Pretreatment with reserpine in six dogs abolished the time dependency."( Time dependency of ventricular fibrillation thresholds determined using trains of stimuli.
Griffin, JC; Jaillon, P; Schnittger, I; Winkle, RA, 1980
)
0.58
"Mice treated with reserpine (5 mg/kg IP), 24 h beforehand, were completely akinetic. "( Potentiation of dopamine-dependent locomotion by clonidine in reserpine-treated mice is restricted to D2 agonists.
Starr, BS; Starr, MS, 1994
)
0.86
"Pretreatment with reserpine markedly depleted catecholamines and reduced (by 30-fold) the potency of bupropion to inhibit LC firing.(ABSTRACT TRUNCATED AT 250 WORDS)"( Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism.
Cooper, BR; Cox, RF; Ferris, RM; Norton, R; Shea, V; Wang, CM, 1994
)
0.61
"Rats treated with reserpine develop spontaneous orofacial dyskinesia that has features similar to tardive dyskinesia (TD) in humans. "( Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia.
Castañeda, E; Davis, DA; Neisewander, JL, 1994
)
0.88
"Treatment with reserpine (0.25 mg/kg s.c., every 48 h) for 4, 11 and 18 days induced consistent and significant increases in the affinity (KD values) of [3H]UK 14304 for the cortical alpha 2-adrenoceptor with no change in receptor density."( Acute and chronic effects of reserpine on biochemical and functional parameters of central and peripheral alpha 2-adrenoceptors.
García-Sevilla, JA; Garro, MA; Giralt, MT; Menargues, A; Miralles, A; Obach, R; Olmos, G; Pineda, J; Ugedo, L, 1993
)
0.92
"Pretreatment with reserpine 8-12 h prior to the CMG recording, antagonized the inhibitory effect of MK-801 on the amplitude of micturition contractions while pretreatment with vehicle had no effect."( Interactions between glutamatergic and monoaminergic systems controlling the micturition reflex in the urethane-anesthetized rat.
de Groat, WC; Roppolo, JR; Yoshiyama, M, 1994
)
0.61
"Treatment with reserpine (5 mg/kg, 90 min before death) caused a complete suppression of 5HT-positive staining, but 5HTP-immunostaining remained in perikarya of the nuclei raphe dorsalis, centralis superior and obscurus."( Effect of reserpine on 5-hydroxytryptophan (5HTP)-immunoreactive neurons in the rat brain.
Fujimiya, M; Kimura, H; Kitahama, K; Maeda, T; Nakazawa, M; Okumiya, K, 1994
)
1.03
"Pretreatment with reserpine has no effect on the extent of the mydriasis induced by ibopamine."( Ocular pharmacokinetics and pharmacodynamics in rabbits of ibopamine, a new mydriatic agent.
Galbiati, I; Gazzaniga, A; Gianesello, V; Soldati, L; Virno, M, 1993
)
0.61
"Rats treated with reserpine for seven days revealed significantly lower values of plasma immunoreactive cationic trypsin (ogen) (39.2 +/- 8.4 vs 66.8 +/- 4.9 ng/ml; P < 0.001), pancreatic juice trypsin (1.9 +/- 0.3 vs 3.2 +/- 0.9 units/mg protein; P < 0.001) and volume (1.6 +/- 0.7 vs 3.1 +/- 0.6 mg/min/g pancreas; P < 0.001) compared to controls."( Plasma immunoreactive cationic trypsin(ogen) pattern in reserpinized rat model of cystic fibrosis. Resemblance to humans.
Weizman, Z, 1996
)
0.62
"Pretreatment with reserpine blocked both responses."( Pressor and tachycardic responses to intravenous substance P in anesthetized rats.
Hancock, JC; Lindsay, GW, 1995
)
0.61
"Pretreatment with reserpine (1 mg/100 g) resulted in a large reduction in the average hypoxia-induced catecholamine response (1.4 +/- 0.3 microM, n = 9), but peak nerve activity was not different from nontreated controls."( Chemoreceptor nerve excitation may not be proportional to catecholamine secretion.
Donnelly, DF, 1996
)
0.62
"Treatment with reserpine markedly reduced the formation of spontaneous lung metastasis and completely abolished the increase in metastases caused by rotational stress without direct effect on tumor cells or blood vessels."( Blockers of adrenergic neurons and receptors, tumor progression and effects of rotational stress in mice.
Giraldi, T; Perissin, L; Rapozzi, V; Zorzet, S,
)
0.47
"Pretreatment with reserpine inhibited the twitch tension, both at control and in the presence of epinephrine."( Low oxygen tension induces positive inotropy and decreases a(i)Na in isolated guinea-pig cardiac ventricular papillary muscles.
Jao, MJ; Yang, JM, 1998
)
0.62
"Treatment with reserpine resulted in gradual reduction in blood pressure and an improvement in ejaculatory dysfunction."( Autonomic studies in hypertensive patient with unusual sexual dysfunction: response to reserpine.
Bhargava, B; Deepak, KK; Narang, R; Paudel, BH; Rai, PK; Saxena, S, 2000
)
0.87
"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine."( Behavioral effects of MK-801 on reserpine-treated mice.
Andreatini, R; Andreazza, AP; Dutra, RC; Tufik, S; Vital, MA, 2002
)
0.92
"Pretreatment with reserpine, pyrogallol or iproniazid inhibited the action of adrenaline."( [Biphasic (ulcer-forming and ulcer-preventing) effect of adrenaline in rats].
Dozaki, T; Imai, K; Mizukami, S, 1975
)
0.58
"Pretreatment with reserpine, guanethidine or phentolamine reduced the basic pressure threshold needed to elicit peristalsis."( Studies on the mechanism of the action of morphine on the peristalsis of guinea pig ileum in situ.
Aldunate, J; Mardones, J; Yojay, L, 1975
)
0.58
"Pretreatment with reserpine (0.3 or 3 mg/kg, 24 hours before the experiment) reduced the norepinephrine (NE) levels in the medial muscle of the cat nictitating membrane to approximately 2% of the control values. "( Possible involvement of a transmitter different from norepinephrine in the residual responses to nerve stimulation of the cat nictitating membrane after pretreatment with reserpine.
Langer, SZ; Pinto, JE, 1976
)
0.78
"Pretreatment with reserpine, if anything, increased the response to terbutaline."( Analysis of the beta-receptor mediated effect on slow-contracting skeletal muscle in vitro.
Waldeck, B, 1977
)
0.58
"Pretreatment with reserpine and alpha-methylparatyrosine did not significantly attenuate the lergotrile-induced inhibition."( Dopamine neurons: effect of lergotrile on unit activity and transmitter synthesis.
Baring, MD; Eng, N; Lakoski, JM; Walters, JR, 1979
)
0.58
"Pretreatment with reserpine reduced waking and spindle sleep while the synthesis inhibitors did not."( The role of endogenous catecholamines in the regulation of electrocortical activity in the encephale isole cat.
Bradley, PB; Candy, JM; Keane, PE, 1976
)
0.58
"Pretreatment with reserpine did not diminish the effect of morphine."( The effect of morphine on the activity evoked in ventrolateral tract axons of the cat spinal cord.
Grossman, W; Jurna, I, 1976
)
0.58
"Pretreatment with reserpine did not affect the norepinephrine cyclic AMP response; however, the phenylephrine cyclic AMP response was abolished."( Cyclic AMP and the positive inotropic effect of norepinephrine and phenylephrine.
Martinez, TT; McNeill, JH, 1977
)
0.58
"Pretreatment with reserpine (5 mg/kg; i.p.; 24 hr earlier) did not prevent the actions of 5HT."( The acute pharmacologic effects of serotonin on the release of insulin and glucagon in the intact rat.
Bryce, GF; Jacoby, JH, 1978
)
0.58
"Pretreatment with reserpine had no effect on the abnormal automaticity."( Ventricular arrhythmias in cardiac anaphylaxis.
Katus, H; Randolf, U; Senges, J, 1977
)
0.58
"Pretreatment with reserpine, 0.5 mg/kg, intramuscularly, for two days did not modify the cerebral circulator and metabolic responses to nitrous oxide."( Cerebral effects of nitrous oxide in the dog.
Inoue, S; Kuramoto, T; Sakabe, T; Takeshita, H, 1978
)
0.58
"Pretreatment with reserpine failed to induce supersensitivity to NE."( The mechanism of contraction of rat aorta to various agonists.
Grollman, A; Krishnamurty, VS, 1976
)
0.58
"Pretreatment with reserpine markedly enhanced the myoclonigenic effect of Amph and rendered it insensitive blockade by GHB, 160 mg/kg."( Pharmacological evidence for a selective antidopaminergic action of gamma-hydroxybutyric acid.
Bieger, D; Hornykiewicz, O; Menon, K, 1976
)
0.58
"Pretreatment with reserpine or alpha-methyl-p-tyrosine (AMPT) causes cerebral amine depletion and reduction of motor activity, which can be reversed by levodopa."( The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or alpha-methyl-p-tyrosine pre-treated mice.
Dolphin, AC; Jenner, P; Marsden, CD, 1976
)
0.79
"Treatment with reserpine, alpha-MT or PCPA prior to stress loading abolished the anti-ulcer effect of gamma-oryzanol, 100 mg/kg, s.c."( [Studies of gamma-oryzanol. (2) The antiulcerogenic action].
Ishikawa, M; Itaya, K; Kitonaga, J, 1976
)
0.6
"Pretreatment with reserpine resulted in decreased volumes of salvia and in elevated salivary concentrations of Ca++ and protein."( Abnormal secretory response to parasympathomimetic and sympathomimetic stimulations from the submaxillary gland of rats treated with reserpine.
Giles, M; Martinez, JR; Quissell, DO; Wood, DL, 1975
)
0.78
"Pre-treatment with reserpine reduced the potency of morphine in depressing twitches of the preparation."( Catecholamines and the actions of morphine on the guinea-pig ileum.
Heimanes, RL, 1975
)
0.57
"3 Pretreatment with reserpine (5 mg/kg) did not alter the ability of morphine to induce tolerance."( Tolerance to morphine-induced calcium depletion in regional brain areas: characterization with reserpine and protein synthesis inhibitors.
Ross, DH, 1975
)
0.79
"Pretreatment with reserpine abolished the positive inotropic effect of propranolol while ganglionic blockade with hexamethonium failed to alter the character of the response."( A positive inotropic effect of propranolol on the canine myocardium: a presynaptic effect.
Daniell, HB; Pierre, AJ; Webb, JG, 1976
)
0.58
"Pretreatment with reserpine prevented the effect of morphine."( Morphine stimulates locomotor activity by an indirect dopaminergic mechanism: possible D-1 and D-2 receptor involvement.
Zarghi, A; Zarrindast, MR, 1992
)
0.61
"Pretreatment with reserpine did not affect the hyperglycemic effect of St-93."( St-93 hyperglycemia in Wistar rats.
Krishnamurthy, A; Thapar, GS; Thomas, GP; Varma, RK,
)
0.45
"Pretreatment with reserpine did not significantly alter the clonidine-induced increase in submandibular calcium content."( Effects of clonidine on the calcium content and morphology of rat salivary glands.
Redman, RS; Yu, JH, 1992
)
0.61
"Treatment with reserpine increased serum prolactin levels but intrapituitary prolactin contents were decreased."( Effect of reserpine on the inhibition of prolactin released from different pituitary constructs in vitro by dopamine, bromocriptine and apomorphine.
Dutt, A; Juneja, HS, 1992
)
1.03
"Treatment with reserpine successfully controlled the dyskinetic movements."( Clenbuterol-induced tardive dyskinesia.
Gatto, E; Gene, R; Micheli, F; Pardal, MF, 1991
)
0.62
"Treatment with reserpine alone did not inhibit the process of reorganization, nor did it enhance the effect of NBM lesion."( Basal forebrain lesions with or without reserpine injection inhibit cortical reorganization in rat hindpaw primary somatosensory cortex following sciatic nerve section.
Biesold, D; Dykes, RW; Hanisch, UK; Webster, HH, 1991
)
0.89
"Pretreatment with reserpine (2 mg/kg) significantly reduced the antinociceptive activity of FR64822, when tested against acetic acid writhing."( Involvement of dopamine in the mechanism of action of FR64822, a novel non-opioid antinociceptive compound.
Nomura, K; Ohkubo, Y; Yamaguchi, I, 1991
)
0.6
"Pretreatment with reserpine (2.5 mg/kg, i.p., 5 hr) resulted in an increase in MSG-induced lethality."( Modulation by serotonin of glutamate-induced lethality in mice.
Igarashi, H; Kamei, J; Kasuya, Y, 1991
)
0.6
"Pretreatment with reserpine 24 h prior to injection of tracer significantly decreased the in vivo binding of both [3H]SCH23390 and [3H]N-methyl-spiperone in a dose-dependent manner."( Reserpine-induced reduction of in vivo binding of SCH 23390 and N-methylspiperone and its reversal by d-amphetamine.
Inoue, O; Langstrom, B; Suhara, T; Tsukada, H; Yonezawa, H, 1991
)
2.05
"Treatment with reserpine (3.0 mg/kg) reduced the density of [3H]p-aminoclonidine binding sites (Bmax, 93.8 +/- 18.4 fmol/mg protein) compared to the density in non-treated rats (154.4 +/- 33.5 fmol/mg protein)."( Inhibition of cyclic AMP accumulation by alpha 2-adrenoceptors in the rat cerebral cortex.
Itoh, T; Kamisaki, Y; Kuno, N, 1990
)
0.62
"Treatment with reserpine reduced ileal norepinephrine content by 98%, reduced basal water absorption consistent with a loss of sympathetic outflow to the mucosa, but did not prevent the increase in water absorption due to intracerebroventricular clonidine."( Regulation of rat ileal water absorption by central alpha 2 adrenergic receptors.
Dong, WH; Fogel, R; Kong, TH; Michelson, G; Pfeiffer, M, 1990
)
0.62
"Pretreatment with reserpine had no effect on either the time to onset or duration of maximal dentate activation."( Cholinergic and adrenergic agents modify the initiation and termination of epileptic discharges in the dentate gyrus.
Lothman, EW; Stringer, JL, 1991
)
0.6
"Treatment with reserpine hampered mental activity, including the functions of memory and attention."( [Effect of reserpine and propranolol on mental work capacity and psychological status of workers with hypertension after exposure to neuro-emotional stress].
Akhunova, NT; Bokovikov, AN; Dasaeva, LA, 1991
)
1.01
"Treatment with reserpine, which increases conversion of peptide B to the heptapeptide in bovine chromaffin cells in culture does not stimulate the accumulation of Met-enkephalyl-Arg6-Phe7 in the human neuroblastoma cells."( Met-enkephalyl-Arg6-Phe7 immunoreactivity in a human neuroblastoma cell line: effect of dibutyryl 3':5'-cyclic AMP and reserpine.
Adams, M; Boarder, MR; Marriott, D, 1986
)
0.82
"Pretreatment with reserpine, a drug known to deplete 5-HT, did not affect the NMTB-induced decrease in lung 5-HT uptake, but did diminish the increased lung wet weight to dry weight ratios seen after NMTB administration in rats and mice and the increased lung wet weight to body weight ratios in mice."( The involvement of serotonin in the pneumotoxicity induced by N-methylthiobenzamide.
Feny, FJ; Gibbs, LS; Traiger, GJ, 1988
)
0.6
"Pretreatment with reserpine had no apparent effect on NT synthesis, as assessed by examination of cycloheximide-induced inhibition of protein synthesis."( Effects of dopamine depletion on striatal neurotensin: biochemical and immunohistochemical studies.
Bean, AJ; Deutch, AY; During, MJ; Roth, RH, 1989
)
0.6
"Pretreatment with reserpine did not alter the dynamic changes of cardiac and liver MT content during myocardial infarction."( [Changes in metallothionein content of the heart and liver during acute myocardial infarction in rats].
Li, JH; Tang, CS; Wang, PJ, 1989
)
0.6
"Treatment with reserpine and discontinuance of antipsychotic drugs was useful for patients with severe symptoms of tardive dyskinesia or akathisia; complete remission with elimination of all drugs was achieved in 4 of 19 treated patients, without recurrence of symptoms."( A therapeutic approach to tardive dyskinesia.
Fahn, S, 1985
)
0.61
"Pretreatment with reserpine abolished the inhibitory effect of yohimbine."( Effect of methoxamine on spontaneous motility of the isolated rat uterus.
Esplugues, J; Estañ, L; Morales-Olivas, FJ; Rubio, E, 1985
)
0.59
"Pretreatment with reserpine (0.25 mg/100 g b.w."( Cardiorespiratory reflex effects induced by intravenous administration of ethanol in rats.
Brugere, S; Canas, M; Penna, M; Saavedra, A,
)
0.45
"Pretreatment with reserpine increased the potency of salbutamol at each concentration of carbachol."( The effect of varying carbachol concentration on the slope of Schild plots of selective beta-adrenoceptor antagonists in the carbachol-contracted guinea-pig trachea.
Donahue, JY; Keith, RA; Salama, AI, 1986
)
0.59
"Pretreatment with reserpine (1 and 5 mg/kg SC), alpha-MPT (100 and 300 mg/kg IP) and reserpine (1 mg/kg) plus alpha-MPT (100 mg/kg) was able to significantly reduce BRC-induced yawning."( The mode of action of bromocriptine following pretreatment with reserpine and alpha-methyl-p-tyrosine in rats.
Mizuki, Y; Ushijima, I; Yamada, M, 1988
)
0.84
"Treatment with reserpine, known to deplete monoamines including dopamine, induced a significant decrease in CRF-ir 24 h post-treatment."( Effect of dopaminergic and alpha-adrenergic modulation on corticotropin-releasing factor immunoreactivity in rat hypothalamus.
George, SR; Haas, DA, 1988
)
0.61
"Pretreatment with reserpine (5 mg/kg, 24 hr), fenfluramine (5 mg/kg, 4 days) or para-chlorophenylalanine (100 or 400 mg/kg, 4 days) antagonised cisplatin-induced emesis."( Reserpine, para-chlorophenylalanine and fenfluramine antagonise cisplatin-induced emesis in the ferret.
Barnes, JM; Barnes, NM; Costall, B; Naylor, RJ; Tattersall, FD, 1988
)
2.04
"Mice treated with reserpine for 24 h became more sensitive to the motor stimulant actions of all four agonists."( Behavioural role of dopamine D1 receptors in the reserpine-treated mouse.
Kilpatrick, IC; Starr, BS; Starr, MS, 1987
)
0.85
"Treatment with reserpine or 6-OH-DA induced a supersensitivity of this effect."( Presynaptic regulation by ACh of the NE mediated responses in the rat vas deferens.
Miranda, HF; Wolstenholme, WW, 1985
)
0.61
"Treatment with reserpine gives no change in total immunoreactivity levels, but does not result in increased accumulation of the heptapeptide [Met]enkephalyl-Arg6-Phe7 at the expense of immunoreactivity that elutes with its immediate precursor, peptide B."( Secretion of [Met]enkephalyl-Arg6-Phe7-related peptides and catecholamines from bovine adrenal chromaffin cells: modification by changes in cyclic AMP and by treatment with reserpine.
Adams, M; Boarder, MR, 1987
)
0.81
"Pretreatment with reserpine (2 mg/kg) significantly reduced the antinociceptive action of nefopam (40 mg/kg), indicating that the interaction of this drug with the monoaminergic systems is important for its effects."( Evidence of the involvement of dopamine in the analgesic effect of nefopam.
Esposito, E; Mennini, T; Merlo-Pich, E; Romandini, S; Samanin, R, 1986
)
0.59
"Pretreatment with reserpine was done as follows: 1 mg/kg of reserpine was injected subcutaneously once each day for 2 days."( [Experimental cerebral vasospasm induced by oxyhemoglobin and the sympathetic nervous system (Part 2): An investigation into denervation supersensitivity].
Endo, S; Iwai, R; Kamiyama, K; Otsuji, T; Sugita, T; Takaku, A, 1988
)
0.6
"Pretreatment with reserpine tended to increase the vasoconstriction induced by 10(-7)-10(-4) M of Nor and the constriction induced by 10(-3) M of Nor was increased statistically (P less than 0.05). "( [Experimental cerebral vasospasm induced by oxyhemoglobin and the sympathetic nervous system (Part 2): An investigation into denervation supersensitivity].
Endo, S; Iwai, R; Kamiyama, K; Otsuji, T; Sugita, T; Takaku, A, 1988
)
0.61
"Pretreatment with reserpine to deplete vesicular stores of DA significantly reduced the ability of intravenous cocaine to suppress A10 DA neuronal activity."( Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: studies in the ventral tegmental area.
Einhorn, LC; Johansen, PA; White, FJ, 1988
)
0.6
"Pretreatment with reserpine has no effect on the response to AVP."( Vasopressin-stimulated turnover of phosphatidylinositol in the decentralised superior cervical ganglion of the rat.
Horn, AM; Lightman, SL, 1988
)
0.6
"Treatment with reserpine caused a 98% depletion of the dopamine tissue content, whereas 60 min after exposure to MFMD the dopamine tissue content was decreased by 40%."( The role of cytoplasmic (newly synthesized) dopamine for the spontaneous and electrically evoked release of dopamine and its metabolites from the isolated neurointermediate lobe of the rat pituitary gland in vitro.
Böhm, E; Muscholl, E; Racké, K, 1987
)
0.61
"Pretreatment with reserpine (5 mg/kg) or prazosin was without significant effect."( Evidence for Des-Tyr1-D-Ala2-leucine5-enkephalinamide calcium agonist activity in vascular smooth muscle.
Giles, TD; Given, MB; Sander, GE, 1987
)
0.6
"Pretreatment with reserpine and alpha-methyl-p-tyrosine did not alter the behavioral effects of ciladopa."( Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug.
Fields, JZ; Gordon, JH; Koller, WC; Perlow, MJ, 1986
)
0.59
"Pretreatment with reserpine prevented the restoration of blood pressure by all drugs."( The effects of meptazinol in comparison with pentazocine, morphine and naloxone in a rat model of anaphylactic shock.
Paciorek, PM; Todd, MH; Waterfall, JF, 1985
)
0.59
"Pretreatment with reserpine does not modify the (+)-amphetamine-induced release of dopamine, in spite of the marked reduction of the striatal dopamine content."( Amphetamine induced release of endogenous dopamine in vitro is not reduced following pretreatment with reserpine.
Arbilla, S; Dennis, T; Langer, SZ; Niddam, R; Scatton, B, 1985
)
0.81
"Pretreatment with reserpine caused a significant attenuation of non-opioid analgesia with both shock parameters while none of the antagonists administered (methysergide, phentolamine, phenoxybenzamine, yohimbine, theophylline, diphenhydramine and scopolamine) were effective.(ABSTRACT TRUNCATED AT 250 WORDS)"( Footshock-induced analgesia: neurochemical correlates and pharmacological profile.
Sarne, Y; Segev, S; Urca, G, 1985
)
0.59
"Treatment with reserpine is particularly effective in diminishing arterial prolyl hydroxylase activity."( Increased collagen synthesis in blood vessels of hypertensive rats and its reversal by antihypertensive agents.
Cardinale, GJ; Fuller, GC; Ooshima, A; Spector, S; Udenfriend, S, 1974
)
0.59
"Pretreatment with reserpine had no influence on the contractions caused by adrenaline, noradrenaline and phenylephrine but abolished or greatly reduced the contractions caused by dopamine."( Reversal by pronethalol of dibenamine blockade: a study on the seminal vesicle of the guinea-pig.
Guimarães, S, 1969
)
0.57
"Pretreatment with reserpine, which inhibited the development of papillary necrosis, had little effect on medullary plasma flow."( Experimental papillary necrosis of the kidney. IV. Medullary plasma flow.
Finer, PM; Heptinstall, RH; Miller, M; Quarles, PA; Solez, K, 1974
)
0.58
"Treatment with reserpine, a compound that depletes norepinephrine from nerves, 1-propranolol, a beta-adrenergic blocking agent, or cycloheximide, an inhibitor of protein synthesis, abolishes the nocturnal increase in serotonin N-acetyltransferase activity, indicating that the enzyme activity is modulated by neural release of norepinephrine from sympathetic nerves via beta-adrenergic receptors, and that the increase in enzyme activity is due to synthesis of new enzyme molecules."( Control of circadian change of serotonin N-acetyltransferase activity in the pineal organ by the beta--adrenergic receptor.
Axelrod, J; Deguchi, T, 1972
)
0.59
"Pre-treatment with reserpine (5 mg/kg, 24 h previously) substantially diminished turning evoked by the cocaine-nialamide combination but potentiated turning resulting from administration of methylamphetamine (5 mg/kg).7."( Behavioural studies of the actions of cocaine, monoamine oxidase inhibitors and iminodibenzyl compounds on central dopamine neurones.
Christie, JE; Crow, TJ, 1973
)
0.57
"Pre-treatment with reserpine caused a much greater attenuation of the pyrogenic response to SM than pre-treatment with alpha-methyl-para-tyrosine (AMPT).5."( The mechanism of the pyrogenic effect of streptococcus cell wall mucopeptide.
Masek, K; Rasková, H; Rotta, J, 1968
)
0.57

Toxicity

Reserpine (3 mg/kg) was given iintraperitoneally 24-26 h prior to METH. Adverse reactions to reserpine were reported in 26 patients. Reserpine did not alter survival time after NMTB or ANTU.

ExcerptReferenceRelevance
" Adverse reactions to reserpine were reported in 26 patients (11."( Clinical toxicity of reserpine in hospitalized patients: a report from the Boston Collaborative Drug Surveillance Program.
Greenblatt, DK; Koch-Wester, J; Pfeifer, HJ,
)
0.76
" The present study was designed to test whether the toxic effects of PCA in the brain are dependent on release of endogenous 5-HT and to identify which stores of 5-HT are involved."( The neurotoxic effects of p-chloroamphetamine in rat brain are blocked by prior depletion of serotonin.
Berger, UV; Grzanna, R; Molliver, ME, 1992
)
0.28
" Reserpine did not alter survival time after NMTB or ANTU and did not shift the 14-day LD50 of NMTB."( The involvement of serotonin in the pneumotoxicity induced by N-methylthiobenzamide.
Feny, FJ; Gibbs, LS; Traiger, GJ, 1988
)
1.19
" The central monoamine stores of rats were significantly decreased with reserpine (5 mg/kg) prior to toxic injections of MDMA."( Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat.
Hekmatpanah, CR; McKenna, DJ; Peroutka, SJ, 1989
)
1.95
" The results indicate that reserpine enhances the cytotoxicity of mitoxantrone and adriamycin in mildly toxic concentrations (1 and 10 micrograms respectively), in CML cells."( Mitoxantrone & adriamycin cytotoxicity enhanced by reserpine in human chronic myeloid leukaemia cells.
Advani, SH; Chitnis, MP; Kamath, NS, 1989
)
0.83
" Experiments were designed to determine whether central catecholaminergic systems are implicated in the toxic and lethal manifestations of soman toxicity and whether the protection afforded by clonidine involves such pathways."( Role of central biogenic amines on the protection afforded by clonidine against the toxicity of soman, an irreversible cholinesterase inhibitor.
Aronstam, RS; Buccafusco, JJ; Graham, JH, 1988
)
0.27
"Malathion-induced marked potentiation of BPMC toxicity (about fivefold) was analyzed by measuring LD50 as an index of acute toxicity."( Contribution of monoaminergic nervous system in potentiation of 2-sec-butylphenyl N-methylcarbamate (BPMC) toxicity by malathion in male mice.
Shirasu, Y; Takahashi, H; Tanaka, J; Tsuda, S, 1987
)
0.27
" DL-152 was found to be toxic to cells of all the tumor models tested (KHT fibrosarcoma, RIF-1 fibrosarcoma, EMT-6 adenocarcinoma and Lewis lung carcinoma) when the drug was given by intraperitoneal injection to the tumor-bearing mouse and cell survival was measured by excision assay."( Factors influencing the toxicity of diethylaminoethylreserpine to tumor cells: studies with four transplantable tumors.
Lehnert, S, 1987
)
0.52
" Hypoxic cells were detectable in 10-day-old lung tumors, a time at which the tumors were still resistant to the toxic effects of DL-152."( Toxicity of diethylaminoreserpine to a transplantable tumor: the significance of the presence of hypoxic cells.
Lehnert, S, 1982
)
0.57
" No clinically significant abnormalities in laboratory variables and no serious adverse effects were encountered."( Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients.
Maharaj, B; van der Byl, K, 1993
)
0.51
" Secondary variables included the change in DBP and SBP after 6 weeks of therapy, the BP normalization rates at 3 and 6 weeks and, concerning tolerability, the rates of adverse events after 6 weeks of therapy."( Low-dose reserpine/thiazide combination in first-line treatment of hypertension: efficacy and safety compared to an ACE inhibitor.
Griebenow, R; Mueller, E; Mutschler, E; Pittrow, DB; Weidinger, G; Welzel, D, 1997
)
0.71
" To determine if the vesicular pool of DA was essential for the expression of METH-induced DA neurotoxicity, reserpine (3 mg/kg, given iintraperitoneally 24-26 h prior to METH) was given prior to a toxic dose regimen of METH."( Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity.
Callahan, BT; McCann, UD; Ricaurte, GA; Yuan, J, 2001
)
0.52
" To verify this hypothesis, we investigated the influence of hypothermia on the toxic activity of both neurotoxins."( Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons.
Cleren, C; Costentin, J; Naudin, B, 2003
)
0.58
" Sea urchins use neurotransmitters as embryonic growth regulatory signals, so that adverse effects on neural substrates for mammalian brain development can be studied in this simple organism."( The sea urchin embryo, an invertebrate model for mammalian developmental neurotoxicity, reveals multiple neurotransmitter mechanisms for effects of chlorpyrifos: therapeutic interventions and a comparison with the monoamine depleter, reserpine.
Bezuglov, VV; Buznikov, GA; Lauder, JM; Milosević, I; Nikitina, LA; Rakić, LM; Slotkin, TA, 2007
)
0.52
" It is known that dopamine (DA) enhances this toxic effect."( Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production.
Cano, J; de Pablos, RM; Herrera, AJ; Machado, A; Navarro, A; Santiago, M; Tomás-Camardiel, M; Villarán, RF, 2008
)
0.35
" Reserpine was toxic to worms (decreased the survival, food intake, development and changed egg laying and defecation cycles)."( Extracellular dopamine and alterations on dopamine transporter are related to reserpine toxicity in Caenorhabditis elegans.
Aschner, M; Caito, S; Chen, P; Fachinetto, R; Gubert, P; Reckziegel, P; Soares, FA, 2016
)
1.57

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacodynamic actions of (S)-2-[4,5-dihydro-5-propyl-2(3H)-furylidene]-1,3-cyclopentanedione (oudenone) were studied in both anesthetized animals and isolated organs."( Pharmacodynamic actions of (S)-2-[4,5-dihydro-5-propyl-2-(3H)-furylidene]-1,3-cyclopentanedione (oudenone).
Koide, T; Ozawa, H, 1976
)
0.26
"The pharmacodynamic activity of (+/-)-1-[4-(2-isopropoxyethoxymethyl)-phenoxy]-3-isopropylamino-2- propranol- hemifumarate (bisoprolol, EMD 33 512) has been investigated under in vitro and in vivo conditions."( Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol.
Becker, KH; Bergmann, R; Bourgois, R; Enenkel, HJ; Fuchs, A; Harting, J; Jonas, R; Lettenbaur, H; Minck, KO; Schelling, P, 1986
)
0.27
"The pharmacodynamic effect of a homologous series of aminomethyldimethyl-(methoxyphenyl)-silane derivatives have been tested on isolated guinea-pig left atria."( Pharmacodynamic specification and membrane stabilising action of a homologous series of silasympathomimetics.
Greeff, K; Schlieper, P; Tawfik, H, 1986
)
0.27
" The pharmacokinetic properties were investigated in the remaining control group and test group."( [Pharmacokinetic characteristics of tetramethylpyrazine and study on hemorheology in rat model of spleen deficiency syndrome].
Huang, X; Ren, P; Wen, AD, 1994
)
0.29
" It might be one of the pharmacokinetic mechanisms of TMP in the SDS model of rats."( [Pharmacokinetic characteristics of tetramethylpyrazine and study on hemorheology in rat model of spleen deficiency syndrome].
Huang, X; Ren, P; Wen, AD, 1994
)
0.29
" In the present study, we have investigated the pharmacokinetic and pharmacodynamic characteristics of ibopamine after ocular application."( Ocular pharmacokinetics and pharmacodynamics in rabbits of ibopamine, a new mydriatic agent.
Galbiati, I; Gazzaniga, A; Gianesello, V; Soldati, L; Virno, M, 1993
)
0.29
"The aim of this study was to assess the pharmacokinetics and subsequent pharmacodynamic interaction of MPC-1304, a dihydropyridine Ca2+ antagonist, with other drugs in animal experiments."( Interaction of some drugs on the pharmacokinetics or pharmacodynamics of MPC-1304, a dihydropyridine Ca2+ antagonist.
Miyake, H; Miyoshi, K; Nakano, M; Nishizaki, J; Umeno, Y; Yoshida, K,
)
0.13
"To explore relationship between the essence of Spleen Deficiency Syndrome (SDS) and pharmacokinetic characteristics (PK)."( [Effect of sijunzi decoction on motilin and pharmacokinetic characteristics of tetramethylpyrazine in rat model of spleen deficiency syndrome].
Huang, X; Jiang, YP; Ren, P, 1997
)
0.3
" The developed method was successfully applied to pharmacokinetic study of fixed dose combination of clopamide, reserpine and dihydroergotoxine in healthy male volunteers."( Validated liquid chromatography-tandem mass spectrometry method for simultaneous determination of clopamide, reserpine and dihydroergotoxine: Application to pharmacokinetics in human plasma.
Attia, KA; Demellawy, MA; Kaddah, MM; Nassar, MW; Sharaf El-Din, MM, 2016
)
0.86
" The compounds were designed with the objective of improving pharmacokinetic properties."( Second-Generation Phenylthiazole Antibiotics with Enhanced Pharmacokinetic Properties.
Abdelghany, TM; Bayoumi, SA; Disouky, AM; El-Morsy, A; Elshafeey, A; Mancy, AS; Mayhoub, AS; Mohammad, H; Seleem, MA; Seleem, MN, 2016
)
0.43

Compound-Compound Interactions

The effect of amphetamine sulfate (AMPH) on beta-phenylethylamine (PEA) and 3-methoxytyramine (3MT) levels in the rat frontal and cingulate cortices, the nucleus accumbens, and the striatum was evaluated. When combined with reserpine (40 micromol/L), different concentrations of propofol were found.

ExcerptReferenceRelevance
" Clonidine and the slightly alpha 1-selective agonist ST587, but not ST91, an alpha-agonist which does not readily cross the blood brain barrier, produced marked stimulation when combined with the selective D2 agonist quinpirole."( Alpha 1 (but not alpha 2)-adrenoceptor agonists in combination with the dopamine D2 agonist quinpirole produce locomotor stimulation in dopamine-depleted mice.
Edis, LE; Eshel, G; Jackson, DM; Kelder, D; Ross, SB, 1990
)
0.28
" Unlike clozapine, neither the selective 5-HT2 receptor antagonist, ritanserin, nor the dopamine D2 receptor antagonists, haloperidol and remoxipride, caused locomotor activation when given alone or in combination with SKF38393."( Why does clozapine stimulate the motor activity of reserpine-pretreated rats when combined with a dopamine D1 receptor agonist?
Bengtsson, A; Jackson, DM; Malmberg, A; Mohell, N, 1995
)
0.54
"The effect of amphetamine sulfate (AMPH) on beta-phenylethylamine (PEA) and 3-methoxytyramine (3MT) levels in the rat frontal and cingulate cortices, the nucleus accumbens, and the striatum were evaluated after the administration of either cocaine or reserpine alone and in combination with AMPH."( Effects of the administration of amphetamine, either alone or in combination with reserpine or cocaine, on regional brain beta-phenylethylamine and dopamine release.
Karoum, F; Mosnaim, AD; Wolf, ME,
)
0.54
" When combined with reserpine (40 micromol/L), different concentrations of propofol (12."( [Protective effects of propofol combined with reserpine on cultured PC12 cells impaired by ischemia and reperfusion].
Cao, JB; Li, YF; Mi, WD; Wang, HL, 2008
)
0.93
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"We will compare the clinical efficacy of thunder-fire moxibustion combined with acupressure with pure thunder-fire moxibustion on Ocular muscle spasm using random control method."( Observation on the clinical effect of thunder-fire moxibustion combined with acupressure on ocular muscle spasm: A clinical randomized controlled trial.
Cao, YF; Cui, PL; Li, Q; Li, TJ; Li, Y; Liu, Y; Lü, YY; Ma, QY; Nian, JY; Wu, Y; Xu, YM; Yang, C; Yang, YX; Zhang, Y; Zheng, YH, 2020
)
0.56

Bioavailability

The oral ED2 degrees C relative to IV ED2 degree C as an indirect indication of absorption rate of the drugs was 15. A stable tritiated or radioiodinated reserpine derivative of high specific activity is being sought to improve assay sensitivity.

ExcerptReferenceRelevance
" A stable tritiated or radioiodinated reserpine derivative of high specific activity is being sought to improve assay sensitivity for use in bioequivalence and bioavailability studies."( Antibody specificity studies for reserpine, its metabolites, and synthetic reserpine congeners: radioimmunoassay.
Loeffler, LJ; Schran, HF, 1979
)
0.81
" In inhibiting reserpine-induced hypothermia, the oral ED2 degrees C relative to IV ED2 degrees C as an indirect indication of absorption rate of the drugs was 15 for both YM-14673 and TRH."( Antagonizing effects of YM-14673, a new TRH derivative, on behavioral and electroencephalographic changes in reserpinized animals.
Iwai, A; Shimizu, M; Yamamoto, M, 1988
)
0.63
" Striatal concentrations of 3,4-dihydroxyphenylacetic acid and homovanillic acid were rapidly reduced by N-0500 both after intraperitoneal and oral administration, indicating that this compound is well absorbed from the gastrointestinal tract and passes the blood-brain barrier to activate DA autoreceptors."( Neuropharmacological profile of a new series of dopamine agonists: N-n-propyl-hexahydronaphthoxazines.
De Vries, JB; Dijkstra, D; Hazelhoff, B; Horn, AS; Mulder, TB; Timmermans, PB; Wynberg, H, 1986
)
0.27
" In humans, prolactin-levels can be used for determining bioavailability of some ergot derivatives and for studying whether dopaminergic mechanism plays a role in their antimigraine effect."( Influence of ergot derivatives on prolactin secretion in rats. Mechanisms of action and clinical implications.
Horowski, R, 1983
)
0.27
" Ibopamine is well absorbed through the cornea, it is rapidly hydrolysed by esterases to epinine and the mydriatic effect is correlated with the concentration of epinine in the aqueous humor."( Ocular pharmacokinetics and pharmacodynamics in rabbits of ibopamine, a new mydriatic agent.
Galbiati, I; Gazzaniga, A; Gianesello, V; Soldati, L; Virno, M, 1993
)
0.29
" Inhibition of intestinal P-gp function using MDR reversing agents may enhance the oral bioavailability of some chemotherapeutic agents."( Comparison of effects of surfactants with other MDR reversing agents on intracellular uptake of epirubicin in Caco-2 cell line.
Hsu, CY; Huang, JD; Lo, YL,
)
0.13
"P-glycoprotein (P-gp) is an efflux transporter involved in limiting the oral bioavailability and tissue penetration of a variety of structurally divergent molecules."( Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
Dantzig, AH; Ekins, S; Kim, RB; Lan, LB; Leake, BF; Schuetz, EG; Schuetz, JD; Shepard, RL; Wikel, JH; Winter, MA; Wrighton, SA; Yasuda, K, 2002
)
0.31
"The present study was designed to investigate the involvement of monoaminergic system(s) in the antidepressant activity of curcumin and the effect of piperine, a bioavailability enhancer, on the bioavailability and biological effects of curcumin."( Antidepressant activity of curcumin: involvement of serotonin and dopamine system.
Bhutani, MK; Bishnoi, M; Kulkarni, SK, 2008
)
0.35
" The stronger in vivo effect of (+)-catechin on L-DOPA methylation compared to the other dietary compounds is due to its better bioavailability in vivo."( Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.
Fukui, M; Kang, KS; Wen, Y; Yamabe, N; Zhu, BT, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The present study aims to evaluate the antidepressant effect of different formulations of Thymoquinone; free Thymoquinone (TQ), Thymoquinone-loaded Chitosan nanoparticles (TQ-TPP-Cs NPs) and Thymoquinone-loaded Chitosan nanoparticles coated with polysorbate 80 (TQ-TPP-Cs NPs-PSb80) that have been prepared to avoid the low bioavailability of TQ."( Thymoquinone-encapsulated chitosan nanoparticles coated with polysorbate 80 as a novel treatment agent in a reserpine-induced depression animal model.
Abd Rabo, AA; Abd-El Daim, TM; Elfeky, AS; Fahmy, HM; Khadrawy, YA; Mostafa, IT; Mustafa, AB, 2020
)
0.77

Dosage Studied

Mice dosed with a combination of reserpine + NMTB presented with core temperatures lower than mice treated with either compound alone. Reserpine in this dosage materially reduces arterial pressure and heart rate; these effects last at least 7 days.

ExcerptRelevanceReference
" 4 The dose-response curve for the pressor action of Wy 20051 was potentiated in reserpine-treated anaesthetized rats."( The evaluation of the novel pressor activity of gamma-piperidinobutyramide (WY 20051, DF480).
Alps, BJ; Devoy, PW; Waterfall, JF, 1976
)
0.48
" For this purpose dose-response relations of seven sympathomimetic amines were compared under the influence of alpha- and/or beta-adrenolytic drugs."( alpha-Adrenoceptors mediating positive inotropic effects on the ventricular myocardium: some aspects of structure-activity relationship of sympathomimetic amines.
Endoh, M; Hillen, B; Krappitz, N; Schümann, HJ, 1976
)
0.26
" In atria incubated with phenoxybenzamine from guinea-pigs pretreated with reserpine only the dopamine dose-response curves were displaced to the right indicating a considerable indirect sympathomimetic component."( Analysis of the inotropic: chronotropic selectivity of dobutamine and dopamine in anaethetised dogs and guinea-pig isolated atria.
Broadley, KJ; Levy, GP; Lumley, P, 1977
)
0.49
"In aortic strips, the dose-response curves for phenylephrine were obtained before and after addition of droperidol."( Droperidol, its alpha-adrenergic blocking action on the aortic strip and inhibitory action on norepinephrine uptake of the adrenergic terminal of the left atrial strip of rabbit.
Kasama, A; Kaya, K; Satoh, M; Yamanaka, I; Yanagisawa, M, 1978
)
0.26
" The dose-response curve for the chronotropic action of phenylephrine was parallel to that of isoprenaline, whilst the dose-response curve for the inotropic action of phenylephrine was less steep than that of isoprenaline."( Characterization of adrenoceptors mediating positive inotropic responses in the ventricular myocardium of the dog.
Endoh, M; Shimizu, T; Yanagisawa, T, 1978
)
0.26
", total dose) did not modify the dose-response curve to 5-HT except for the lowest dose."( Analysis of the contractile effect of 5-hydroxytryptamine on the isolated posterior communicating artery of the cat.
Gómez, B; Lluch, S; Marco, EJ; Marín, J; Salaices, M, 1979
)
0.26
" There was a fairly low proportion of patients from each group who were on the drug in any given year, and a fairly wide range of total dosage received."( Matched-pairs study of reserpine use and breast cancer.
Fischer, S; Laska, EM; Meisner, M; Siegel, C; Wanderling, J, 1975
)
0.57
" In view of the clinical dosage levels, it is sugg ested that the antiarrhythmic effects of OPC-1085 depend predominantly on its beta blocking action."( Cardiac electrophysiologic action of carteolol hydrochloride (OPC-1085), a new beta-adrenergic blocking agent.
Ozawa, M; Toda, H; Watanabe, Y, 1978
)
0.26
" FS-32 showed anti-reserpine activity in a dose-dependent manner, whereas imipramine exhibited a bell-shaped dose-response pattern."( Pharmacological studies on a new thymoleptic antidepressant, 1-[3-(dimethylamino)propyl]-5-methyl-3-phenyl-1H-indazole (FS-32).
Fujimura, Y; Ikeda, Y; Iwasaki, T; Koide, T; Matsushita, H; Nagashima, R; Shindo, M; Shiraki, Y; Suzuki, S; Takano, N, 1979
)
0.59
"Effects of electrical stimulation of the hippocampus (HPC), lateral amygdala (1-AMYG) and midbrain central gray matter (CG) on the release of ovulatory gonadotropin were examined using proestrous Wistar rats with or without pretreatment with reserpine, atropine or p-chlorophenylalanine (PCPA) at such dosage that had been confirmed not to block ovulation."( Cholinergic and serotonergic neural links and the inhibitory effects of hippocampus, lateral amygdala and central gray matter on gonadotropin release.
Kawagoe, S; Kawakami, M; Kimura, F, 1976
)
0.44
" Mean pD2 values are presented to illustrate the shifts of the dose-response curves after reserpine treatment."( Noradrenergic subsensitivity and supersensitivity of the cerebral cortex after reserpine treatment.
French, SW; Narod, ME; Palmer, DS, 1976
)
0.7
" Dose-response relationships for isoproterenol (IP) reveal a noncompetitive inhibition of the inotropic action of the catecholamine by ACh."( Catecholamine antagonism of acetylcholine and dibutyrl guanosine 3',-5'-monophosphate in the mammalian ventricular myocardium.
Jacob, R; Schwegler, M, 1975
)
0.25
" Phentolamine, on the other hand, shifted the phenylephrine dose-response curve for contractility to the right without affecting the other parameters."( Biochemical and mechanical effects of phenylephrine on the heart.
McNeill, JH; Verma, SC, 1976
)
0.26
"2 mg/kg) of apomorphine reduced locomotion in a dose-dependent manner, while the reduction after higher doses was less pronounced, indicating a biphasic dose-response relationship."( Catecholamine receptor agonists: effects on motor activity and rate of tyrosine hydroxylation in mouse brain.
Strömbom, U, 1976
)
0.26
" Subsequent to obtaining the first dose-response curve for norepinephrine, aortic strips were less sensitive to norepinephrine."( Specific alpha-adrenergic receptor desensitization in vascular smooth muscle.
Barron, KW; Carrier, O; Wedell, EK, 1978
)
0.26
" 24 h after injection of these doses of reserpine this drug only increased the pressor effect of lower doses of NA without shifting the dose-response curve to the left."( [Effect of reserpine on the potency of alpha receptor blockers].
Benthe, VH; Göthert, M; Krug, J, 1975
)
0.91
" With l-dopa it was antogonised when the dose of morphine was minimal but with increased dosage of morphine, there was no significant effect."( Morphine analgesia and its modification by drugs altering serotonin (5-HT) and dopamine levels in the brain.
Gupta, SK; Shinde, S,
)
0.13
" A beneficial response was noted in most patients when reserpine was substituted for their currently prescribed standard neuroleptic; in some cases lithium dosage could then be reduced."( Lithium plus reserpine in refractory manic patients.
Bacher, NM; Lewis, HA, 1979
)
0.88
" NA (30, 50 micrograms) also produced similar effects to those of 5HT, but DA at the same dosage produced no significant changes in the amplitude and discharge rate of spikes."( Effects of intraventricularly administered serotonin, noradrenaline, dopamine and metaraminol on the reserpine-induced spikes recorded from the medial nucleus trapezoides in rabbits.
Kimura, K; Kimura, Y; Ohata, K; Takagi, H, 1979
)
0.48
" The dosage schedule was one tablet once daily for most patients."( Hypertension in the elderly: review of therapy with a hydroflumethiazide-reserpine combination.
Elkowitz, EB, 1979
)
0.49
" Despite the significant reduction (approximately 50%) of plasma volume loss in this dosage group, there were no significant alterations in either cardiac output or mean arterial pressure."( Effects of reserpine upon thermal stress-induced cardiovascular changes.
Hilton, JG, 1979
)
0.65
" In part of the experiments the animals were pretreated with reserpine at a dosage of 2X0."( [Studies on the mechanism of action of clonidine after pretreatment with reserpine (author's transl)].
Dülme, HJ; Tauberger, G; Thoneick, HU, 1978
)
0.73
" Propranolol (10(-8) and 10(-7) M) produced a parallel shift to the right in the log dose-response curves of ethylephrine with no decrease in the maximal response, indicating that the antagonism was competitive."( Positive inotropic effect of ethylephrine on the isolated rat atria.
Aramendía, P; Márquez, MT; Puntoni de Mikulić, LE, 1977
)
0.26
" The sensitivity of the longitudinal muscle of the fundus to cholinergic agonists and serotonin was not modified by chronic sympathectomy or vagotomy when determined from the ED50 of the dose-response curve."( [Changes in the response to drugs of the rat stomach after a chronic vagotomy and a sympathectomy (author's transl)].
Kamata, K; Kasuya, Y; Watanabe, M, 1978
)
0.26
"A reliable and selective high-pressure liquid chromatographic procedure for the quantitative determination of chlorthalidone in pharmaceutical dosage forms is described."( Quantitative determination of chlorthalidone in pharmaceutical dosage forms by high-pressure liquid chromatography.
Moody, JE; O'Hare, MJ; Tan, E, 1979
)
0.26
" Although the three treatment regimens were similar with respect to safety and efficacy, the reserpine-hydroflumethiazide combination offers the advantages of more convenient dosage at lower cost."( Step 2 regimens in hypertension. An assessment.
Berry, C; Finnerty, FA; Gyftopoulos, A; McKenney, A, 1979
)
0.48
" While 3 to 100 mg/kg of TRH reduced pentobarbital sleeping time when administered prior to the barbiturate, a dose-response relationship to TRH could not be established."( Effects of thyrotropin-releasing hormone (TRH) on the actions of pentobarbital and other centrally acting drugs.
Breese, GR; Cooper, BR; Cott, JM; Lipton, MA; Plotnikoff, NP; Prange, AJ, 1975
)
0.25
"1 Dose-response curves for the positive inotropic and chronotropic responses to isoprenaline were obtained in atria from untreated guinea-pigs and those receiving various reserpine pretreatments."( Selective reserpine-induced supersensitivity of the positive inotropic and chronotropic responses to isoprenaline and salbutamol in guinea-pig isolated atria.
Broadley, KJ; Lumley, P, 1977
)
0.85
"47-fold shift to the left in the dose-response curve to norepinephrine and carbachol, respectively, after pretreatment with reserpine."( Potassium release from the rat submaxillary gland in vitro. III. Effects of pretreatment with reserpine.
Martinez, JR, 1977
)
0.68
" Cumulative dose-response curves for the positive inotropic and chronotropic responses of isolated guinea-pig atria to isoprenaline and the partial agonist salbutamol were plotted as a percentage of the maximum response to isoprenaline."( The influence of temperature upon reserpine-induced supersensitivity of guinea-pig isolated atria to isoprenaline and salbutamol.
Broadley, KJ; Duncan, C, 1977
)
0.54
" Dose-response curves for stimulant agonists were obtained in isolated vasa deferentia which were depolarized by a K-rich, Na-free solution."( The effects of denervation, cocaine, 6-hydroxydopamine and reserpine on the characteristics of drug-induced contractions of the depolarized smooth muscle of the rat and guinea-pig vas deferens.
Westfall, DP, 1977
)
0.5
" The dose-response curves for the two last-mentioned dopamine metabolites closely follow those for MAO A and dopamine-deaminating activity, whether clorgyline or deprenil was used as MAO inhibitor."( Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
Delini-Stula, A; Maître, L; Waldmeier, PC, 1976
)
0.26
" The therapeutic cycles were standardized, for each drug, in the way of administration, dosage and total duration of the treatment."( [Therapeutic possibilities in idiopathic headaches. Analysis of about 1000 cases].
Agostoni, A; Brandi, G; Cottino, A; Gai, V; Gastaldi, L; Lisino, F; Nattero, G, 1976
)
0.26
" The effect of acetylcholine is also significantly potentiated by pretreatment with 6-hydroxydopamine or denervation, but not by reserpine, while the dose-response curve for carbachol is not affected by the specific cholinesterase inhibitor BW 284 C51, denervation or 6-hydroxydopamine."( Uptake and release of catecholamines in sympathetic nerve fibers in the spleen of the cod, Gadus morhua.
Holmgren, S; Nilsson, S, 1976
)
0.46
" The maximum level of concentration in the blood was seen within 4 hr after administration of Li2CO3, and a greater part of the orally dosed Li2CO3 was excreted into the urine."( [Pharmacokinetics and general pharmacological actions of lithium salts administered singly or repeatedly].
Aihara, H; Akiyama, F; Nozu, T; Ozawa, H; Sasajima, M, 1976
)
0.26
" Atria from reserpine-treated (1, 3 or 4 mg/kg 24 hr before) and untreated rabbits were placed in an isolated organ bath for determination of dose-response relationships for norepinephrine, or were used for electrolyte assay."( The influence of reserpine on the responsiveness to norepinephrine and electrolyte contents of rabbit atria.
Carrier, O; Healy, MD; Ramirez, SG; Turlapaty, PD, 1976
)
0.97
" The excitability of the superior cervical ganglion of the rat was not diminished after a three-day treatment with L-Dopa, Benseraside (Ro 4-4602/1) and Iproniazid, at a dosage below the toxic level (table I)."( [Endogenous catecholamines and excitability of the superior cervical ganglion of the rat (author's transl)].
Burlet, DB, 1976
)
0.26
" For the inhibition of the hypotensive action of clonidine by protriptyline a parallel shift of the dose-response curve was obtained, indicating the possibility of a competitive antagonism."( Interaction between centrally acting hypotensive drugs and tricyclic antidepressants.
van Zwieten, PA, 1975
)
0.25
" The main metabolite of piribedil, S 584, had no clear-cut pharmacologic action in our hands at the dosage used."( Apomorphine and piribedil in rats: biochemical and pharmacologic studies.
Barbeau, A; Butterworth, RF; Poignant, JC, 1975
)
0.25
"Mice were given several atropine injections at a high dosage level."( Sensitivity changes to morphine and other drugs induced by cholinergic blockade.
Contreras, E; Quijada, L; Tamayo, L, 1975
)
0.25
" But 3 or 5 days after prior reserpinisation, FLA-63 in the same dosage suppressed or profoundly depressed self-stimulation without eliciting signs of general incapacity."( Self-stimulation and noradrenaline: evidence that inhibition of synthesis abolishes responding only if the "reserve" pool is dispersed first.
Franklin, KB; Herberg, LJ, 1975
)
0.25
" Collaborators were supplied with 3 composites, each from a different dosage level of commercial tablets."( Collaborative study of a semiautomated fluorometric method for the determination of reserpine in tablets.
Kreienbaum, MA, 1976
)
0.48
" In the DA1 blockade groups the ANP dose-response curve was shifted to the right, in a parallel fashion."( Interaction of atrial natriuretic peptide with DA1 receptors in preconstricted isolated perfused rat lungs.
Polak, MJ; Romano, JT; Taylor, DA, 1992
)
0.28
" In the cerebral cortex, reserpine treatment shifted only the early portion of the methacholine dose-response curve to the right."( Subacute reserpine treatment reveals preferential coupling between the M3 muscarinic receptor subtype and phosphatidylinositol turnover.
Gardier, RW; Killian, LN, 1992
)
1
" The dose-response curve for APO-induced yawning was not changed by alpha MPT (200 mg/kg), while the suppression of exploration induced by APO, but not by pergolide, was enhanced by pretreatment with alpha MPT."( Yawning and suppression of exploration induced by dopamine agonists: no relation to extracellular striatal levels of dopamine.
Ståhle, L; Ungerstedt, U, 1990
)
0.28
" The dose-response curve for amphetamine was shifted downward and to the right by reserpine but was flattened by AMPT."( Depletion of catecholamines in the brain of rats differentially affects stimulation of locomotor activity by caffeine, D-amphetamine, and methylphenidate.
Finn, IB; Holtzman, SG; Iuvone, PM, 1990
)
0.5
" Dose-response curves for the effects of PPA and amphetamine (administered IP, 15 min presession) were then determined (ED50 = 35."( Evaluation of the pharmacological similarities between phenylpropanolamine and amphetamine: effects on schedule-controlled behavior.
Jarvis, MF; Wagner, GC, 1990
)
0.28
" The dose-response relationships of norepinephrine and sympathetic nerve stimulation were enhanced by 10(-6) M cocaine in control muscles; this did not occur in muscles from reserpine pretreated ferrets."( Effects of cocaine on excitation-contraction coupling of aortic smooth muscle from the ferret.
Egashira, K; Morgan, JP; Morgan, KG, 1991
)
0.47
" Ketamine, 3 X 10(-4) M, produced a shift to the right of the dose-response curve without altering the maximum contractile responses to carbachol, but had no effect on dose-response curves to substance P, the putative noncholinergic transmitter in these bronchial segments."( Differential effect of ketamine on cholinergic- and noncholinergic-induced contractions of isolated guinea-pig bronchi.
Brunson, DB; Buckner, CK; Laravuso, RB; Leblanc, PH; Will, JA, 1987
)
0.27
" An investigation of reserpine's effects on core temperature revealed that mice dosed with a combination of reserpine + NMTB presented with core temperatures lower than mice treated with either compound alone."( Effect of reserpine on N-methylthiobenzamide-induced pulmonary edema: role of lung norepinephrine and hypothermia.
Gibbs, LS; Traiger, GJ, 1989
)
1
" In mice pretreated with reserpine and various doses of alpha methyl-p-tyrosine (alpha MPT, intraperitoneally), the degree of stimulation produced by (+)-amphetamine was dependent on the amount and frequency of alpha MPT dosage - the higher and more frequent the dose, the more effective the blockade."( The involvement of dopamine D1 and D2 receptors in the locomotor stimulation produced by (+)-amphetamine in naive and dopamine-depleted mice.
Edwards, SR; Jackson, DM; Ross, SB, 1989
)
0.58
" of clonidine, UK-14,304 and B-HT 933 respectively, and the log dose-response curves for all 3 agonists were bell-shaped."( The thermogenic actions of alpha 2-adrenoceptor agonists in reserpinized mice are mediated via a central postsynaptic alpha 2-adrenoceptor mechanism.
Bill, DJ; Hughes, IE; Stephens, RJ, 1989
)
0.28
" Yohimbine caused about a 30 fold shift to the right in the dose-response curve whereas idazoxan almost completely abolished the mydriatic response to (+)-Amp."( Mechanism of dexamphetamine-induced mydriasis in the anaesthetized rat.
Hey, JA; Ito, T; Koss, MC, 1989
)
0.28
" Reserpine in this dosage materially reduces arterial pressure and heart rate; these effects last at least 7 days."( Responses of the three-toed sloth, Bradypus tridactylus, to some commonly used pharmacologic agents. II. Chloralose and reserpine.
Da Costa, CP; Duarte, DP; Huggins, SE; Leal, AM, 1989
)
1.4
" Treatment of reserpinized rats with pargyline, a non-selective inhibitor of monoamine oxidase, in order to increase cerebral 5-HT levels, shifts the PCA dose-response curve for inducing the 5-HT behavioural syndrome to the left."( 5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats.
Kuhn, DM; Wolf, WA; Youdim, MB, 1985
)
0.27
" Although some patients remained normotensive after discontinuation of step II drugs, a greater proportion returned to elevated BP than when step II dosage was unchanged."( Effects of reduction in drugs or dosage after long-term control of systemic hypertension.
Borreson, RE; Fisher, SG; Freis, ED; Hamburger, R; Mezey, KC; Mukherji, B; Neal, WW; Perry, HM; Taguchi, JT; Thomas, JR, 1989
)
0.28
" Dose-response curves revealed that maximal hyperglycemia was associated with hypoinsulinemia."( 5-HT1A and alpha-2 adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-n-propylamino)tetralin in the conscious rat.
Chaouloff, F; Jeanrenaud, B, 1987
)
0.27
" beta-Adrenoceptor antagonists produced a bell-shaped dose-response curve on histamine contractions in cat isolated lung parenchyma strip."( The response of cat airways to histamine in vivo and in vitro.
Blaber, LC; Fryer, AD, 1985
)
0.27
" Methoxamine produced a dose-related increase in uterine activity, prazosin produced a rightward displacement of the dose-response curve of methoxamine reaching the same maximal effect."( Effect of methoxamine on spontaneous motility of the isolated rat uterus.
Esplugues, J; Estañ, L; Morales-Olivas, FJ; Rubio, E, 1985
)
0.27
" These differences may be explained only partially by an increased susceptibility of the LS mice to the hypothermia and toxic effects caused by AMPT administration, as they persist with non-toxic AMPT dosage regimens and under conditions where the degree of hypothermia is comparable in both lines of mice."( Alpha-methyl-para-tyrosine effects in mice selectively bred for differences in sensitivity to ethanol.
Clay, KL; French, TA; Murphy, RC; Weiner, N, 1985
)
0.27
" In two cases, reduction in reserpine dosage did not result in relapse into psychosis."( Reserpine and phencyclidine-associated psychosis: three case reports.
Berlant, JL, 1985
)
2.01
" The thrombin dose-response relationship was complex and did not have a classic sigmoidal shape, whether the endothelium was functional or not."( Alpha adrenoceptor antagonists selectively reduce thrombin-stimulated contraction in rabbit arteries.
Bevan, JA; Garland, CJ, 1986
)
0.27
" Isolated aortic rings were mounted in tissue baths for the measurement of isometric contraction and 5-HT dose-response curves were obtained in the presence and absence of receptor antagonists."( Receptors for 5-hydroxytryptamine in rabbit blood vessels: activation of alpha adrenoceptors in rabbit thoracic aorta.
Murray, DL; Purdy, RE; Stupecky, GL, 1987
)
0.27
" The pressor response to levamisole was not modified by either reserpinization, acute bilateral adrenalectomy or pretreatment with cocaine, whereas pretreatment with dexamethasone, nialamide or pyroaallol shifted the dose-response curve to the right."( Investigation of some effects of levamisole on dog blood pressure.
Gulati, OD; Hemavathi, KG; Shah, KK,
)
0.13
" Reserpinization shifted the (-)-norephedrine dose-response curve slightly to the right, indicating that only a minor portion of its activity is due to the release of stored endogenous catecholamines."( Adrenergic receptor subtype activation by (+)-, (-)- and (+/-)-norephedrine in the pithed rat.
Maher, TJ; Moya-Huff, FA, 1987
)
0.27
" Tityustoxin caused a slight leftward shift of the dose-response curves to adrenaline and norepinephrine and a large potentiation of the frequency-response curves to electrical stimulation."( Effects of tityustoxin on the rat isolated tail artery.
Catanzaro, OL; Savino, EA, 1985
)
0.27
" Twice daily doses (50 mg/kg body wt) of the non-selective beta-adrenergic agonist, isoproterenol, for six days, increased Ca-ATPase specific activity of parotid gland by 17 per cent but that of submandibular gland was the same as controls; with dobutamine, the same dosage caused a 53 per cent decrease in submandibular activity and a 31 per cent decrease in parotid."( Ca-ATPase activity in salivary glands of rats treated with reserpine, isoproterenol, terbutaline or dobutamine.
Cheung, H; Schneyer, CA, 1987
)
0.52
" Pretreatment of the rats with reserpine (5 mg/kg) did not produce any modification of the dose-response curve to dopamine."( Relaxant effect of dopamine on the isolated rat uterus.
Estañ, L; Martinez-Mir, I; Morales-Olivas, FJ; Rubio, E, 1988
)
0.56
" Prior reserpinization did not significantly shift the cumulative dose-response curves for l-NOR and PPA."( Cardiovascular differences between phenylpropanolamine and its related norephedrine isomers in the rat.
Kiritsy, PJ; Maher, TJ; Moya-Huff, FA, 1987
)
0.27
" Dose-response curves to serotonin were not altered in the high potassium medium whereas those to adrenaline displayed slight changes."( Responses of potassium-depolarized rat tail arteries to adrenaline and serotonin.
Polidoro, JH; Savino, EA, 1987
)
0.27
" The dose-response curves of the effect of 10-210 mM of acetone on the ACR and the peak of NE release were parallel."( Correlation between positive chronotropic effect and norepinephrine release induced by acetone in the rat right atrium.
Chentanez, T; Sadavongvivad, C; Tantrarungroj, K, 1987
)
0.27
" Epinephrine stimulation of AC was affected by reserpine and was characterized by an upward shift of the epinephrine dose-response curve with no change in the epinephrine EC50."( Reserpine-induced supersensitivity in adenylate cyclase preparations from guinea-pig heart.
Cros, GH; McNeill, JH, 1987
)
1.97
" After 3 and 6 months of maintenance therapy, blood pressures were measured 24 hours after the previous day's dosing to evaluate the persistence of the antihypertensive effect."( The management of severe hypertension with minoxidil in a once-a-day treatment regimen.
Bayley, A; Fraser, HS; Hassell, TA; Nicholson, GD, 1985
)
0.27
"The effect of prior administration of reserpine on fentanyl dose-response curves for loss of the righting reflex and prevention of purposeful movement response to noxious stimulation was studied in rats."( Reserpine-induced changes in anesthetic action of fentanyl.
Brown, PT; Kissin, I, 1985
)
1.98
" The dose-response relationship for hyperactivity in grouped mice following the injection of morphine sulphate has been established."( Monoamine mediation of the morphine-induced activation of mice.
Carroll, BJ; Sharp, PT, 1972
)
0.25
"3 A second cannabis extract (II) with a different ratio of cannabinoids (also administered in dosage equivalent to 10 mg Delta(9)-THC/kg) failed to affect pentobarbitone anaesthesia in mice."( Interaction of cannabis and general anaesthetic agents in mice.
Chesher, GB; Jackson, DM; Starmer, GA, 1974
)
0.25
" Hexamethonium and hyoscine did not affect the dose-response relationship for NA."( Studies of the interaction of 5-hydroxytryptamine and the perivascular innervation of the guinea-pig caecum.
Drakontide, AB; Gershon, MD, 1972
)
0.25
"Inotropic dose-response curves were constructed for a series of beta-adrenoceptor antagonists, based on the inotropic responses of isolated dog trabecular muscles stimulated to contract at a regular rate."( Comparative partial agonist activity of -adrenoceptor antagonists.
Nayler, WG, 1972
)
0.25
" Type I sensitizations are appropriately described by determining the dose-ratio (horizontal shift of the dose-response curve) and type II sensitizations by assessing the change in the magnitude of the response."( A new approach to the measurement and classification of forms of supersensitivity of autonomic effector responses.
Kalsner, S, 1974
)
0.25
" In adult cats, cocaine (1 and 10 mug/ml) or denervation produced a shift to the left of dose-response curves to (-)-noradrenaline, whereas they failed to modify dose-response curves to (-)-isoprenaline."( Effects of cocaine or denervation on responses of isolated strips of cat spleen to (-)-noradrenaline and (-)-isoprenaline.
Granata, AR; Langer, SZ, 1973
)
0.25
" These changes included decreases in visual exploration and locomotion, and increases in self-huddling, posturing, and tremor; and 2) the behavioral effects of repeated daily dosage were not cumulative nor was tolerance developed by the drugged monkeys."( Effects of reserpine on the social behavior of rhesus monkeys.
Eising, RG; Harlow, HF; McKinney, WT; Moran, EC; Suomi, SJ, 1971
)
0.64
" The shifted dose-response curve was not parallel to the original."( Modification by prostaglandin E 2 (PGE 2 ) of the response of guinea-pig isolated vasa deferentia and atria to adrenergic stimuli.
Bhagat, B; Dhalla, NS; Ginn, D; La Montagne, AE; Montier, AD, 1972
)
0.25
" The magnitude of the supersensitivity was inversely correlated with the slope of the dose-response curves to the four agonists."( Nonspecific supersensitivity of the guinea-pig vas deferens produced by decentralization and reserpine treatment.
Westfall, DP, 1970
)
0.47
" The dose-response curve for propranolol inhibition of 125I-hydroxybenzylpindolol binding duplicated that reported for its physiologic action."( Beta receptor occupancy. Assessment in the intact animal.
Homcy, CJ; Kopiwoda, S; Strauss, HW, 1980
)
0.26
" Dose-response relations for the depressant effects are similar for pacemaker frequency and for tension development in atrial and papillary muscle."( Stimulant and depressant effects of beta-adrenoceptor blocking agents on isolated heart muscle. A positive inotropic effect not mediated through andrenoceptors.
Blinks, JR; Kaumann, AJ, 1980
)
0.26
" These findings indicate that to establish the actual responses to high external potassium, non cumulative dose-response curves must be performed."( Responses of the rat tail artery to high external potassium concentration.
Polidoro, JH; Savino, EA, 1982
)
0.26
" The present work investigates in vitro the inhibitory dose-response curves to histamine, 4-methyl-histamine and 2-pyridylethylamine in depolarized (KCl 37 mM) uterus from estrogenous sensitized rats."( [Inhibitory action of histamine on the isolated rat uterus].
Esplugues, J; Marti-Bonmati, E; Morales-Olivas, FJ; Morcillo, E; Rubio, E,
)
0.13
" Cocaine plus reserpine shift the dose-response curve for phenylephrine to the left."( Mechanism of action of phenylephrine on isolated guinea-pig atria rate.
Nigro, D; Scivoletto, R, 1983
)
0.63
" Pre-treatment of the rats with syrosingopine shifted the dose-response curve to the left (enhancement) while combined propranolol (800 micrograms/kg) and phentolamine (800 micrograms/kg) shifted the dose-response curve to the right (depression)."( Rat endometrial bioelectric activity in vivo and in vitro: effects of adrenaline.
Levin, RJ; Phillips, JC, 1983
)
0.27
"6 mM) produced a non-parallel shift to the right of dose-response curves to (-)-isoprenaline in K+ depolarized uterine preparations from the guinea-pig."( Is Ro 03-7894 an irreversible antagonist at beta-adrenoceptor sites?
Krstew, E; Malta, E; McPherson, GA; Molenaar, P; Raper, C, 1984
)
0.27
" Administration of nitrazepam with other drugs, except aminopyrine, or of estazolam together with haloperidol exhibited an anticonvulsive pattern different from the case of dosing with either drug alone."( [Pharmacology of a 1H-1, 2, 4-triazolyl benzophenone derivative (450191-S), a new sleep-inducer (III). Behavioral study on interactions of 450191-S and other drugs in mice].
Horiuchi, M; Ibii, N; Yamamoto, K, 1984
)
0.27
" In both preparations only the combined application of phentolamine (10(-6) M) and pindolol (3 X 10(-8) M) shifted the entire dose-response curves for the positive inotropic effect of dopamine to the right, while either antagonist used separately had no effect."( The mode of direct action of dopamine on the rabbit heart.
Brodde, OE; Inui, J; Motomura, S; Schümann, HJ,
)
0.13
" 2 The dose-response relation for each agonist was established, as also were the ED50 values."( Characterization of the rat parotid beta-adrenoceptor.
Carlsöö, B; Danielsson, A; Henriksson, R; Idahl, LA, 1981
)
0.26
" The reduction of oestradiol-17 beta dosage from 60 mg to 30-40 mg day-1 with progesterone at 150 or 200 mg day-1 for the initial 7 days increased both milk yield and the success rate of the hormonal induction of lactation and eliminated pelvic fractures and excessive oestrous activity in treated cows."( Artificial induction of lactation in dry cows.
Bílek, J; Pícha, J; Skarda, J; Tersch, P; Urbanová, E, 1982
)
0.26
" Three days post-AMI the dose-response curve for isoproterenol of right ventricular dP/dtmax was significantly depressed, while the inotropic effect of histamine was not impaired."( Impaired beta-adrenergic stimulation in the uninvolved ventricle post-acute myocardial infarction: reversible defect due to excessive circulating catecholamine-induced decline in number and affinity of beta-receptors.
Baumann, G; Blömer, H; Blümel, G; Erhardt, WD; Felix, SB; Ludwig, L; Riess, G, 1981
)
0.26
" For MES testing, mice were injected with either reserpine, yohimbine, propranolol, haloperidol or metergoline prior to dosing with TET."( Pharmacological and biochemical evaluation of triethyltin's anticonvulsant effects.
Fox, DA,
)
0.39
" Imidazole had no effect on the dose-response relationship for Ca2+ in the presence of potassium, 40 mM."( Imidazole-induced potentiation of the contractile response to various agonists in vascular smooth muscle.
Hester, RK; Ishida, Y; Shibata, S; Suzuki, Y, 1982
)
0.26
" We feel that in developing countries, where the cost of therapy is important, reserpine in a dosage of less than 0,1 mg/d plus a thiazide derivative in low dosage is preferable to a beta-blocker plus a thiazide derivative in the treatment of hypertension."( Reserpine plus hydrochlorothiazide and sotalol plus hydrochlorothiazide in Black and Indian hypertensive patients.
Bhigjee, AI; Hoosen, S; Seedat, YK, 1984
)
1.94
" DHEC antagonized 5-HT in a non competitive manner, shifting to the right and flattening the dose-response curves of this agonist."( Inhibition of norepinephrine- and 5-hydroxytryptamine-induced contraction on rat aorta by dihydroergocristine.
D'Agostino, G; Dondi, G; Grana, E; Zonta, F, 1984
)
0.27
"33 mg/kg reserpine was a reduction in maternal weight gained during both dosing periods."( Postnatal toxicity following prenatal reserpine exposure in rats: effects of dose and dosing schedule.
Buelke-Sam, J; Kimmel, CA; Kimmel, GL; Nelson, CJ; Newport, GD; Slikker, W; Webb, PJ, 1984
)
0.96
" showed moderate effects, but the dosage also inhibited cysteamine-stimulated acid secretion."( Effects of a gastric antisecretory-cytoprotectant 2-methyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine-3-acetonitrile (Sch 28 080) on cysteamine, reserpine and stress ulcers in rats.
Barnett, A; Brown, AD; Chiu, PJ; Gerhart, C, 1984
)
0.47
" They had simultaneously started therapy with, or increased the dosage of, chlorthalidone or hydrochlorothiazide for the treatment of hypertension."( Serum cholesterol during treatment of hypertension with diuretic drugs.
Ames, RP; Peacock, PB, 1984
)
0.27
"3 mg/kg) or prazosin in high dosage (0."( Bronchopulmonary effects of clonidine on the bronchomotor responses of the guinea-pig.
Advenier, C; Floch, A; Mallard, B, 1983
)
0.27
" AM was not able to cause contraction of strips obtained from dogs pretreated with reserpine; phentolamine shifted the dose-response curve of AM to the right."( On the mechanism of action of amezinium methylsulphate on the dog saphenous vein.
Araújo, D; Caramona, MM; Osswald, W, 1983
)
0.49
" Incubation of tissues with papaverine (1 hr) changed the usual dose-response curve to isoproterenol into a low, monotonous effect, independent of the agonist dose."( Papaverine-induced changes on cardiac inotropism with special reference to a D-propranolol antagonism.
Aramendía, P; Márquez, MT, 1982
)
0.26
" The latter depends on the dosage schedule and fails in developing adaptive changes to chronic reserpine administration."( [Central depletion of transmitters by reserpine and motor behavior in the rat (author's transl)].
Funk, KF; Schmidt, J; Westermann, KH, 1980
)
0.75
" 6-OHDA produced a leftward shift of the dose-response curve of NA."( Comparative studies of the effects of 5-hydroxytryptamine and noradrenaline on the rat anococcygeus muscle.
Goyal, RK; Patel, NM; Verma, SC, 1981
)
0.26
" After sacrifice, acini were prepared, and amylase dose-response curves to carbamylcholine (Cch) and secretin were established."( Alterations of pancreatic amylase secretion in the reserpinized rat model of cystic fibrosis. Effects of cerulein and EGF.
Benrezzak, O; Bérubé, FL; Morisset, J; Vanier, M, 1994
)
0.29
" Oral dosing with amiodarone has no such effect."( Sympatholytic action of intravenous amiodarone in the rat heart.
Dart, AM; Du, XJ; Esler, MD, 1995
)
0.29
" The dose-response relationship shifted to the left following REMs deprivation (ED50 values in the group-housed, isolated, and REMs-deprived mice were 250, 200, and 27 micrograms/kg, respectively)."( Monoamine depletion attenuates the REM sleep deprivation-induced increase in clonidine response in the forced swimming test.
Asakura, W; Matsumoto, K; Ohta, H; Watanabe, H, 1994
)
0.29
" Only trace amounts of 306U73 were detected after bupropion dosing for the Porsolt test."( Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism.
Cooper, BR; Cox, RF; Ferris, RM; Norton, R; Shea, V; Wang, CM, 1994
)
0.29
" Clemizole and reserpine treatment did not produce any modification of the dose-response curve to histamine."( Effect of histamine on the longitudinal and circular muscle of the oestrogen dominated rat uterus.
Estañ, L; Herrero, J; Martínez-Mir, I; Morales-Olivas, FJ; Rubio, E, 1993
)
0.64
"5 to 37 fold) to the right of the dose-response curve for clonidine without significant change of maximum inhibitory effect, in a manner compatible with competitive antagonism (ED50B = 29."( Modulation by central postsynaptic alpha 2-adrenoceptors of the jaw-opening reflex induced by orofacial stimulation in rats.
Barturen, F; García-Sevilla, JA; García-Vallejo, P, 1994
)
0.29
" However, the incidences of multiple mammary gland tumors were significantly increased in dosed females from both lines."( Chemical effects in transgenic mice bearing oncogenes expressed in mammary tissue.
Braun, AG; Rao, GN; Russfield, A; Seilkop, S; Tennant, RW, 1993
)
0.29
" The dose-response curves for the effects of aminophylline in the presence of Ni2+ on Td and dT/dt max during direct single-pulse stimulation were significantly shifted to the right."( Some new evidence on antifatigue action of aminophylline on the isolated hemidiaphragm of the rat.
Prostran, M; Todorović, Z; Varagić, VM, 1993
)
0.29
" The ED50 values 4 h after oral dosing were 13."( Topiramate: preclinical evaluation of structurally novel anticonvulsant.
Davis, CB; Dodgson, SJ; Gardocki, JF; Maryanoff, BE; Nortey, SO; Raffa, RB; Schupsky, JJ; Shank, RP; Vaught, JL,
)
0.13
"Isolated rabbit kidneys were perfused with Krebs-Henseleit solution in an open system designed to allow study of dose-response relationships."( The effect of indomethacin and reserpine on renal vascular escape.
de Lima e Forti, CA; Fonteles, MC, 1993
)
0.57
" If the DBP did not reach 90 mmHg after four weeks, the dosage was doubled."( Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients.
Maharaj, B; van der Byl, K, 1993
)
0.51
"Combined treatment with propranolol and reserpine enhanced acetylcholine-induced dose-response curves for bronchoconstriction in guinea pigs in vivo."( Pharmacological model for airway hypersensitivity produced by propranolol and reserpine in guinea pigs.
Goto, S; Inagaki, N; Koda, A; Nagai, H, 1993
)
0.78
" The dose-response curve for dopamine to stimulate the heart rate (HR) closely resembled that for the norepinephrine release."( The mechanisms underlying heart stimulation by dopamine, with special reference to direct and indirect beta adrenoceptor stimulation.
Habuchi, Y; Komori, T; Nishio, M; Tanaka, H; Yamamoto, T; Yoshimura, M,
)
0.13
" After 6 weeks of treatment with one capsule daily, mean reductions in sitting BP from baseline at 24 hours after dosing in the reserpine-clopamid combination, reserpine, clopamid, and nitrendipine groups were -23."( Different concepts in first-line treatment of essential hypertension. Comparison of a low-dose reserpine-thiazide combination with nitrendipine monotherapy. German Reserpine in Hypertension Study Group.
Kirch, W; Krönig, B; Pittrow, DB; Weidinger, G; Welzel, D, 1997
)
0.72
" Incipient congenic strains of D2R-deficient mice demonstrated an orderly gene dosage reduction in locomotion superimposed on both extremes of parental background locomotor activity."( Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations.
Bunzow, JR; Burkhart-Kasch, S; Fang, Y; Gerhardt, GA; Grandy, DK; Kelly, MA; Lessov, CN; Low, MJ; Phillips, TJ; Rubinstein, M; Zhang, G, 1998
)
0.3
" The dose-response curves of (+)-norfenfluramine-induced [3H]5-HT release were superimposable in hippocampus and hypothalamus, and also superimposable on the curve for (+)-fenfluramine-induced [3H]5-HT release; the dopamine releasing potency of (+)-norfenfluramine in the striatum was more than ten times lower."( In vitro studies on the mechanism by which (+)-norfenfluramine induces serotonin and dopamine release from the vesicular storage pool.
Gobbi, M; Mennini, T; Parazzoli, A, 1998
)
0.3
" AMPH at a dosage of 1 mg/kg significantly increased PEA concentration only in the striatum."( Effects of the administration of amphetamine, either alone or in combination with reserpine or cocaine, on regional brain beta-phenylethylamine and dopamine release.
Karoum, F; Mosnaim, AD; Wolf, ME,
)
0.36
" accelerated the chronic ulcer healing with a bell-shaped dose-effect curve and the best dosage was 10 kU."( Effect of recombinant human basic fibroblast growth factor on stomach ulcers in rats and mice.
Gao, MT; Li, WG; Rao, CM; Wang, JZ; Wu, YJ, 1999
)
0.3
" Increases in serum PRL levels are enhanced when daily dosages are administered via multiple-daily dosing of the test compound, which results in higher sustained blood levels of the test compounds."( Detection of dopaminergic modulators in a tier I screening battery for identifying endocrine-active compounds (EACs).
Cook, JC; Davis, LG; Frame, SR; O'Connor, JC,
)
0.13
" These results suggested that 2-weeks treatment with reserpine is sufficient for detection of testicular toxicity, although higher dosage levels are appropriate than for 4-weeks treatment."( Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 7). Effects of reserpine in 2- and 4-weeks studies.
Nakatsuji, S; Noto, T; Ohishi, Y; Saegusa, T; Takaura, Y; Yamauchi, K, 2000
)
0.77
" The effect of huperzine A on memory impairments exhibited an inverted U-shaped dose-response pattern."( Effect of huperzine A on working memory in reserpine- or yohimbine-treated monkeys.
Cai, JX; Ou, LY; Tang, XC, 2001
)
0.57
"In a controlled study (the control group receiving pyribenzamine) it was observed that reserpine, in the dosage used, had no effect on weight loss in patients receiving d-amphetamine sulphate (Dexedrine(R)) and methyl cellulose (Cellothyl(R)) while on 1,000-calorie diets as compared with the control group."( Reserpine in weight reduction. The effect in obese patients on 1,000-calorie diets: a controlled study.
SMITH, MC, 1959
)
1.9
" Bretylium and guanethidine depress the slopes of the dose-response curves for the pressor and nictitating membrane contracting effects of tyramine."( Comparison of bretylium and guanethidine: tolerance, and effects on adrenergic nerve function and responses to sympathomimetic amines.
BOURA, AL; GREEN, AF, 1962
)
0.24
" Dose-response curves were established for the noradrenaline-induced (10(-12) to 10(-7) mol/kg) increase of diastolic blood pressure in pithed rats treated with tubocurarine, propranolol, and atropine."( Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation.
Dendorfer, A; Dominiak, P; Raasch, W; Ziegler, A, 2004
)
0.32
"01), and the high dosage significantly inhibited the activity of MAO-A in hypothalamus (P<0."( [Effect of madecassoside on depression behavior of mice and activities of MAO in different brain regions of rats].
Chen, Y; Han, T; Liu, MR; Qin, LP; Rui, YC; Zheng, HC, 2004
)
0.32
" perforatum, 5-THP, at the dosage without any side-effects, caused the tremble in the mice."( [Experimental study of the total flavonoid in Hypericum perforatum on depression].
Liu, JX; Tu, PF; Wang, JN; Wei, CE; Xu, L; Zhao, MB, 2005
)
0.33
" The rectal temperature decreased to 29 degrees C 6h post dosing and thereafter sustained at lower values (24-25 degrees C) until 96 h post dosing."( Hypothermia-related testicular toxicity of reserpine in mice.
Fukuda, M; Kitaura, K; Matsumoto, S; Minami, T; Sato, M, 2007
)
0.6
"A self-aspirating, liquid microjunction surface sampling probe/electrospray emitter mass spectrometry system was demonstrated for use in the direct analysis of spotted and dosed drugs and their metabolites in thin tissue sections."( Liquid microjunction surface sampling probe electrospray mass spectrometry for detection of drugs and metabolites in thin tissue sections.
Kertesz, V; Koeplinger, KA; Kong, AN; Van Berkel, GJ; Vavrek, M, 2008
)
0.35
" However, the dose-response pattern could not be determined because of the small number of trials."( Blood pressure lowering efficacy of reserpine for primary hypertension.
Perez, MI; Shamon, SD, 2009
)
0.63
" However, we could not make definite conclusions regarding the dose-response pattern because of the small number of included trials."( Blood pressure lowering efficacy of reserpine for primary hypertension.
Perez, MI; Shamon, SD, 2009
)
0.63
"This article reviews the chemistry, pharmacology, pharmacokinetics, therapeutic use, tolerability, drug-interaction potential, and dosing and administration of TBZ."( Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
Guay, DR, 2010
)
0.36
" It is one of very few drugs whose dosing is based, in part, on the results of genotyping (in its case, genotyping for CYP2D6 metabolizer status)."( Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
Guay, DR, 2010
)
0.36
"100 healthy adult male SD rats, with a mean weight of 200 g, were randomly divided into five groups in average: control group, reserpine treated group, atropine treated group, treatment groups with Lizhong Pill at high dose and low dose (equal to the dosage of crude drugs for 4 g/kg/d and 8 g/kg/d)."( Effects on neuroendocrinoimmune network of Lizhong Pill in the reserpine induced rats with spleen deficiency in traditional Chinese medicine.
Guo, Y; Jia, H; Liu, Z; Lu, A; Xu, S; Zha, Q; Zhang, W; Zhao, N, 2011
)
0.81
" These candidates were subjected to a dose-response bioactivity assay, measuring an increase in α-tubulin K40 acetylation in two neuronal cell lines, which yielded five compounds bioactive in both cell lines and eight compounds bioactive in at least one of the cell lines tested."( Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.
Choi, SH; Kazantsev, AG; Khanfar, MA; Quinti, L; Silverman, RB; Wang, H, 2014
)
0.4
" However, we could not determine the dose-response pattern because of the small number of trials."( Blood pressure-lowering efficacy of reserpine for primary hypertension.
Perez, MI; Shamon, SD, 2016
)
0.71
" However, we could not make definite conclusions regarding the dose-response pattern because of the small number of included trials."( Blood pressure-lowering efficacy of reserpine for primary hypertension.
Perez, MI; Shamon, SD, 2016
)
0.71
" Mice dosed with reserpine (0."( Monoamine system disruption induces functional somatic syndromes associated symptomatology in mice.
Azuma, R; Kawasaki, S; Miwa, M; Murai, S; Nagakura, Y; Ohsaka, N; Saito, H; Takahashi, S; Takebayashi, Y, 2018
)
0.82
" For many years' clinicians have used it for the treatment of high blood pressure, but with the passage of time and introduction of new anti-hypertensive drugs, the usage of reserpine has gone down drastically most probably due to poorly understood mechanism of action and multiple misleading adverse effects precisely due to high dosing of reserpine."( Therapeutic potential of reserpine in metabolic syndrome: An evidence based study.
Paliwal, S; Sharma, S; Verma, K, 2022
)
1.22
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
first generation antipsychoticAntipsychotic drugs which can have different modes of action but which tend to be more likely than second generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements; such body movements can become permanent even after treatment has ceased.
adrenergic uptake inhibitorAdrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
EC 3.4.21.26 (prolyl oligopeptidase) inhibitorAny EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26).
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
yohimban alkaloid
alkaloid ester
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (128)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency36.96750.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency17.78280.044717.8581100.0000AID485341
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency56.23410.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency22.38720.177814.390939.8107AID2147
interleukin 8Homo sapiens (human)Potency66.82420.047349.480674.9780AID651758
endonuclease IVEscherichia coliPotency6.30960.707912.432431.6228AID1708
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency32.31050.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency19.95260.012610.691788.5700AID887
RAR-related orphan receptor gammaMus musculus (house mouse)Potency30.52200.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency21.05210.173734.304761.8120AID1346859; AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency10.78870.004110.890331.5287AID493107; AID504467
USP1 protein, partialHomo sapiens (human)Potency25.28550.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency10.00000.35487.935539.8107AID624146
SMAD family member 3Homo sapiens (human)Potency21.05210.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency22.73830.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency15.25820.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency14.12540.180013.557439.8107AID1460
ThrombopoietinHomo sapiens (human)Potency31.62280.02517.304831.6228AID917; AID918
AR proteinHomo sapiens (human)Potency38.11370.000221.22318,912.5098AID1259243; AID1259247; AID588516; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency68.45010.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency29.88160.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency19.30890.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency36.29320.001022.650876.6163AID1224838; AID1224839; AID1224893
regulator of G-protein signaling 4Homo sapiens (human)Potency18.86970.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency7.03570.01237.983543.2770AID1346984; AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency4.46680.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency22.44610.000214.376460.0339AID588532; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency33.49150.003041.611522,387.1992AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency18.41830.000817.505159.3239AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency24.30590.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency20.29920.375827.485161.6524AID588526; AID588527; AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency18.68120.005428.02631,258.9301AID1346982; AID1346985; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency32.61870.000229.305416,493.5996AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency24.54540.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency15.48710.00108.379861.1304AID1645840
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency28.18380.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency22.88010.001024.504861.6448AID588534; AID588535; AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency19.20240.001019.414170.9645AID588536; AID588537; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency18.77650.023723.228263.5986AID588541; AID588543; AID743222; AID743223; AID743241
caspase-3Homo sapiens (human)Potency68.45010.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency32.64270.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.22730.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency41.28000.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency33.35370.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.72180.001628.015177.1139AID1224843; AID1224895
activating transcription factor 6Homo sapiens (human)Potency50.36630.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency50.366319.739145.978464.9432AID1159509
Bloom syndrome protein isoform 1Homo sapiens (human)Potency17.78280.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency47.754823.934123.934123.9341AID1967
hemoglobin subunit betaHomo sapiens (human)Potency31.62280.31629.086131.6228AID925
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency42.80000.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency44.96470.006026.168889.1251AID488953; AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency40.87070.010039.53711,122.0200AID588547
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency25.92900.00419.984825.9290AID504444
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency2.87490.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency28.60950.000323.4451159.6830AID743065; AID743066; AID743067
importin subunit beta-1 isoform 1Homo sapiens (human)Potency28.12525.804836.130665.1308AID540253; AID540263
DNA polymerase betaHomo sapiens (human)Potency31.62280.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency7.94330.039816.784239.8107AID995
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency42.23954.466824.832944.6684AID651749
flap endonuclease 1Homo sapiens (human)Potency21.78960.133725.412989.1251AID588795
snurportin-1Homo sapiens (human)Potency28.12525.804836.130665.1308AID540253; AID540263
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency28.18380.010323.856763.0957AID2662
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency45.47810.000627.21521,122.0200AID651741; AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency37.02640.425612.059128.1838AID504536; AID504891
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency11.58215.804816.996225.9290AID540253
DNA polymerase eta isoform 1Homo sapiens (human)Potency7.94330.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency10.00000.050127.073689.1251AID588590
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency28.18380.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency19.70230.004611.374133.4983AID463097; AID504364; AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency18.10560.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency3.98110.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency28.81920.177824.735279.4328AID488949
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency39.81070.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency7.07950.251215.843239.8107AID504327
caspase-1 isoform alpha precursorHomo sapiens (human)Potency7.94330.000311.448431.6228AID900
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency7.26800.00106.000935.4813AID943; AID944
lethal factor (plasmid)Bacillus anthracis str. A2012Potency15.84890.020010.786931.6228AID912
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency31.62280.025911.239831.6228AID602313
lamin isoform A-delta10Homo sapiens (human)Potency17.78280.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency10.00000.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency44.03720.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency24.54540.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency24.54540.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency36.72170.002319.595674.0614AID651631
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency44.03720.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency37.57800.026622.448266.8242AID651802
Caspase-7Homo sapiens (human)Potency7.94333.981118.585631.6228AID889
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency24.54540.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency24.54540.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency30.13130.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)9.07000.11007.190310.0000AID1443980; AID1449628; AID1473738; AID1674183; AID681139
ATP-dependent translocase ABCB1Mus musculus (house mouse)Ki17.90003.50005.60676.9300AID681138
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)3.20920.00022.318510.0000AID310120; AID310122; AID364884; AID681126; AID681127; AID681131; AID681579; AID681580; AID681581; AID681582
ATP-dependent translocase ABCB1Homo sapiens (human)Ki5.41600.02002.35948.5900AID150616; AID681142; AID681143; AID681356; AID681611
Quinolone resistance protein NorAStaphylococcus aureusIC50 (µMol)8.54297.00008.50009.7000AID1356615; AID1360841; AID1471299; AID372221; AID612622; AID695899; AID750896
DNA topoisomerase 1Homo sapiens (human)IC50 (µMol)160.00000.02101.862610.0000AID402038
ATP-dependent translocase ABCB1Mus musculus (house mouse)Ki4.03002.10004.31507.4800AID681137
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki1.00000.00000.385510.0000AID1387457
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)4.15200.00010.813310.0000AID625163
Mu-type opioid receptorHomo sapiens (human)Ki1.68600.00000.419710.0000AID625163
Chromaffin granule amine transporterHomo sapiens (human)IC50 (µMol)0.05000.05000.05000.0500AID1794818; AID1912448
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)IC50 (µMol)0.01770.00100.01460.1000AID1802429
Synaptic vesicular amine transporterHomo sapiens (human)IC50 (µMol)0.01470.01320.48594.2000AID1387455; AID1794817; AID1912471
Synaptic vesicular amine transporterHomo sapiens (human)Ki0.34840.00530.83242.7600AID1387446; AID1387447; AID1387454
Synaptic vesicular amine transporterBos taurus (cattle)Ki0.00100.00103.335010.0000AID321546
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Ki20.00000.13002.37856.9000AID681157
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)68.40002.41006.343310.0000AID1473739
Canalicular multispecific organic anion transporter 1Homo sapiens (human)Ki295.00004.70006.40508.1100AID681596
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)16.90090.00401.966610.0000AID1377577; AID1873214; AID364887
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Synaptic vesicular amine transporterHomo sapiens (human)Kd0.00800.00800.03950.0710AID1387453
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Quinolone resistance protein NorAStaphylococcus aureusMMC6.57006.57006.57006.5700AID1201798
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (328)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
DNA topological changeDNA topoisomerase 1Homo sapiens (human)
chromatin remodelingDNA topoisomerase 1Homo sapiens (human)
circadian rhythmDNA topoisomerase 1Homo sapiens (human)
response to xenobiotic stimulusDNA topoisomerase 1Homo sapiens (human)
programmed cell deathDNA topoisomerase 1Homo sapiens (human)
phosphorylationDNA topoisomerase 1Homo sapiens (human)
peptidyl-serine phosphorylationDNA topoisomerase 1Homo sapiens (human)
circadian regulation of gene expressionDNA topoisomerase 1Homo sapiens (human)
embryonic cleavageDNA topoisomerase 1Homo sapiens (human)
chromosome segregationDNA topoisomerase 1Homo sapiens (human)
DNA replicationDNA topoisomerase 1Homo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
monoamine transportChromaffin granule amine transporterHomo sapiens (human)
xenobiotic transportChromaffin granule amine transporterHomo sapiens (human)
serotonin uptakeChromaffin granule amine transporterHomo sapiens (human)
proton transmembrane transportChromaffin granule amine transporterHomo sapiens (human)
aminergic neurotransmitter loading into synaptic vesicleChromaffin granule amine transporterHomo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
response to amphetamineSynaptic vesicular amine transporterHomo sapiens (human)
serotonin secretion by mast cellSynaptic vesicular amine transporterHomo sapiens (human)
histamine secretion by mast cellSynaptic vesicular amine transporterHomo sapiens (human)
neurotransmitter transportSynaptic vesicular amine transporterHomo sapiens (human)
chemical synaptic transmissionSynaptic vesicular amine transporterHomo sapiens (human)
locomotory behaviorSynaptic vesicular amine transporterHomo sapiens (human)
response to toxic substanceSynaptic vesicular amine transporterHomo sapiens (human)
post-embryonic developmentSynaptic vesicular amine transporterHomo sapiens (human)
monoamine transportSynaptic vesicular amine transporterHomo sapiens (human)
dopamine transportSynaptic vesicular amine transporterHomo sapiens (human)
sequestering of neurotransmitterSynaptic vesicular amine transporterHomo sapiens (human)
serotonin uptakeSynaptic vesicular amine transporterHomo sapiens (human)
histamine uptakeSynaptic vesicular amine transporterHomo sapiens (human)
neurotransmitter loading into synaptic vesicleSynaptic vesicular amine transporterHomo sapiens (human)
somato-dendritic dopamine secretionSynaptic vesicular amine transporterHomo sapiens (human)
proton transmembrane transportSynaptic vesicular amine transporterHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processSynaptic vesicular amine transporterHomo sapiens (human)
aminergic neurotransmitter loading into synaptic vesicleSynaptic vesicular amine transporterHomo sapiens (human)
response to potassium ionSynaptic vesicular amine transporterBos taurus (cattle)
xenobiotic transportSynaptic vesicular amine transporterBos taurus (cattle)
serotonin uptakeSynaptic vesicular amine transporterBos taurus (cattle)
dopamine uptakeSynaptic vesicular amine transporterBos taurus (cattle)
somato-dendritic dopamine secretionSynaptic vesicular amine transporterBos taurus (cattle)
proton transmembrane transportSynaptic vesicular amine transporterBos taurus (cattle)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (119)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA bindingDNA topoisomerase 1Homo sapiens (human)
chromatin bindingDNA topoisomerase 1Homo sapiens (human)
double-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
single-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
RNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA topoisomerase type I (single strand cut, ATP-independent) activityDNA topoisomerase 1Homo sapiens (human)
protein serine/threonine kinase activityDNA topoisomerase 1Homo sapiens (human)
protein bindingDNA topoisomerase 1Homo sapiens (human)
ATP bindingDNA topoisomerase 1Homo sapiens (human)
DNA binding, bendingDNA topoisomerase 1Homo sapiens (human)
protein domain specific bindingDNA topoisomerase 1Homo sapiens (human)
supercoiled DNA bindingDNA topoisomerase 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Mus musculus (house mouse)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
monoamine transmembrane transporter activityChromaffin granule amine transporterHomo sapiens (human)
monoamine:proton antiporter activityChromaffin granule amine transporterHomo sapiens (human)
xenobiotic transmembrane transporter activityChromaffin granule amine transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activityChromaffin granule amine transporterHomo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
protein bindingSynaptic vesicular amine transporterHomo sapiens (human)
monoamine transmembrane transporter activitySynaptic vesicular amine transporterHomo sapiens (human)
monoamine:proton antiporter activitySynaptic vesicular amine transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySynaptic vesicular amine transporterHomo sapiens (human)
monoamine:proton antiporter activitySynaptic vesicular amine transporterBos taurus (cattle)
xenobiotic transmembrane transporter activitySynaptic vesicular amine transporterBos taurus (cattle)
organic cyclic compound bindingSynaptic vesicular amine transporterBos taurus (cattle)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (75)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
nuclear chromosomeDNA topoisomerase 1Homo sapiens (human)
P-bodyDNA topoisomerase 1Homo sapiens (human)
fibrillar centerDNA topoisomerase 1Homo sapiens (human)
male germ cell nucleusDNA topoisomerase 1Homo sapiens (human)
nucleusDNA topoisomerase 1Homo sapiens (human)
nucleoplasmDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
perikaryonDNA topoisomerase 1Homo sapiens (human)
protein-DNA complexDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneATP-dependent translocase ABCB1Mus musculus (house mouse)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
endoplasmic reticulum membraneChromaffin granule amine transporterHomo sapiens (human)
clathrin-sculpted monoamine transport vesicle membraneChromaffin granule amine transporterHomo sapiens (human)
synaptic vesicle membraneChromaffin granule amine transporterHomo sapiens (human)
terminal boutonChromaffin granule amine transporterHomo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
centrosomeSynaptic vesicular amine transporterHomo sapiens (human)
plasma membraneSynaptic vesicular amine transporterHomo sapiens (human)
synaptic vesicleSynaptic vesicular amine transporterHomo sapiens (human)
membraneSynaptic vesicular amine transporterHomo sapiens (human)
axonSynaptic vesicular amine transporterHomo sapiens (human)
dendriteSynaptic vesicular amine transporterHomo sapiens (human)
secretory granule membraneSynaptic vesicular amine transporterHomo sapiens (human)
synaptic vesicle membraneSynaptic vesicular amine transporterHomo sapiens (human)
intracellular membrane-bounded organelleSynaptic vesicular amine transporterHomo sapiens (human)
clathrin-sculpted monoamine transport vesicle membraneSynaptic vesicular amine transporterHomo sapiens (human)
dopaminergic synapseSynaptic vesicular amine transporterHomo sapiens (human)
terminal boutonSynaptic vesicular amine transporterHomo sapiens (human)
synaptic vesicle membraneSynaptic vesicular amine transporterHomo sapiens (human)
axonSynaptic vesicular amine transporterBos taurus (cattle)
dendriteSynaptic vesicular amine transporterBos taurus (cattle)
secretory granule membraneSynaptic vesicular amine transporterBos taurus (cattle)
synaptic vesicle membraneSynaptic vesicular amine transporterBos taurus (cattle)
chromaffin granuleSynaptic vesicular amine transporterBos taurus (cattle)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (546)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1802429[3H]Serotonin Uptake Assay from Article 10.1074/jbc.M113.502971: \\Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.\\2013The Journal of biological chemistry, Nov-08, Volume: 288, Issue:45
Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.
AID1801851LoxA HTP Assay from Article 10.1021/acs.biochem.6b00338: \\Biochemical and Cellular Characterization and Inhibitor Discovery of Pseudomonas aeruginosa 15-Lipoxygenase.\\2016Biochemistry, 06-14, Volume: 55, Issue:23
Biochemical and Cellular Characterization and Inhibitor Discovery of Pseudomonas aeruginosa 15-Lipoxygenase.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID283053Increase in 5 ug Norfloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 64 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID678767TP_TRANSPORTER: increase in liver concentration in mdr1a(-/-) mouse2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
AID624626Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1717738Cytotoxicity against African green monkey Vero E6 cells incubated for 2 days by the MTS assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID433832Inhibition of efflux pump in Streptococcus pneumoniae Spn-RC2 assessed as change in ciprofloxacin MIC by agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1867995Inhibition of efflux pump in Gram-positive methicillin-susceptible Staphylococcus aureus ATCC 25923 assessed as relative fluorescence index using ethidium bromide as substrate at 25 uM and measured after 1 hr by fluorescence based microtiter plate reader 2022European journal of medicinal chemistry, Jul-05, Volume: 237Application of partially aromatic ortho-quionone-methides for the synthesis of novel naphthoxazines with improved antibacterial activity.
AID520922Inhibition of ABC efflux pump in Streptococcus pneumoniae M168 assessed as increase in accumulation of ciprofloxacin by fluorometric uptake assay relative to sStreptococcus pneumoniae M42008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID283072Increase in 5 ug moxifloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 128 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID520909Antibacterial activity against Streptococcus pneumoniae M234 by microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID624622Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1515248Inhibition of NorA in Staphylococcus aureus 1199B assessed as reduction in ethidium bromide efflux at 50 uM measured over 5 mins interval for 30 mins by fluorescence assay relative to control2019Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2
Synthesis of amides from (E)-3-(1-chloro-3,4-dihydronaphthalen-2-yl)acrylic acid and substituted amino acid esters as NorA efflux pump inhibitors of Staphylococcus aureus.
AID730546Potentiation of vinblastine-induced cytotoxicity in human MCF7 cells at 5 ug/ml after 72 hrs by SRB assay2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Purgin II, a resin glycoside ester-type dimer and inhibitor of multidrug efflux pumps from Ipomoea purga.
AID193687Percent change in diastolic blood pressure (mmHg)in anesthetized rats by i.v. administration1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Further hypotensive metabolites from Verbesina caracasana.
AID1460607Inhibition of NorA in Staphylococcus aureus SA1199B harboring GrlA A116E mutant assessed as potentiation of CPX-induced antimicrobial activity up to 100 ug/ml by checkerboard assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID1387448Binding affinity to human VMAT2 expressed in HEK293 cell membranes in presence of 2 mM Mg-ATP by scintillation counting method2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID681580TP_TRANSPORTER: inhibition of JC-1 efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID680277TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Reserpine: 40 uM) in MDR1-expressing NIH-3T3 cells2004Biochemical and biophysical research communications, Mar-19, Volume: 315, Issue:4
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
AID1673335Induction of cellularization in human primary myotube assessed as beta-actin level at 100 nM in presence of BIO incubated for 72 hrs by Western blot analysis (Rvb = 1.095 No_unit)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
A novel indirubin derivative that increases somatic cell plasticity and inhibits tumorigenicity.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID612619Inhibition of wild-type norA expressing Staphylococcus aureus 1199 assessed as reduction in ciprofloxacin MIC2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID563234Inhibition of MFS efflux pump in Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 75 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID283058Increase in 5 ug ciprofloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 32 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID1221964Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID401285Reversal of P-gp-mediated multidrug resistance in human MCF/ADR cells assessed as increase in rhodamine 6G accumulation1996Journal of natural products, Jan, Volume: 59, Issue:1
Bicinchoninic acid protein assay in the determination of adriamycin cytotoxicity modulated by the MDR glycoprotein.
AID681131TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID1891668Inhibition of biofilm formation in Staphylococcus aureus 272123 at 100 uM incubated for 48 hrs by crystal violet staining based analysis2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67New diarylpentanoids and chalcones as potential antimicrobial adjuvants.
AID1176900Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay2015Journal of natural products, Jan-23, Volume: 78, Issue:1
Jalapinoside, a macrocyclic bisdesmoside from the resin glycosides of Ipomea purga, as a modulator of multidrug resistance in human cancer cells.
AID612589Antibacterial activity against Staphylococcus aureus 1199B norA++ and A116E GrlA mutation by M7-A7 CLSI microdilution method2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID695911Inhibition of norA in Staphylococcus aureus SA-1199B overexpressing norA assessed as fold reduction in ciprofloxacin MIC at 6.25 ug/ml by checkerboard assay2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Chalcone inhibitors of the NorA efflux pump in Staphylococcus aureus whole cells and enriched everted membrane vesicles.
AID750894Antibacterial activity against wild type Staphylococcus aureus ATCC 25923 assessed as growth inhibition by microdilution method2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID171908Change in heart rate after 18 hours of dosing was measured in conscious normotensive male rats at a dose of 5 mg/kg administered intraperitoneally in 5 rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID695897Inhibition of norA-mediated ethidium bromide efflux in methicillin-resistant Staphylococcus aureus SA-1199B at 10 ug/ml by spectrofluorometric analysis2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Chalcone inhibitors of the NorA efflux pump in Staphylococcus aureus whole cells and enriched everted membrane vesicles.
AID180800Change in heart rate after iv administration of 8 uM/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID1387455Inhibition of human VMAT2 expressed in HEK293 cell membranes assessed as reduction in [3H[-5HT uptake pre-incubated for 10 mins before [3H[-5HT addition and measured after 6 mins2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID520903Antibacterial activity against Streptococcus pneumoniae M169 by microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID1387454Displacement of [3H](+)-syn-Ethyl 1-(2-(2,4-Dioxo-1,2-dihydroquinazolin-3(4H)-yl)ethyl)-4-(4-fluorophenyl)piperidine-3-carboxylate from human VMAT2 expressed in HEK293 cell membranes incubated for 60 mins by scintillation counting method2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID401294Reversal of P-gp-mediated multidrug resistance in human MCF/ADR cells assessed as ratio of adriamycin ED50 without drug to adriamycin ED50 with drug at 0.15 uM after 6 days by BCA assay1996Journal of natural products, Jan, Volume: 59, Issue:1
Bicinchoninic acid protein assay in the determination of adriamycin cytotoxicity modulated by the MDR glycoprotein.
AID1356626Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by ATP bioluminescence assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.
AID520904Antibacterial activity against Streptococcus pneumoniae M184 by microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID171914Change in heart rate after 3 hours of dosing was measured in conscious normotensive male rats at a dose of 5 mg/kg administered intraperitoneally in 5 rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID612590Potentiation of ciprofloxacin-antibacterial activity against wild-type Staphylococcus aureus ATCC 25923 assessed as reduction in ciprofloxacin MIC by M7-A7 CLSI microdilution method2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID688501Inhibition of MDR in vinblastine-sensitive human MCF7 cells assessed as decrease in vinblastine IC50 at 5 ug/mL after 72 hrs by SRB assay2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Mammalian multidrug resistance lipopentasaccharide inhibitors from Ipomoea alba seeds.
AID310120Inhibition of P-glycoprotein expressed in A2780/ADR cells by calcein AM assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
New functional assay of P-glycoprotein activity using Hoechst 33342.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1668639Antibacterial activity against Staphylococcus aureus 1199B assessed as inhibition of efflux pump by measuring increase in intracellular accumulation of ethidium bromide at 0.25 times of MIC after 30 mins by fluorescence assay2020Journal of natural products, 05-22, Volume: 83, Issue:5
Constituents of Two
AID372221Inhibition of NorA efflux pump in Staphylococcus aureus K3092 assessed as inhibition of EtBr efflux2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
The phenolic diterpene totarol inhibits multidrug efflux pump activity in Staphylococcus aureus.
AID1387457Displacement of [125I]DOI from human 5HT2A receptor expressed in HEK293 cell membranes2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID762417Antimicrobial activity against Mycobacterium smegmatis MC2 155 ATCC 700084 after 72 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 667-Hydroxy-(E)-3-phenylmethylene-chroman-4-one analogues as efflux pump inhibitors against Mycobacterium smegmatis mc² 155.
AID433819Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 assessed as ethidium bromide uptake at 20 ug/ml2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID750895Antibacterial activity against Staphylococcus aureus 1199B overexpressing NorA and grlA A116E mutant assessed as growth inhibition by microdilution method2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.
AID497827Protection against fragile X syndrome phenotypes in Fmr1 null mutant Drosophila Fmr1'3/TM6C assessed as embryo viability at 40 uM at 25 degC by flow cytometry relative to untreated homozygous embryos2008Nature chemical biology, Apr, Volume: 4, Issue:4
Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID283060Increase in 5 ug ofloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 128 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID433816Antimicrobial activity against Streptococcus pneumoniae Spn-058 assessed as bacterial load2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID433825Inhibition of efflux pump in Streptococcus pneumoniae Spn-RC2 assessed as reduction in levofloxacin MIC by agar microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1201807Inhibition of NorA in fluoroquinolone-resistant Staphylococcus aureus 1199B assessed as increase in ethidium bromide uptake at 5 to 20 ug/ml after 20 mins by fluorimetry2015European journal of medicinal chemistry, May-05, Volume: 95Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: study of 6-substituted pyridine-3-boronic acid derivatives.
AID510384Inhibition of Staphylococcus aureus 1199B norA efflux pump assessed as potentiation of ciprofloxacin MIC by spectrophotometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Substituted dihydronaphthalenes as efflux pump inhibitors of Staphylococcus aureus.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID730543Inhibition of p-glycoprotein in human vinblastine-resistant MCF7 cells assessed as increase of rhodamine-123 accumulation at 5 ug/ml measured up to 50 mins2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Purgin II, a resin glycoside ester-type dimer and inhibitor of multidrug efflux pumps from Ipomoea purga.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID372220Inhibition of MsrA efflux pump in Staphylococcus aureus RN4220 assessed as reduction in erythromycin MIC at 20 ug/ml2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
The phenolic diterpene totarol inhibits multidrug efflux pump activity in Staphylococcus aureus.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1312953Aqueous solubility of the compound in PBS after 2 hrs by turbidity assay2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Second-Generation Phenylthiazole Antibiotics with Enhanced Pharmacokinetic Properties.
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID520923Inhibition of ABC efflux pump in Streptococcus pneumoniae M186 assessed as increase in accumulation of ciprofloxacin by fluorometric uptake assay relative to wild type2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID321546Inhibition of dopamine uptake at VMAT in bovine chromaffin granule ghosts2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Vesicular monoamine transporter substrate/inhibitor activity of MPTP/MPP+ derivatives: a structure-activity study.
AID1472089Kinetic solubility of compound in simulating fasting state biorelevant media at pH 6.5 after 2 hrs by shake flask method2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID695899Inhibition of norA-mediated ethidium bromide efflux in methicillin-resistant Staphylococcus aureus SA-1199B by spectrofluorometric analysis2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Chalcone inhibitors of the NorA efflux pump in Staphylococcus aureus whole cells and enriched everted membrane vesicles.
AID406529Inhibition of NorA efflux pump in Staphylococcus aureus 1199B assessed as fold reduction of ciprofloxacin MIC at 25 ug/ml2008Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13
Citral derived amides as potent bacterial NorA efflux pump inhibitors.
AID1891665Inhibition of Multidrug resistance efflux pump in Staphylococcus aureus 272123 assessed as relative fluorescence index using ethidium bromide as substrate at 25 uM by fluorescence based analysis2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67New diarylpentanoids and chalcones as potential antimicrobial adjuvants.
AID339872Inhibition of NorA deficient Staphylococcus aureus K2378 assessed as fold reduction of ciprofloxacin MIC at 25 ug/mL by microdilution technique2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump.
AID612584Antibacterial activity against NorA-expressing Staphylococcus aureus 1199B by M7-A7 CLSI microdilution method2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID678754TP_TRANSPORTER: increase in spleen concentration in mdr1a(-/-) mouse2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
AID283086Increase in 16 ug/ml Norfloxacin accumulation in Staphylococcus aureus SA1199B mutant overexpressing NorA at 128 ug/ml after 20 mins2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID681582TP_TRANSPORTER: inhibition of Calcein-AM efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID1515255Inhibition of NorA Staphylococcus aureus 1199B assessed as reduction in ethidium bromide efflux at 6.25 to 50 uM measured at 5 mins interval for 30 mins by fluorescence assay relative to control2019Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2
Synthesis of amides from (E)-3-(1-chloro-3,4-dihydronaphthalen-2-yl)acrylic acid and substituted amino acid esters as NorA efflux pump inhibitors of Staphylococcus aureus.
AID171826Change in systolic blood pressure after iv administration of 8 uM/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID1473773AUC in human at 0.1 to 1 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1356616Antimicrobial activity against Staphylococcus aureus SA-1199B expressing wild type norA and co-expressing GrlA A116E mutant by microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.
AID520902Antibacterial activity against Streptococcus pneumoniae R6 by microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID192884Maximum rate of rise of the left ventricular isovolumetric pressure was measured after iv administration of 8 uM/kg in anesthetized rats; ratio given for dP/dt1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID193680Maximum rate of rise of the left ventricular isovolumetric pressure (dP/dt, an index of cardiac inotropism in mmHg/sec)in anesthetized rats by i.v. administration1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Further hypotensive metabolites from Verbesina caracasana.
AID1360841Inhibition of Staphylococcus aureus SA-1199B NorA assessed as reduction in EtBr efflux measured over 5 mins by fluorescence assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position.
AID563236Inhibition of MFS efflux pump in apramycin-resistant cmlR1 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 25 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID283073Increase in 5 ug moxifloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 64 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID762412Inhibition of multidrug resistance efflux pump in Mycobacterium smegmatis MC2 155 ATCC 700084 assessed as reduction in EtBr MIC at 40 mg/L by MTT assay relative to control2013European journal of medicinal chemistry, Aug, Volume: 667-Hydroxy-(E)-3-phenylmethylene-chroman-4-one analogues as efflux pump inhibitors against Mycobacterium smegmatis mc² 155.
AID1473774Drug concentration at steady state in human at 0.1 to 1 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID402038Inhibition of human recombinant DNA topoisomerase12005Journal of natural products, Jun, Volume: 68, Issue:6
Indole alkaloids and other constituents of Rauwolfia serpentina.
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID520920Inhibition of ABC efflux pump in Streptococcus pneumoniae M184 assessed as increase in accumulation of ciprofloxacin by fluorometric uptake assay relative to wild type2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID730547Inhibition of p-glycoprotein in human vinblastine-resistant MCF7 cells cultured in vinblastine-free medium assessed as potentiation of vinblastine-induced cytotoxicity at 5 ug/ml after 72 hrs by SRB assay2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Purgin II, a resin glycoside ester-type dimer and inhibitor of multidrug efflux pumps from Ipomoea purga.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1668648Potentiation of norfloxacin-induced antibacterial activity against Staphylococcus aureus 1199B assessed as fold reduction in norfloxacin MIC at 20 mg/L by broth dilution assay relative to norfloxacin alone2020Journal of natural products, 05-22, Volume: 83, Issue:5
Constituents of Two
AID750887Inhibition of NorA in Staphylococcus aureus K2378 assessed as reduction of ciprofloxacin MIC at 0.78 to 100 ug/mL relative to control2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.
AID1395177Potentiation of ciprofloxacin-induced antibacterial activity against wild type Staphylococcus aureus SA1199 assessed as fold reduction in ciprofloxacin MIC at 32.9 uM after 18 to 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150N,N'-disubstituted cinnamamide derivatives potentiate ciprofloxacin activity against overexpressing NorA efflux pump Staphylococcus aureus 1199B strains.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID730548Inhibition of p-glycoprotein in human vinblastine-resistant MCF7 cells cultured in medium containing vinblastine assessed as potentiation of vinblastine-induced cytotoxicity at 5 ug/ml after 72 hrs by SRB assay2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Purgin II, a resin glycoside ester-type dimer and inhibitor of multidrug efflux pumps from Ipomoea purga.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID180820Heart rate was measured prior to dosing in conscious normotensive male rats at a dose of 5 mg/kg administered intraperitoneally in 5 rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID401297Reversal of P-gp-mediated multidrug resistance in human MCF/ADR cells assessed as ratio of adriamycin ED50 without drug to adriamycin ED50 with drug at 1.23 uM after 6 days by BCA assay1996Journal of natural products, Jan, Volume: 59, Issue:1
Bicinchoninic acid protein assay in the determination of adriamycin cytotoxicity modulated by the MDR glycoprotein.
AID406536Inhibition of NorA efflux pump in Staphylococcus aureus 1199 assessed as fold reduction of ciprofloxacin MIC at 25 ug/ml2008Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13
Citral derived amides as potent bacterial NorA efflux pump inhibitors.
AID520914Antibacterial activity against Streptococcus pneumoniae M236 by microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID171912Change in heart rate after 24 hours of dosing was measured in conscious normotensive male rats at a dose of 5 mg/kg administered intraperitoneally in 5 rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID283063Increase in 5 ug ofloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 16 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID283059Increase in 5 ug ciprofloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 16 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID1668644Potentiation of norfloxacin-induced antibacterial activity against Staphylococcus aureus XU212 assessed as tetracycline MIC at 20 mg/L by broth dilution assay (Rvb = 32 mg/L)2020Journal of natural products, 05-22, Volume: 83, Issue:5
Constituents of Two
AID372218Inhibition of tetK efflux pump in Staphylococcus aureus XU212 assessed as reduction in tetracycline MIC at 20 ug/ml2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
The phenolic diterpene totarol inhibits multidrug efflux pump activity in Staphylococcus aureus.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID197291Changes in diastolic Blood pressure following iv administration at (8 umol/kg) anesthetized rats2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
Novel hypotensive agents from Verbesina caracasana. 8. Synthesis and pharmacology of (3,4-dimethoxycinnamoyl)-N(1)-agmatine and synthetic analogues.
AID433840Inhibition of efflux pump in ciprofloxacin pretreated Streptococcus pneumoniae Spn-RC2 at 20 ug/ml by ethidium bromide uptake assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID1387447Displacement of [3H]DHTB from human VMAT2 expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting method2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID1873214Inhibition of ABCG2 (unknown origin) expressed in human NCI-H460 cells mediated pheophorbide A efflux for 2 to 20 hr by fluorescence plate reader analysis2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID206399Concentration required to reduce Minimum inhibitory concentration (MIC) of Norfloxacin against Staphylococcus aureus 1199B by 4 folds2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Structural differences between paroxetine and femoxetine responsible for differential inhibition of Staphylococcus aureus efflux pumps.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID520919Inhibition of ABC efflux pump in Streptococcus pneumoniae M169 assessed as increase in accumulation of ciprofloxacin by fluorometric uptake assay relative to wild type2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID283067Increase in 5 ug levofloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 16 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID433837Antimicrobial activity against Streptococcus pneumoniae Spn-RC2 infected in one-compartment pharmacodynamic system assessed as regrowth of bacteria administered at simulated at 750 mg dosage regimen every 12 hrs measured on day 82007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID283071Increase in 5 ug sparfloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 16 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID584115Antibacterial activity against Escherichia coli KAM32 harboring pSP72 by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID170679Tested for the change in diastolic blood pressure administered at 8 ug/kg intravenously in anesthetized rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID680104TP_TRANSPORTER: increase in kidney concentration in mdr1a(-/-) mouse2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
AID180833Tested for change in heart rate administered at 8 uM/kg iv in anesthetized rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID1668640Antibacterial activity against Staphylococcus aureus 1199B assessed as inhibition of efflux pump by measuring increase in intracellular accumulation of ethidium bromide after 30 mins by fluorescence assay2020Journal of natural products, 05-22, Volume: 83, Issue:5
Constituents of Two
AID1674184Toxicity in po dosed human assessed as maximum daily dose2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
AID524632Inhibition of ABC efflux pump in Streptococcus pneumoniae M186 assessed as increase in accumulation of ethidium bromide by fluorescence method after 10 mins relative to wild type2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID695895Inhibition of norA-mediated ethidium bromide efflux in methicillin-resistant Staphylococcus aureus SA-1199B at 2.5 ug/ml by spectrofluorometric analysis2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Chalcone inhibitors of the NorA efflux pump in Staphylococcus aureus whole cells and enriched everted membrane vesicles.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID510387Inhibition of Staphylococcus aureus 1199 norA efflux pump assessed as potentiation of ciprofloxacin MIC by spectrophotometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Substituted dihydronaphthalenes as efflux pump inhibitors of Staphylococcus aureus.
AID520926Inhibition of ABC efflux pump in Streptococcus pneumoniae M168 assessed as increase in accumulation of ethidium bromide by fluorescence method after 10 mins relative to Streptococcus pneumoniae M42008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID762407Antimicrobial activity against Mycobacterium smegmatis MC2 155 ATCC 700084 at 40 mg/L after 72 hrs by MTT assay in presence of EtBr2013European journal of medicinal chemistry, Aug, Volume: 667-Hydroxy-(E)-3-phenylmethylene-chroman-4-one analogues as efflux pump inhibitors against Mycobacterium smegmatis mc² 155.
AID1356615Inhibition of NorA in Staphylococcus aureus SA-1199B expressing GrlA A116E mutant assessed as reduction in EtBr efflux incubated for 5 mins by fluorescence based assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.
AID433827Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 assessed as change in levofloxacin MIC at 20 ug/ml by broth macrodilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID1668652Potentiation of norfloxacin-induced antibacterial activity against Staphylococcus aureus 1199B assessed as norfloxacin MIC at 20 mg/L by broth dilution assay (Rvb = 32 mg/L)2020Journal of natural products, 05-22, Volume: 83, Issue:5
Constituents of Two
AID405927Cytotoxicity against human Hep2 cells after 72 hrs2008Journal of natural products, Jun, Volume: 71, Issue:6
Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of Ipomoea murucoides.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID433796Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 assessed as reduction in levofloxacin MIC by broth microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID678764TP_TRANSPORTER: increase in lung concentration in mdr1a(-/-) mouse2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
AID433828Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 assessed as change in ciprofloxacin MIC at 20 ug/ml by broth macrodilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID1473775Ratio of drug concentration at steady state in human at 0.1 to 1 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID433830Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 assessed as change in ciprofloxacin MIC by agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID520907Antibacterial activity against Streptococcus pneumoniae M231 by microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID364884Inhibition of P-gp in human adriamycin-resistant A2780 cells by Hoechst 33342 assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
AID750891Antibacterial activity against Staphylococcus aureus 1199 overexpressing wild type norA assessed as growth inhibition by microdilution method2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID283070Increase in 5 ug sparfloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 32 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID396092Inhibition of NorA efflux pump in Staphylococcus aureus K2361 assessed as reduction of ethidium bromide efflux at 30 uM for 5 mins2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.
AID402037Inhibition of human recombinant DNA topoisomerase-22005Journal of natural products, Jun, Volume: 68, Issue:6
Indole alkaloids and other constituents of Rauwolfia serpentina.
AID433800Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 assessed as reduction in levofloxacin MIC by agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID669748Inhibition of norA in wild type Staphylococcus aureus SA1199 expressing assessed as potentiation of ciprofloxacin MIC by checkerboard assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
AID433829Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 assessed as change in levofloxacin MIC by agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID563231Inhibition of MFS efflux pump in Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 10 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID339870Intrinsic solubility in water2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump.
AID433822Inhibition of efflux pump in Streptococcus pneumoniae Spn-RC2 assessed as reduction in ciprofloxacin MIC at 20 ug/ml by broth microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID1360838Growth inhibition of Staphylococcus aureus SA-1199 expressing wild type norA by microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1356633Antimicrobial activity against NorA overexpressing Staphylococcus aureus SA-K2378 by microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.
AID681155TP_TRANSPORTER: increase in bodipy intracellular accumulation (Bodipy: 0.2 uM) in SK-E2 cells (expressing BSEP)2003Pharmaceutical research, Apr, Volume: 20, Issue:4
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID688496Inhibition of MDR in vinblastine-resistant human MCF7 cells assessed as decrease in vinblastine IC50 at 5 ug/mL after 72 hrs by SRB assay2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Mammalian multidrug resistance lipopentasaccharide inhibitors from Ipomoea alba seeds.
AID401298Reversal of P-gp-mediated multidrug resistance in human MCF/ADR cells assessed as ratio of adriamycin ED50 without drug to adriamycin ED50 with drug at 2.46 uM after 6 days by BCA assay1996Journal of natural products, Jan, Volume: 59, Issue:1
Bicinchoninic acid protein assay in the determination of adriamycin cytotoxicity modulated by the MDR glycoprotein.
AID1221965Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID681581TP_TRANSPORTER: inhibition of Fluo-3-AM efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID283560Antibacterial activity against Escherichia coli HNCE4 after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID681143TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in MDR1-expressing LLC-PK1 cells2002Molecular pharmacology, May, Volume: 61, Issue:5
Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
AID339863Antibacterial activity against wild type Staphylococcus aureus ATCC 25923 by microdilution technique2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump.
AID1360844Inhibition of Staphylococcus aureus SA-1199B NorA assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring minimum potetntiation concentration causing 4 fold reduction in ciprofloxacin MIC by ciprofloxacin assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1176908Reversal of multidrug-resistance in vinblastin-sensitive human MCF7 cells assessed as reduction in vinblastine IC50 at 5 ug/ml relative to IC50 vinblastine alone2015Journal of natural products, Jan-23, Volume: 78, Issue:1
Jalapinoside, a macrocyclic bisdesmoside from the resin glycosides of Ipomea purga, as a modulator of multidrug resistance in human cancer cells.
AID750897Inhibition of NorA in Staphylococcus aureus 1199B harboring grlA A116E mutant assessed as inhibition of ethidium bromide efflux at 50 uM measured for 5 mins by fluorometric analysis relative to control2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.
AID1891667Inhibition of biofilm formation in Staphylococcus aureus ATCC 25923 at 100 uM incubated for 48 hrs by crystal violet staining based analysis2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67New diarylpentanoids and chalcones as potential antimicrobial adjuvants.
AID1515258Inhibition of NorA in Staphylococcus aureus 1199B assessed as reduction in ethidium bromide accumulation at 25 uM measured at 5 mins interval for 60 mins by fluorescence assay relative to control2019Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2
Synthesis of amides from (E)-3-(1-chloro-3,4-dihydronaphthalen-2-yl)acrylic acid and substituted amino acid esters as NorA efflux pump inhibitors of Staphylococcus aureus.
AID283078Increase in 30 ug chloramphenicol antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 32 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID563237Inhibition of MFS efflux pump in apramycin-resistant cmlR1 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 50 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID171997Systolic blood pressure was measured prior to dosing in conscious normotensive male rats at a dose of 5 mg/kg administered intraperitoneally in 5 rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID681139TP_TRANSPORTER: increase in dihydrofluorescein intracellular accumulation (dihydrofluorescein: 1 uM) in SK-E2 cells (expressing BSEP)2003Pharmaceutical research, Apr, Volume: 20, Issue:4
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
AID563235Inhibition of MFS efflux pump in apramycin-resistant cmlR1 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 10 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID433833Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 infected in one-compartment pharmacodynamic system assessed as repid killing administered levofloxacin at simulated oral dose regimen of 500 mg in human measured on day 62007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID1717737Selectivity index, ratio of CC50 for African green monkey Vero E6 cells to EC50 for SARS-CoV infected in African green monkey Vero E6 cells2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID283077Increase in 30 ug chloramphenicol antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 64 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID1673338Induction of cellularization in human primary myotube assessed as alpha-tubulin level at 100 nM in presence of BIO incubated for 72 hrs by Western blot analysis (Rvb = 0.674 No_unit)2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
A novel indirubin derivative that increases somatic cell plasticity and inhibits tumorigenicity.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1129457Solubility of the compound in PBS buffer after 16 hrs2014European journal of medicinal chemistry, Apr-09, Volume: 76Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.
AID678772TP_TRANSPORTER: increase in heart concentration in mdr1a(-/-) mouse2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
AID310122Inhibition of P-glycoprotein by Hoechst assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
New functional assay of P-glycoprotein activity using Hoechst 33342.
AID520925Inhibition of ABC efflux pump in Streptococcus pneumoniae M184 assessed as increase in accumulation of ethidium bromide by fluorescence method after 10 mins relative to wild type2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID1221963Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID283083Increase in 16 ug/ml Norfloxacin accumulation in wild type Staphylococcus aureus SA1199 at 128 ug/ml after 20 mins2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID563241Inhibition of MFS efflux pump in apramycin-resistant cmlR2 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 50 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID389741Inhibition of NorA efflux pump in Staphylococcus aureus 1199B assessed as fold reduction of ciprofloxacin MIC at 25 ug/ml2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Piperine analogs as potent Staphylococcus aureus NorA efflux pump inhibitors.
AID433838Inhibition of ciprofloxacin-induced efflux pump expression in Streptococcus pneumoniae Spn-058 after 5 hrs by ethidium bromide uptake assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID171918Change in heart rate after 48 hours of dosing was measured in conscious normotensive male rats at a dose of 5 mg/kg administered intraperitoneally in 5 rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID563233Inhibition of MFS efflux pump in Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 50 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1387452Binding affinity to human VMAT2 expressed in HEK293 cell membranes assessed as half life at 14 to 22 nM in presence of 2 mM Mg-ATP by scintillation counting method2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID750892Antibacterial activity against Staphylococcus aureus K2378 overexpressing norA assessed as growth inhibition by microdilution method2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.
AID688504Inhibition of MDR in drug-sensitive human MCF7 cells assessed as decrease in vinblastine IC50 at 5 ug/mL after 72 hrs by SRB assay2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Mammalian multidrug resistance lipopentasaccharide inhibitors from Ipomoea alba seeds.
AID283074Increase in 5 ug moxifloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 32 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID193699Percent change in systolic blood pressure (mmHg)in anesthetized rats by i.v. administration1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Further hypotensive metabolites from Verbesina caracasana.
AID1221957Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID564973Antimicrobial activity against Mycobacterium bovis BCG by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID171741Change in blood pressure after 48 hours of dosing was measured in conscious normotensive male rats at a dose of 5 mg/kg administered intraperitoneally in 5 rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID283054Increase in 5 ug Norfloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 32 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID283075Increase in 5 ug moxifloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 16 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID612587Antibacterial activity against Staphylococcus aureus K2378 bearing norA++ efficient mutation by M7-A7 CLSI microdilution method2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID1221982Fraction absorbed in human2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID433836Antimicrobial activity against Streptococcus pneumoniae Spn-058 infected in one-compartment pharmacodynamic system assessed as prevention of regrowth administered ciprofloxacin at simulated oral dose regimen of 750 mg in human every 12 hrs measured on day2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID1428419Inhibition of multidrug resistance efflux pump in multidrug resistant human MCF7 cells cultured in vinblastine containing medium assessed as potentiation of vinblastine-induced cytotoxicity by measuring fold reduction in vinblastine IC50 at 5 ug/ml after
AID1360839Growth inhibition of Staphylococcus aureus SA-1199B expressing wild type norA and co-expressing GrlA A116E mutant by microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1891670Inhibition of quorum sensing system in Serratia marcescens AS-1 assessed as reduction in pigment production incubated for 24 to 48 hrs2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67New diarylpentanoids and chalcones as potential antimicrobial adjuvants.
AID171729Change in blood pressure after 12 hours of dosing was measured in conscious normotensive male rats at a dose of 5 mg/kg administered intraperitoneally in 5 rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID306327Inhibition of NorA pump in fluoroquinolone-resistant Staphylococcus aureus SA1199B assessed as drug level causing 8-fold reduction of Norfloxacin MIC2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
N-caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors.
AID646200Inhibition of p-glycoprotein in vinblastine-sensitive human MCF7 cells assessed as decrease in rhodamine 123 accumulation at 5 ug/ml after 30 mins by flow cytometry2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells.
AID283052Increase in 5 ug Norfloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 128 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID283082Increase in 64 ug/ml Norfloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 128 ug/ml by checker board method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID681356TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) in MDR1-expressing MDCK cells2002Pharmaceutical research, Jun, Volume: 19, Issue:6
Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?
AID1356634Antimicrobial activity against mepA deficient Staphylococcus aureus SA-K2885 by microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.
AID227552Ratio of performance time under the effect and corresponding control performance time1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID669742Inhibition of norA-mediated EtBr efflux in Staphylococcus aureus SA1199B overexpressing norA and expressing A116E GrlA mutation at 50 uM by fluorometry2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
AID401296Reversal of P-gp-mediated multidrug resistance in human MCF/ADR cells assessed as ratio of adriamycin ED50 without drug to adriamycin ED50 with drug at 0.62 uM after 6 days by BCA assay1996Journal of natural products, Jan, Volume: 59, Issue:1
Bicinchoninic acid protein assay in the determination of adriamycin cytotoxicity modulated by the MDR glycoprotein.
AID433795Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 assessed as reduction in ciprofloxacin MIC by broth microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID681126TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID564978Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring inactivated p55 gene by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1623073Inhibition of MDR protein in human MCF7/Vin cells cultured in presence of vinblastine assessed as reversal fold at 5 ug/ml after 72 hrs by sulforhodamine B assay2019Journal of natural products, 03-22, Volume: 82, Issue:3
Amarisolide F, an Acylated Diterpenoid Glucoside and Related Terpenoids from Salvia amarissima.
AID364887Inhibition of ABCG2 in human mitoxantrone-resistant MCF7 cells by Hoechst 33342 assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
AID1221966Ratio of plasma AUC in po dosed mdr1 knock out mouse to plasma AUC in po dosed wild type mouse2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1176906Reversal of multidrug-resistance in human MCF7 cells assessed as reduction in vinblastine IC50 at 5 ug/ml relative to IC50 vinblastine alone2015Journal of natural products, Jan-23, Volume: 78, Issue:1
Jalapinoside, a macrocyclic bisdesmoside from the resin glycosides of Ipomea purga, as a modulator of multidrug resistance in human cancer cells.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID520917Inhibition of ABC efflux pump in Streptococcus pneumoniae M184 assessed as reduction in ciprofloxacin MIC at 80 ug/ml2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID1176902Cytotoxicity against vinblastin-sensitive human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay2015Journal of natural products, Jan-23, Volume: 78, Issue:1
Jalapinoside, a macrocyclic bisdesmoside from the resin glycosides of Ipomea purga, as a modulator of multidrug resistance in human cancer cells.
AID520911Antibacterial activity against Streptococcus pneumoniae M4 by microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID564988Antimicrobial activity against Mycobacterium bovis BCG harboring pPAZ23 carrying p27-p55 operon by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID646196Reversal of p-glycoprotein-mediated drug resistant in vinblastine-resistant human MCF7 cells assessed as ratio of IC50 for vinblastin to IC50 for vinblastin in presence of compound at 5 ug/ml after 72 hrs by SRB assay2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1356624Synergistic potentiation of ciprofloxacin-induced antimicrobial activity against norA deleted Staphylococcus aureus SA-K1902 at 0.78 to 100 ug/ml by microdilution method based Checkerboard assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.
AID170848Tested for the change in systolic blood pressure administered at 8 ug/kg intravenously in anesthetized rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID1460606Inhibition of Staphylococcus aureus SAK2378 norA assessed as potentiation of CPX-induced antimicrobial activity up to 100 ug/ml by checkerboard assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
AID171920Change in heart rate after 6 hours of dosing was measured in conscious normotensive male rats at a dose of 5 mg/kg administered intraperitoneally in 5 rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID372219Inhibition of NorA efflux pump in Staphylococcus aureus 1199B gene assessed as reduction in Norfloxacin MIC at 20 ug/ml2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
The phenolic diterpene totarol inhibits multidrug efflux pump activity in Staphylococcus aureus.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1073742Aqueous solubility of compound in phosphate buffer assessed as solubility limit after 2 hrs by turbidity analysis2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant Staphylococcus aureus.
AID1515250Potentiation of ciprofloxacin-induced antibacterial activity in norA-deleted Staphylococcus aureus K1758 assessed as reduction in ciprofloxacin MIC at 0.8 to 50 ug/ml by broth checkerboard microdilution method relative to control2019Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2
Synthesis of amides from (E)-3-(1-chloro-3,4-dihydronaphthalen-2-yl)acrylic acid and substituted amino acid esters as NorA efflux pump inhibitors of Staphylococcus aureus.
AID192930Maximum rate of rise of the left ventricular isovolumetric pressure administered at 8 uM/kg iv in anesthetized rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID1360840Inhibition of Staphylococcus aureus SA-1199B NorA assessed as reduction in EtBr efflux at 50 uM measured over 5 mins by fluorescence assay relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position.
AID1123424Toxicity in mouse assessed as effect on central nervous system1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
The benzodiazepine story.
AID433831Inhibition of efflux pump in Streptococcus pneumoniae Spn-RC2 assessed as change in levofloxacin MIC by agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID669745Antibacterial activity against wild type Staphylococcus aureus SA1199 expressing norA by microdilution method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
AID1387453Binding affinity to human VMAT2 expressed in HEK293 cell membranes by scintillation counting method based saturation binding assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID1176901Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay in presence of vinblastine2015Journal of natural products, Jan-23, Volume: 78, Issue:1
Jalapinoside, a macrocyclic bisdesmoside from the resin glycosides of Ipomea purga, as a modulator of multidrug resistance in human cancer cells.
AID1221956Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID283558Antibacterial activity against Escherichia coli AG102 with marR1 mutation after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID339876Inhibition of NorA overexpressing Staphylococcus aureus K2378 assessed as fold reduction of ciprofloxacin MIC at 25 ug/mL by microdilution technique2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump.
AID1395155Growth inhibition of wild type Staphylococcus aureus SA1199 assessed as non-toxic concentration after 18 to 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150N,N'-disubstituted cinnamamide derivatives potentiate ciprofloxacin activity against overexpressing NorA efflux pump Staphylococcus aureus 1199B strains.
AID624623Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1515256Growth inhibition of Staphylococcus aureus 1199 at 50 ug/ml by broth microdilution method2019Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2
Synthesis of amides from (E)-3-(1-chloro-3,4-dihydronaphthalen-2-yl)acrylic acid and substituted amino acid esters as NorA efflux pump inhibitors of Staphylococcus aureus.
AID612583Inhibition of NorA in Staphylococcus aureus 1199B assessed as inhibition of ethidium bromide efflux at 50 uM by fluorimetry2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID283084Increase in 16 ug/ml Norfloxacin accumulation in Staphylococcus aureus SA1199B mutant overexpressing NorA measured per mg of cell protein at 128 ug/ml after 5 mins2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1623072Inhibition of MDR protein in human MCF7/Vin cells cultured in absence of vinblastine assessed as reversal fold at 5 ug/ml after 72 hrs by sulforhodamine B assay2019Journal of natural products, 03-22, Volume: 82, Issue:3
Amarisolide F, an Acylated Diterpenoid Glucoside and Related Terpenoids from Salvia amarissima.
AID1395191Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 72 hrs by MTT assay2018European journal of medicinal chemistry, Apr-25, Volume: 150N,N'-disubstituted cinnamamide derivatives potentiate ciprofloxacin activity against overexpressing NorA efflux pump Staphylococcus aureus 1199B strains.
AID1515249Potentiation of ciprofloxacin-induced antibacterial activity in Staphylococcus aureus 1199 assessed as reduction in ciprofloxacin MIC at 0.8 to 50 ug/ml by broth checkerboard microdilution method relative to control2019Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2
Synthesis of amides from (E)-3-(1-chloro-3,4-dihydronaphthalen-2-yl)acrylic acid and substituted amino acid esters as NorA efflux pump inhibitors of Staphylococcus aureus.
AID1668641Potentiation of norfloxacin-induced antibacterial activity against Staphylococcus aureus XU212 assessed as fold reduction in tetracycline MIC at 20 mg/L by broth dilution assay relative to tetracycline alone2020Journal of natural products, 05-22, Volume: 83, Issue:5
Constituents of Two
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID520924Inhibition of ABC efflux pump in Streptococcus pneumoniae M169 assessed as increase in accumulation of ethidium bromide by fluorescence method after 10 mins relative to wild type2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID681611TP_TRANSPORTER: transepithelial transport of digoxin (basal to apical) in Caco-2 cells2003Pharmaceutical research, Feb, Volume: 20, Issue:2
Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter.
AID646197Reversal of p-glycoprotein-mediated drug resistant in vinblastine-sensitive human MCF7 cells assessed as ratio of IC50 for vinblastin to IC50 for vinblastin in presence of compound at 5 ug/ml after 72 hrs by SRB assay2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells.
AID695898Inhibition of norA-mediated ethidium bromide efflux in methicillin-resistant Staphylococcus aureus SA-1199B at 20 ug/ml by spectrofluorometric analysis2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Chalcone inhibitors of the NorA efflux pump in Staphylococcus aureus whole cells and enriched everted membrane vesicles.
AID612588Antibacterial activity against wild-type norA expressing Staphylococcus aureus 1199 by M7-A7 CLSI microdilution method2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID1428421Potentiation of vinblastine-induced cytotoxicity against vinblastine-sensitive human MCF7 cells assessed as fold reduction in vinblastine IC50 at 5 ug/ml after 72 hrs by SRB assay relative to vinblastine alone
AID1360845Cytotoxicity against human HepG2 cells assessed as reduction in cell number after 24 hrs by bioluminescence assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position.
AID520916Inhibition of ABC efflux pump in Streptococcus pneumoniae M169 assessed as reduction in ciprofloxacin MIC at 80 ug/ml2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID171906Change in heart rate after 12 hours of dosing was measured in conscious normotensive male rats at a dose of 5 mg/kg administered intraperitoneally in 5 rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID612622Inhibition of NorA in Staphylococcus aureus 1199B assessed as inhibition of ethidium bromide efflux dose response curve based fluorometric assay2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID433813Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 with harboring Ser79Tyr mutation in parC gene assessed as decrease in ciprofloxacin MIC2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID396089Inhibition of MepA efflux pump in Staphylococcus aureus K2361 assessed as reduction of ethidium bromide efflux at 30 uM for 5 mins2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID171744Change in blood pressure after 6 hours of dosing was measured in conscious normotensive male rats at a dose of 5 mg/kg administered intraperitoneally in 5 rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID750896Inhibition of NorA in Staphylococcus aureus 1199B harboring grlA A116E mutant assessed as inhibition of ethidium bromide efflux measured for 5 mins by fluorometric analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.
AID1360837Growth inhibition of Staphylococcus aureus ATCC 25923 by microdilution method2018European journal of medicinal chemistry, Jul-15, Volume: 155Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position.
AID114097Compound was evaluated for its lack of depresant effect on the CNS as measured by the forced coordinated motor activity on 10 mice1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID564983Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring pPAZ23 carrying p27-p55 operon by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID433835Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 infected in one-compartment pharmacodynamic system assessed as repid killing administered levofloxacin at simulated oral dose regimen of 750 mg in human every 24 hrs measured on day 102007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID1356635Antimicrobial activity against mepA overexpressing Staphylococcus aureus SA-K2886 by microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.
AID563242Inhibition of MFS efflux pump in apramycin-resistant cmlR2 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 75 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID401295Reversal of P-gp-mediated multidrug resistance in human MCF/ADR cells assessed as ratio of adriamycin ED50 without drug to adriamycin ED50 with drug at 0.30 uM after 6 days by BCA assay1996Journal of natural products, Jan, Volume: 59, Issue:1
Bicinchoninic acid protein assay in the determination of adriamycin cytotoxicity modulated by the MDR glycoprotein.
AID283080Antibacterial activity against Staphylococcus aureus2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID433817Antimicrobial activity against Streptococcus pneumoniae Spn-RC2 infected in one-compartment pharmacodynamic system assessed as decrease in bacterial density administered at simulated at 500 mg QD dosage regimen for 10 days measured after 24 hrs by quantit2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID1129456Solubility of the compound in PBS buffer after 45 mins2014European journal of medicinal chemistry, Apr-09, Volume: 76Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.
AID681166TP_TRANSPORTER: Western blot, LS180 cell1996Molecular pharmacology, Feb, Volume: 49, Issue:2
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
AID283065Increase in 5 ug levofloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 64 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1221961Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1371164Aqueous solubility of the compound in PBS after 2 hrs by turbidimetric method2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Investigating the Antibacterial Activity of Biphenylthiazoles against Methicillin- and Vancomycin-Resistant Staphylococcus aureus (MRSA and VRSA).
AID563232Inhibition of MFS efflux pump in Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 25 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID520908Antibacterial activity against Streptococcus pneumoniae M230 by microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID624629Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID484804Inhibition of NorA in Staphylococcus aureus SA-1199B assessed as reduction in ethidium bromide efflux at 50 uM by fluorimetry2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID563238Inhibition of MFS efflux pump in apramycin-resistant cmlR1 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 75 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID681667TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 1 uM, Reserpine: 20 uM) in Bsep-expressing LLC-PK1 cells2000Molecular pharmacology, Jan, Volume: 57, Issue:1
Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein.
AID283055Increase in 5 ug Norfloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 16 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID1377577Inhibition of BCRP (unknown origin)2017European journal of medicinal chemistry, Sep-29, Volume: 138Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer.
AID1779689Aqueous solubility of the compound at pH 7.4 by turbidimetric method
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1387449Binding affinity to human VMAT2 expressed in HEK293 cell membranes assessed as observed associate rate combatant at 14 to 22 nM in presence of 2 mM Mg-ATP by scintillation counting method2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID681596TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical) in MRP2-expressing MDCK cells2002Pharmaceutical research, Jun, Volume: 19, Issue:6
Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa?
AID1891666Inhibition of Multidrug resistance efflux pump in Salmonella enterica serovar typhimurium SL1344 (SE03) assessed as relative fluorescence index using ethidium bromide as substrate at 25 uM by fluorescence based analysis2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67New diarylpentanoids and chalcones as potential antimicrobial adjuvants.
AID283069Increase in 5 ug sparfloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 64 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID624628Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1515257Growth inhibition of norA-deleted Staphylococcus aureus K1758 at 50 ug/ml by broth microdilution method2019Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2
Synthesis of amides from (E)-3-(1-chloro-3,4-dihydronaphthalen-2-yl)acrylic acid and substituted amino acid esters as NorA efflux pump inhibitors of Staphylococcus aureus.
AID283066Increase in 5 ug levofloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 32 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID283057Increase in 5 ug ciprofloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 64 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID520912Antibacterial activity against Streptococcus pneumoniae M168 by microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID433839Induction of efflux pump expression in Streptococcus pneumoniae Spn-RC2 after 5 hrs by ethidium bromide uptake assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID193688Percent change in heart rate expressed in beats / min in anesthetized rats by i.v. administration1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Further hypotensive metabolites from Verbesina caracasana.
AID1356614Inhibition of NorA in Staphylococcus aureus SA-1199B expressing GrlA A116E mutant assessed as reduction in EtBr efflux at 50 uM incubated for 5 mins by fluorescence based assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.
AID520905Antibacterial activity against Streptococcus pneumoniae M246 by microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID646203Inhibition of p-glycoprotein expression in vinblastine-sensitive human MCF7 cells at 5 ug/ml after 24 hrs by by immunofluorescence flow cytometry relative to control2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells.
AID197300Changes in systolic Blood pressure following iv administration at (8 umol/kg) anesthetized rats2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
Novel hypotensive agents from Verbesina caracasana. 8. Synthesis and pharmacology of (3,4-dimethoxycinnamoyl)-N(1)-agmatine and synthetic analogues.
AID433814Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 with harboring mutation in parC gene assessed as decrease in levofloxacin MIC2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID1127995Toxicity in Staphylococcus aureus ATCC 25923 after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
AID1203463Antimicrobial activity against Pseudomonas aeruginosa assessed as inhibition of microbial growth at 100 uM after 24 hrs2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Combinatorial Libraries As a Tool for the Discovery of Novel, Broad-Spectrum Antibacterial Agents Targeting the ESKAPE Pathogens.
AID554098Inhibition of NorA in Staphylococcus aureus 1199B assessed as reduction in ethidium bromide efflux at 50 uM by fluorimetry after 5 mins2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Discovery of novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus.
AID1428417Inhibition of multidrug resistance efflux pump in multidrug resistant human MCF7 cells cultured in vinblastine free medium assessed as potentiation of vinblastine-induced cytotoxicity by measuring fold reduction in vinblastine IC50 at 5 ug/ml after 72 hrs
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID681127TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID520910Antibacterial activity against Streptococcus pneumoniae M233 by microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID563240Inhibition of MFS efflux pump in apramycin-resistant cmlR2 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 25 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID433791Antimicrobial activity against Streptococcus pneumoniae Spn-058 at 5.5 to 8 log10 CFU/ml bacterial density measured within 24 hrs2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID339871Inhibition of NorA in Staphylococcus aureus ATCC 25923 assessed as fold reduction of ciprofloxacin MIC at 25 ug/mL by microdilution technique2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID171738Change in blood pressure after 3 hours of dosing was measured in conscious normotensive male rats at a dose of 5 mg/kg administered intraperitoneally in 5 rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID122480Lack of depressant effect on the CNS as measured by the forced coordinated motor activity on mice was expressed as time elapsed from dosing required to obtain maximum hypotensive or antihypertensive effect1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID520921Inhibition of ABC efflux pump in Streptococcus pneumoniae M4 assessed as increase in accumulation of ciprofloxacin by fluorometric uptake assay relative to wild type2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID1891669Inhibition of quorum sensing system in Chromobacterium violaceum wild type 85 assessed as reduction in pigment production incubated for 24 to 48 hrs2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67New diarylpentanoids and chalcones as potential antimicrobial adjuvants.
AID750888Reduction of ciprofloxacin MIC in norA-deficient Staphylococcus aureus K1902 at 0.78 to 100 ug/mL2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.
AID283081Increase in 2 ug/ml Norfloxacin antibacterial activity against wild type Staphylococcus aureus SA1199 at 128 ug/ml by checker board method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID1243939Kinetic solubility of the compound in PBS2015European journal of medicinal chemistry, Aug-28, Volume: 101Discovery and characterization of aryl isonitriles as a new class of compounds versus methicillin- and vancomycin-resistant Staphylococcus aureus.
AID612586Antibacterial activity against Staphylococcus aureus K1902 bearing norA-deficient mutation by M7-A7 CLSI microdilution method2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID1867993Inhibition of efflux pump in Gram-positive methicillin and oxacillin-resistant Staphylococcus aureus ATCC 43300 assessed as relative fluorescence index using ethidium bromide as substrate at 25 uM and measured after 1 hr by fluorescence based microtiter p2022European journal of medicinal chemistry, Jul-05, Volume: 237Application of partially aromatic ortho-quionone-methides for the synthesis of novel naphthoxazines with improved antibacterial activity.
AID750889Inhibition of wild type NorA in Staphylococcus aureus 1199 assessed as reduction of ciprofloxacin MIC at 0.78 to 100 ug/mL2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.
AID433815Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 harboring mutation in parC and garA gene assessed as decrease in ciprofloxacin MIC2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID171668Change in diastolic blood pressure after iv administration of 8 uM/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID1201798Inhibition of NorA in fluoroquinolone-resistant Staphylococcus aureus 1199B assessed as minimum modulatory concentration require to potentiate 2 ug/ml ciprofloxacin-induced antibacterial activity2015European journal of medicinal chemistry, May-05, Volume: 95Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: study of 6-substituted pyridine-3-boronic acid derivatives.
AID283068Increase in 5 ug sparfloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 128 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID563239Inhibition of MFS efflux pump in apramycin-resistant cmlR2 null mutant Streptomyces coelicolor assessed as reduction in chloramphenicol MIC at 10 ug/ml after 48 hrs relative to control2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.
AID1127992Inhibition of NorA in fluoroquinolone-resistant Staphylococcus aureus 1199B assessed as potentiation of 4 ug/ml of ciprofloxacin MIC at 100 ug/ml after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
AID433826Induction of efflux pump expression in Streptococcus pneumoniae Spn-058 after 5 hrs by ethidium bromide uptake assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID510382Inhibition of Staphylococcus aureus 1199B norA efflux pump by spectrophotometry2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Substituted dihydronaphthalenes as efflux pump inhibitors of Staphylococcus aureus.
AID1515246Inhibition of NorA in Staphylococcus aureus 1199B assessed as minimum concentration required to effectively reduce ciprofloxacin MIC by four fold by broth checkerboard microdilution method2019Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2
Synthesis of amides from (E)-3-(1-chloro-3,4-dihydronaphthalen-2-yl)acrylic acid and substituted amino acid esters as NorA efflux pump inhibitors of Staphylococcus aureus.
AID681565TP_TRANSPORTER: uptake in OCT2-expressing HEK293 cells1998The Journal of biological chemistry, Nov-20, Volume: 273, Issue:47
Transport of monoamine transmitters by the organic cation transporter type 2, OCT2.
AID1356628Antimicrobial activity against Staphylococcus aureus ATCC 25923 by microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.
AID695915Inhibition of norA in Staphylococcus aureus ATCC 29213 overexpressing norA assessed as fold reduction in ciprofloxacin MIC at 6.25 ug/ml by checkerboard assay2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Chalcone inhibitors of the NorA efflux pump in Staphylococcus aureus whole cells and enriched everted membrane vesicles.
AID1221960Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1356632Antimicrobial activity against NorA deficient Staphylococcus aureus SA-K1902 by microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.
AID433834Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 infected in one-compartment pharmacodynamic system assessed as repid killing administered levofloxacin at simulated oral dose regimen of 750 mg in human every 12 hrs measured on day 62007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID1867992Antibacterial activity against Gram-positive methicillin and oxacillin-resistant Staphylococcus aureus ATCC 43300 assessed as inhibition of efflux pump by measuring intracellular accumulation of ethidium bromide at 25 uM and measured every minute for 1 hr2022European journal of medicinal chemistry, Jul-05, Volume: 237Application of partially aromatic ortho-quionone-methides for the synthesis of novel naphthoxazines with improved antibacterial activity.
AID612585Antibacterial activity against wild-type Staphylococcus aureus ATCC 25923 by M7-A7 CLSI microdilution method2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump.
AID339867Inhibition of NorA pump-mediated ethidium bromide efflux in Staphylococcus aureus K1199B at 50 uM by fluorimetric analysis2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID171735Change in blood pressure after 24 hours of dosing was measured in conscious normotensive male rats at a dose of 5 mg/kg administered intraperitoneally in 5 rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID1717802Antiviral activity against SARS-CoV infected in African green monkey Vero E6 cells assessed as reduction in viral replication by ELISA2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1473776Ratio of drug concentration at steady state in human at 0.1 to 1 mg, po QD after 24 hrs to IC50 for human MRP2 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1395190Inhibition of NorA in Staphylococcus aureus SA1199B assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring fold reduction in ciprofloxacin MIC at 32.9 uM after 18 to 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150N,N'-disubstituted cinnamamide derivatives potentiate ciprofloxacin activity against overexpressing NorA efflux pump Staphylococcus aureus 1199B strains.
AID1387446Displacement of [3H]reserpine from human VMAT2 expressed in HEK293 cell membranes incubated for 60 mins by scintillation counting method2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID283056Increase in 5 ug ciprofloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 128 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID750893Antibacterial activity against norA-deficient Staphylococcus aureus K1902 assessed as growth inhibition by microdilution method2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID402039Cytotoxicity against human HL60 cells by MTT assay2005Journal of natural products, Jun, Volume: 68, Issue:6
Indole alkaloids and other constituents of Rauwolfia serpentina.
AID520906Antibacterial activity against Streptococcus pneumoniae M240 by microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID433821Induction of efflux pump expression in Streptococcus pneumoniae Spn-058 harboring mutation in gyrA gene at 20 ug/ml2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID1356623Inhibition of NorA in Staphylococcus aureus SA-K2378 assessed as synergistic potentiation of ciprofloxacin-induced antimicrobial activity at 0.78 to 100 ug/ml by microdilution method based Checkerboard assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.
AID283079Increase in 30 ug chloramphenicol antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 16 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID762400Inhibition of multidrug resistance efflux pump in Mycobacterium smegmatis MC2 155 ATCC 700084 assessed as EtBr accumulation at 128 mg/L measured every 3 mins interval for 45 mins by fluorometric method2013European journal of medicinal chemistry, Aug, Volume: 667-Hydroxy-(E)-3-phenylmethylene-chroman-4-one analogues as efflux pump inhibitors against Mycobacterium smegmatis mc² 155.
AID679339TP_TRANSPORTER: transepithelial transport (basal to apical) in mdr1a-expressing LLC-PK1 cell2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
AID1356627Cytotoxicity in human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by ATP bioluminescence assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.
AID389750Inhibition of NorA efflux pump in Staphylococcus aureus 1199 assessed as fold reduction of ciprofloxacin MIC at 25 ug/ml2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Piperine analogs as potent Staphylococcus aureus NorA efflux pump inhibitors.
AID310121Inhibition of P-glycoprotein expressed in MDCK-MDR1 cells by calcein AM assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
New functional assay of P-glycoprotein activity using Hoechst 33342.
AID1471299Inhibition of Staphylococcus aureus 1199B NorA assessed as reduction in ethidium bromide efflux by fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID520915Antibacterial activity against Streptococcus pneumoniae M235 by microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID1221962Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID681579TP_TRANSPORTER: inhibition of Tetramethylrosamine efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID695896Inhibition of norA-mediated ethidium bromide efflux in methicillin-resistant Staphylococcus aureus SA-1199B at 5 ug/ml by spectrofluorometric analysis2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Chalcone inhibitors of the NorA efflux pump in Staphylococcus aureus whole cells and enriched everted membrane vesicles.
AID433824Inhibition of efflux pump in Streptococcus pneumoniae Spn-RC2 assessed as reduction in ciprofloxacin MIC by agar microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID283061Increase in 5 ug ofloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 64 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID401284Displacement of N-(p-azido-[3-125I]salicyl)-N'-beta-aminoethylvindesine from P-glycoprotein at 12.4 uM1996Journal of natural products, Jan, Volume: 59, Issue:1
Bicinchoninic acid protein assay in the determination of adriamycin cytotoxicity modulated by the MDR glycoprotein.
AID669749Inhibition of norA overexpressed in Staphylococcus aureus SA1199B coexpressing A116E GrlA mutation assessed as potentiation of ciprofloxacin MIC by checkerboard assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID283062Increase in 5 ug ofloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 32 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID1221958Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID520918Inhibition of ABC efflux pump in Streptococcus pneumoniae M186 assessed as reduction in ciprofloxacin MIC at 80 ug/ml2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID681138TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in mdr1b-expressing LLC-PK1 cells2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
AID669744Antibacterial activity against Staphylococcus aureus SA1199B overexpressing norA and expressing A116E GrlA mutation by microdilution method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
AID283559Antibacterial activity against Escherichia coli AG102MB after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID1176907Reversal of multidrug-resistance in human MCF7 cells in presence of vinblastine assessed as reduction in vinblastine IC50 at 5 ug/ml relative to IC50 vinblastine alone2015Journal of natural products, Jan-23, Volume: 78, Issue:1
Jalapinoside, a macrocyclic bisdesmoside from the resin glycosides of Ipomea purga, as a modulator of multidrug resistance in human cancer cells.
AID150616Concentration giving half of the maximal ATPase activity calculated for the high-affinity binding site of the CHO P-Glycoprotein (P-gp) in two-affinity model2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
AID669747Antibacterial activity against Staphylococcus aureus SAK2378 overexpressing norA by microdilution method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
AID283085Increase in 16 ug/ml Norfloxacin accumulation in Staphylococcus aureus SA1199B mutant overexpressing NorA measured per milligram of cell protein at 128 ug/ml after 20 mins2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID646195Reversal of p-glycoprotein-mediated drug resistant in human MCF7 cells grown in vinblastine-free medium assessed as ratio of IC50 for vinblastin to IC50 for vinblastin in presence of compound at 5 ug/ml after 72 hrs by SRB assay2012Journal of natural products, Jan-27, Volume: 75, Issue:1
Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells.
AID1387463Cytotoxicity in HEK293 cells expressing human VMAT2 assessed as reduction in cell viability at 1 uM incubated for 24 hrs by MTT assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID171731Change in blood pressure after 18 hours of dosing was measured in conscious normotensive male rats at a dose of 5 mg/kg administered intraperitoneally in 5 rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Investigations on the chemistry of berbanes. 10. Synthesis of raunescinone analogues with hypotensive and antihypertensive activity.
AID29139Calculated dissociation constant (pKa, calculated with ACD/pKa)2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
AID433823Inhibition of efflux pump in Streptococcus pneumoniae Spn-RC2 assessed as reduction in levofloxacin at 20 ug/ml MIC by broth microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID669746Antibacterial activity against norA-deficient Staphylococcus aureus SAK1902 by microdilution method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
AID681137TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in mdr1a-expressing LLC-PK1 cells2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
AID1867994Antibacterial activity against Gram-positive methicillin-susceptible Staphylococcus aureus ATCC 25923 assessed as inhibition of efflux pump by measuring intracellular accumulation of ethidium bromide at 25 uM and measured every minute for 1 hr by fluoresc2022European journal of medicinal chemistry, Jul-05, Volume: 237Application of partially aromatic ortho-quionone-methides for the synthesis of novel naphthoxazines with improved antibacterial activity.
AID283064Increase in 5 ug levofloxacin antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 128 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID433799Inhibition of efflux pump in Streptococcus pneumoniae Spn-058 assessed as reduction in ciprofloxacin MIC by agar dilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID681157TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes1994Nature, Dec-08, Volume: 372, Issue:6506
Drug excretion mediated by a new prototype of polyspecific transporter.
AID1387456Inhibition of VMAT2 in C57Bl/6J mouse striatal membranes assessed as reduction in [3H[-5HT uptake pre-incubated for 10 mins before [3H[-5HT addition and measured after 8 mins2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID283076Increase in 30 ug chloramphenicol antibacterial activity against Staphylococcus aureus SA1199B mutant overexpressing NorA at 128 ug/ml by disk diffusion method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1356631Antimicrobial activity against Staphylococcus aureus SA-1199B expressing wild type norA by microdilution method2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.
AID750890Inhibition of NorA in Staphylococcus aureus ATCC 25923 assessed as reduction of ciprofloxacin MIC at 0.78 to 100 ug/mL2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1891671Inhibition of quorum sensing system in Chromobacterium violaceum CV026 assessed as reduction in pigment production co-cultured with Sphingomonas paucimobilis Ezf 10-17 for 24 to 48 hrs2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67New diarylpentanoids and chalcones as potential antimicrobial adjuvants.
AID296572Effect on ethidium bromide efflux in quinolone/macrolide-resistant Staphylococcus aureus NorA by measuring remaining initial ethidium concentration at 20 mg/L after 10 mins2007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Synthesis and evaluation of new arylbenzo[b]thiophene and diarylthiophene derivatives as inhibitors of the NorA multidrug transporter of Staphylococcus aureus.
AID1674183Inhibition of human BSEP expressed in HEK293 cell membrane vesicles assessed as reduction in 3H-TCA uptake incubated for 5 mins by radiodetection method2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
AID681167TP_TRANSPORTER: Northern blot from LS174T cell2001The Journal of biological chemistry, May-04, Volume: 276, Issue:18
Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin.
AID520913Antibacterial activity against Streptococcus pneumoniae M186 by microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
AID339869Lipophilicity, log P of the compound2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump.
AID681130TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1356617Inhibition of NorA in Staphylococcus aureus SA-1199B expressing GrlA A116E mutant assessed as minimal potentiating drug concentration causing 8 fold reduction in ciprofloxacin MIC by microdilution method based Checkerboard assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction.
AID1395156Growth inhibition of Staphylococcus aureus SA1199B over-expressing NorA assessed as non-toxic concentration after 18 to 24 hrs by broth microdilution method2018European journal of medicinal chemistry, Apr-25, Volume: 150N,N'-disubstituted cinnamamide derivatives potentiate ciprofloxacin activity against overexpressing NorA efflux pump Staphylococcus aureus 1199B strains.
AID433820Inhibition of efflux pump in Streptococcus pneumoniae Spn-RC2 assessed as ethidium bromide uptake at 20 ug/ml2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
AID681142TP_TRANSPORTER: increase in Vinblastine intracellular accumulation in MDR1-expressing LLC-PK1 cells2002Molecular pharmacology, May, Volume: 61, Issue:5
Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1345075Human Vesicular monoamine transporter 1 (SLC18 family of vesicular amine transporters)1996Proceedings of the National Academy of Sciences of the United States of America, May-14, Volume: 93, Issue:10
Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.
AID1345057Human Vesicular monoamine transporter 2 (SLC18 family of vesicular amine transporters)1996Proceedings of the National Academy of Sciences of the United States of America, May-14, Volume: 93, Issue:10
Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14,420)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012290 (85.23)18.7374
1990's1076 (7.46)18.2507
2000's572 (3.97)29.6817
2010's358 (2.48)24.3611
2020's124 (0.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.12 (24.57)
Research Supply Index9.67 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index120.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (66.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials223 (1.43%)5.53%
Reviews522 (3.36%)6.00%
Case Studies129 (0.83%)4.05%
Observational0 (0.00%)0.25%
Other14,672 (94.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
A Phase I Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension [NCT02684786]Phase 10 participants (Actual)Interventional2016-07-31Withdrawn(stopped due to IRB did not approve)
[NCT00000514]Phase 30 participants Interventional1984-06-30Completed
[NCT00000499]Phase 20 participants Interventional1980-09-30Completed
Mechanisms of Refractory Hypertension (Reserpine) [NCT03223272]Phase 27 participants (Actual)Interventional2015-07-23Completed
Phase 2, Double-Blind, Placebo-Controlled Trial of Reserpine for the Treatment of Cocaine Dependence [NCT00033033]Phase 2140 participants Interventional2001-07-31Completed
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]Phase 310,251 participants (Actual)Interventional1999-09-30Completed
Assessment of Interactions Between IV Methamphetamine and Reserpine [NCT00267657]Phase 130 participants Interventional2004-01-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00000620 (6) [back to overview]Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00000620 (6) [back to overview]Stroke in the Blood Pressure Trial.
NCT03223272 (1) [back to overview]Change Ambulatory Systolic Blood Pressure

Death From Any Cause in the Glycemia Trial.

"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control391
Glycemia Trial: Standard Control327

[back to top]

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control503
Glycemia Trial: Standard Control543

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control208
BP Trial: Standard Control237

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate291
Lipid Trial: Placebo310

[back to top]

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate641
Lipid Trial: Placebo667

[back to top]

Stroke in the Blood Pressure Trial.

Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control36
BP Trial: Standard Control62

[back to top]

Change Ambulatory Systolic Blood Pressure

Twenty-four hour ambulatory systolic blood pressure (NCT03223272)
Timeframe: Baseline and 8 weeks

InterventionmmHg (Mean)
Reserpine-29.3

[back to top]